Exploring the improvement of human cell cryopreservation by Timothy J. Morris (7127759)
Exploring the Improvement of
Human Cell Cryopreservation
Timothy James Morris
A Doctoral Thesis
Submitted in partial fulfilment of the requirements
for the degree of
Doctor of Philosophy
Centre for Biological Engineering
Department of Chemical Engineering
Loughborough University
Submitted 25 March 2015 | Defended 6 July 2015 | Published 5 October 2015
© Timothy James Morris, 2015
Abstract
Doctor of Philosophy
Exploring the Improvement of Human Cell Cryopreservation
by Timothy James Morris
Regenerative medicine is an emerging technology and with hundreds of cell therapies cur-
rently in clinical trials there is a need to expand the limited knowledge related to their storage,
shipment and preservation. The most widely used medium for human cell cryopreservation
is 10%wt dimethyl sulfoxide (DMSO) in serum. However given its potential toxicity, DMSO
usage is a key issue in cryopreservation. Methods specify the need to reduce cell exposure
time to DMSO above 0°C as much as possible but the maximum amount of time cells can
be exposed to DMSO to prevent a detrimental e↵ect needs to be clarified. There are also
regulatory issues and concerns with the xenotoxicity, ethics and supply of the other core
component in the standard cryomedia formulation: Foetal Bovine Serum (FBS). Develop-
ing a viable alternative to FBS is crucial. In cryobiology literature thawing appears poorly
understood. A stable process is as vital as freezing to prevent injury to cells. Protocols are
currently too vague for cell therapy regulation and need improvement.
The time dependent DMSO cytotoxicity was evaluated by overexposing cells to DMSO during
and/or after cryopreservation. A broad investigation found that after 1 hour overexposure
post thaw viability of human mesenchymal stem cells (hMSCs) was reduced from 96.3±0.6%
to 74.1±4.0% and the co-expression of five key hMSC markers was changed from 97.9±1.3%
to 68.3±2.6%. This significant change could cause indicate a change in product e cacy
and a↵ect patient health, to prevent this, DMSO exposure must be kept to below 1 hour.
A range of alternative vehicle solutions were screened and human platelet lysate (hPL)
investigated as an alternative. In depth experimentation with hPL as a cryopreservation
vehicle solution and culture supplement (in place of FBS) found it to be a worthy, statistically
similar alternative. With no xenological or ethical concerns, lower costs than other serum-free
alternatives hPL could allow for a move away from xenological components.
A heat transfer model was developed and determined that 720J is required to thaw a vial.
Using the heat transfer model and additional factors such as pre-thaw stabilisation and on
thaw dilution, a two-stage experiment found that the current standard process (warming in
a 37°C waterbath) within the current paradigm of a 1.8mL cryovial is optimal but further
work is required to define the process for scaled-up product.
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Introduction
Cell therapies are the focus of numerous commercial and academic research groups globally
and have potential to revolutionise medicine[174, 298]. Cell therapies form part of regenera-
tive medicine and involve the transplantation of living cells into patients. Here cell therapies
di↵er from recombinant protein production as the cell is the product and therefore the vi-
ability, identity and function of the cells should form a much more significant part of the
release criteria.
Cryopreservation is a necessary step in the development of cell therapy processes. Regarded
as a peripheral process, it is nonetheless vital to get products to the patient[220]. More
specifically, the process of cryopreservation allows the decoupling of production from delivery
whilst maintaining viability and e cacy and for significant stock piles of cell material in
the form of cell banks to be produced and used as necessary for research, development or
production. Decoupled delivery and production can be from both a geographic and time
perspective. Evidence exists of thawed cryopreserved samples being viable decades after first
preservation[268].
Cryopreservation involves the use of very low temperatures to preserve living cells. At the
research and development scale cells are stored in small sealable tubes called cryovials. To
ensure human cells’ survival they are usually suspended cells in a protective cryomedium
classically made up of 10%wt dimethyl sulfoxide (DMSO)[302] in foetal bovine sera (FBS).
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This solution is then subjecte this solution to a slow-freezing process cooling to -80°C before
being kept in liquid nitrogen (LN2) dewars called cryostores. To revive the cells a vial is
rapidly warmed, usually in a 37°C waterbath and then diluted with fresh medium before
subsequent cell culture or transplantation[58, 81].
Whilst this process has been shown to be viable for a number of cell phenotypes, with
viabilities in excess of 90% being observed on thaw[2, 162], there are regarded to be a
number of problems, issues and challenges with this current art.
• First and foremost, the most widely used cryoprotective agent (CPA)- DMSO- is re-
garded as a toxin[74], with evidence of damage to both cells and to patients treated
with cryopreserved cells[55]. However as of yet no definitive evidence has been found
for the maximum time to which cells can be exposed to to DMSO before detrimental
e↵ects on cellular viability, identity and function occur, let alone the mechanism by
which this may occur.
• Sera are the most commonly used vehicle solution for cryopreservation[109] . It is used
in high concentration in combination with a CPA to provide nutrients to cells[116, 152]
as they are frozen and later resuscitated. It is often extracted from cattle which raises-
amongst others- questions of xenotoxicity, variability and ethics[32] and so development
of a process moving away from animal derived components is a key challenge.
• To recover viable cells from their cryopreserved state requires careful thawing, protocols
usually advise rapid warming in a 37°C waterbath[276]. From a clinical processing
perspective this is insu cient, with clinical sta↵ likely to be performing the thawing[33]
it is essential for more definition of the critical parameters to be defined.
• Whilst significant progress has been made scaling-up stem cell culture[218], no par-
allel progress has been made in technologies to preserve the large numbers of cells
required[232]. A viable technology will need to be able to preserve large volumes,
whilst not running into the issues of cryoinjury from intra-cellular ice formation caused
by flawed freezing.
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• No viable technology currently exists for shipping large volumes of cells in a cryopre-
served state- both packaging and cooling- which is both viable within current shipment
pathways and preserves cells at an acceptable state i.e. liquid nitrogen temperatures
<-150°C. With doses likely to exceed billions of cells[233] and large numbers of pa-
tients, developing a successful technology to deliver large numbers of cryopreserved
cells is essential.
• Input variability is another important hurdle to overcome. All cells are di↵erent, indeed
even a specific cell type from a variety of donors exhibit substantial variation[250]. It is
likely that a bespoke solution will be needed for each cell product. Defining parameters
for a platform technology, for example, that could be used to preserve a wide range of
cell therapy products would be significantly beneficial.
Meeting these challenges will be key to overall successful development of cell therapy prod-
ucts. It is the aim of this thesis to discuss and present solutions to a number of these
issues.
Chapter 2
Review of the Literature
Cryopreservation is often defined as the use of very low temperatures to preserve cells and
tissues with their structures intact and with negligible metabolic activity[121, 122]. For the
most part this means long term storage in liquid (-196°C) or vapour phases (⇡-150°C) of
nitrogen[124]. This review investigates scientific literature to develop a picture of the current
art of cryopreservation, determine the needs of cryopreservation for the quickly expanding
cell therapy industry and define core issues of which solutions to will be vital for a successful
cryopreservation industry. In cell therapy development the actual act of cryopreservation is
regarded as a peripheral process [220], see Figure 2.1, yet it is still essential for core cell
processing operations, including culture maintenance and banking, storage and to ensure
viable commercial delivery through supply chains. Considering storage and transport is
essential for the development of a successful commercialised clinical cell therapy[162] and
cryopreservation is more than likely to be one of two viable processes for the delivery of living
cell products.[52, 227]
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Figure 2.1: Schematic of the process development of a cell therapy. (Taken from Ratcli↵e
et al [220], with cryopreservation highlighted as a peripheral process)
A major issue in cryobiology relates to the freezing of water as this causes solutes that remain
in the liquid phase to increase in concentration and this is known as the solute exclusion
phenomenon. Another important issue include is injury due to piercing of cell membranes
caused by ice crystals. As such, cryopreservation protocols aim to reduce these factors by
either limiting the amount of ice nucleated within the cells or prevent changes to the cell
composition. A phenomenon known as the two factor hypothesis [182], where the optimal
survival of cells on thaw depends on an optimal freezing rate that is neither too fast or too
slow. Changes to cellular composition a↵ect the osmotic balance and therefore cells can
be a↵ected by solute or electrolyte toxicity. By suppressing ice formation, the consequences
thereof should also be prevented [74, 196, 308]. From a more process specific perspective,
cryopreservation allows the producer to separate the production of a cell-based therapeutic
from its subsequent delivery. The delivery of a cell therapy could be years on from production,
or thousands of miles from the site of manufacture. Developing a e↵ective process will allow
this business supply chain structure to be viable.
Living cell preservation can trace its history back to the 17th century, although true investiga-
tions into low temperature biology began with Hammond, Walton and Luyet[101, 165, 291]
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in the 1930s, before starting to actively mature in the 1940s and 50s. Cryopreservation is
well understood for bacterial stocks; the so called “Glycerol Stocks” [102, 120] because in
microbiology glycerol is one of the most widely used CPAs, another common CPA in this
industry is DMSO[85, 302]. It is also a mature process in reproductive medicine; the storage
of sperm, oocytes and embryos is commonly performed for in vitro fertilisation (IVF) pa-
tients. Given that human embryonic stem cells (hESCs), currently a major area of research
in regenerative medicine, are derived from embryos, the knowledge gained from reproductive
medicine is of special interest. Of more interest, with hundreds of active clinical trials[201],
are mesenchymal stem cells. These cells are believed to have substantial immunomodulatory
properties, and untold regenerative abilities giving products based on these cells possible
“blockbuster” status.
Interestingly, certain animals are also able to naturally freeze themselves successfully such
as the larvae of Pyrrharctia isabella, the Banded Woolly Bear Caterpillar which due to
evolutionary adaptations can successfully survive being frozen due to environmental changes
over up to 14 successive winters in the Arctic [154]. Hundreds of insect species, amphibians
and reptiles have some form of freeze tolerance and it will be interesting to see if it is
possible to apply the techniques developed by 4 billion years of evolution to modern cell
culture technology[264].
Current research and development appears to be lacking in process specific technologies
relevant to the freezing and storage of living cells at extremely low temperatures. Research
often states that cryopreservation was used, but with no reference to a protocol [203] or a
standard procedure (e.g. 10%wt DMSO in serum with slow freezing) is used with no further
citation[121]. Indeed, even protocols that are cited in literature often contain ambiguous
terms like “work quickly”, have been empirically derived or are not fully scientifically under-
stood [58, 103] with no additional definition or if the protocol is discussed timing is quite
often not stated at all[159]. This is a key gap in knowledge although these methods do
enable successful preservation. Using these protocols cells are regularly thawed with via-
bilities in excess of 90% [91, 104], but the possibilities of patient trauma[55] and reduced
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viability/proliferation after long exposure[11, 123] requires the use of DMSO to be much
better defined.
Use of bovine sera and its isolation from foetal cattle also raises questions. Serum is derived
from the liquid from clots when the blood coagulates. It is rich in growth factors and
is low in antibodies but its use is deprecated because of the risks, not to mention the
ethical issues. There is risk of numerous viruses and, theoretically, the transfer Bovine
spongiform encephalopathy (BSE)[58]. Thawing is a surprisingly ambiguous topic in scientific
literature as little published work exists investigating defined processes for this vital part of a
cryopreservation cycle. It is more than likely that clinical sta↵ will be performing the actual
act of thawing and so the development of more specific thawing protocols is crucial.
Other issues assessed in this review include scaling-up cryopreservation processes, the ship-
ment of products and how input variability could substantially a↵ect output quality. Given
that the health of patients could eventually be on the line, the investigation and development
of an e cient, well characterised and regulatory approved process is highly desirable for all
sectors of the medical research community.
2.1 Looking to the past of human cell cryopreservation and
cryobiology
The first investigations into preservation of living organisms was perhaps as far back as the
17th century. In 1663, Henry Power reported that small worms- what are now known to be
nematodes- that he had frozen in a mixture of snow and salt and thawed three hours later
“made their re-appearance and danced and frisked about as lively as ever.”[157]
Biology at low temperatures has been actively investigated since the 1930s. To begin with,
studies focused on reproductive cells- primarily sperm. Hammond and Walton in 1929 in
an example of scientific serendipity attempted to cross wild hares and rabbit and for the
purposes of this experiment had to store Hare testes and sperm at ranges of temperatures,
the lowest being 55°F (room temperature). They noted significantly lowered sperm motility
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but that the lower the temperature the higher the motility once warmed, they then moved on
to cooling to 0°C [101]. After cooling to 0°C they observed that a reduction in temperature
caused an increase in survival, this then caused Walton to investigate freezing [291].
In 1937, Father Basile Luyet, now regarded as the father of modern cryobiology, vitrified the
spermatozoa of frogs in “liquid air” in 2M sucrose and spread into a thin film on a glass slip.
He was able to recover and revive this sperm [165]. He did not report as to whether viable
embryos could be created from these frozen spermatozoa, but noted good motility on thaw.
In 1945 AS Parkes reported on perhaps the first successful preservation of human sperm
using LN2, i.e. to -196°C. He noted however that an earlier study had attempted similar with
fowl sperm, which revived and were capable of e↵ecting fertilisation, but that the produced
embryos died very early on [208]. In his study, he found that using vitrification straws of
between 0.15-1mm and lower temperatures provided for higher sperm survival and motility
on thaw in larger volumes. Lastly, he noted that freezing and thawing rate does not appear
to be the primary factor in spermatozoa survival.
Chris Polge in the late 1940s discovered methods of freezing several species but it was not
until 1952 that the calf “Frosty I” was born in Cambridge, its embryo fertilised with sperm
that had been frozen [96]. In 1953, a first reported human pregnancy from human sperm
was reported by Bunge and Sherman [79]. By 1956, they had recorded nine pregnancies
from twenty-six patients inseminated with cryopreserved sperm. This process continued to
develop and is now widely used globally [46].
In 1953 James Lovelock also discussed the mechanism of glycerol as a CPA, and later
demonstrated the e↵ect of fifteen di↵erent compounds as CPAs including methanol, ethanol,
ethylene-glycol, erythritol and sucrose. He subsequently demonstrated the first uses of
DMSO as a cryoprotectant in 1959[164].
In 1957, a full issue of Proceedings of the Royal Society B, under the chairmanship of AS
Parkes, focused on “A Discussion on Viability of Mammalian Cells and Tissues after Freez-
ing”. Here Parkes made the first mention of the term “Cryobiology”, using cryo meaning
cold, from the Greek[209]. Over a dozen studies discussed the current findings. Several
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focused on either whole organisms and reproductive cells. From a regenerative medicine
perspective, perhaps the most interesting is from Jones et al, where factors a↵ecting red
blood cell viability on thaw were discussed [133]. They noted that after 6 months storage
in a glycerol-citrate-phosphate medium cell survival was 75%. They investigated a range
of freezing temperatures and glycerol concentrations observing that cells stored at -20°C
in 3.0M glycerol underwent 10% haemolysis and that “the use of 4.0M glycerol might not
only reduce haemolysis but also...improve post-transfusion survival”. They also mentioned
at higher temperatures haemolysis became di cult to prevent and so higher concentrations
of glycerol were needed.
Over the late 1950s and 1960s, key work focused on the physics of cryobiology, perhaps
culminating in 1972 with the publication of the “two-factor hypothesis” by Peter Mazur[182]
(See Figure 2.2, from a 2000 paper by Gao et al [87]). Briefly, a too high, or too low freezing
rate can kill cells by means of freezing injury. This has become the foundation of freezing
processes, and the ramifications of this are discussed in more detail in Section 2.2.1.
Figure 2.2: The Two Factor Hypothesis: Relation (inverted “U” shape) between percentage
of survival and cooling rate in three types of cells. Stem cells refer to mouse bone marrow
stem cells, and hamster cells refer to hamster oocytes. RBC refers to human red blood
cells. (Taken from Gao et al [87])
Review of the Literature 10
By 1960, LN2 had become the refrigerant of choice in the agricultural and reproduc-
tive medicine industry. Work had then moved to target the freezing and storage of fer-
tilised embryos, in the early 1970s reports detail the first live mice born from cryopreserved
embryos[301]. Essentially techniques designed by Hammond, Luyet and Parkes had matured
over 40 years. Reports show the development of frozen embryos to the 2 cell, 4 cell, 8 cell
and blastocyst stage. In parallel with this was the development of IVF- the birth of Louise
Brown in 1978 a major milestone in reproductive medicine. It was not until six years later
in 1984 that Zeilmaker reported successful pregnancy from frozen embryos[316].
Over the past thirty years, as medicine has developed further, cryopreservation has become
an e↵ective standard for the preservation of live cells: there are almost 16,000 mentions of
“cryopreservation” in literature between 1975 and 2013. Work focuses on preserving more
delicate and “di cult” to cryopreserve tissues for example there are studies investigating
more primitive reproductive tissue- in 2004 Donnez[66] reported the successful pregnancy
of a woman who had autotransplantion of ovarian tissue after su↵ering from Hodgkin’s
lymphoma. She delivered a healthy girl.
A focus of cryopreservation in the present day relates to the long term storage and delivery
of regenerative medicine and cell therapy products. The same questions that a↵ect regen-
erative medicine, a↵ect cryopresrvation studies. Should autologous or allogeneic therapies
be developed? Should cells be modified to fit protocols? Technology is getting far more
sophisticated- whole processes will soon be controlled. The following parts of this review
detail recent work.
2.2 Motivation for Cryopreservation
This section tackles the question “Why Cryopreserve?”. There are two versions of this
question, each being a key motivation behind why cryopreservation has become such a
vibrant area of scientific research over the past 80+ years. First, in Section 2.2.1, the
question of why advanced techniques are required above mere freezing alone is considered
and understanding, for example why tissue cultures can’t be frozen like food. Secondly, in
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Section 2.2.2 the question of why cryopreservation is needed as a technique or process for
research, manufacturing and supply chains is answered.
2.2.1 Why Cryopreserve? Cryoinjury
Cryoinjury is a major issue in cryopreservation; cells can be damaged, or worse killed due to
the e↵ect of intraceullar ice crystals upon them. Interestingly, it appears that it is not the
cold temperature per se that causes damage, it the formation of ice inside or outside the cell
[77], this is in contrast to hypothermic preservation mentioned below in Section 2.5.3, where
cells begin to denature biologically. Ice crystal formation is the primary reason for the use of
CPAs as these control or prevent ice formation as cells are cooled to cryogenic temperatures,
but CPAs also often have a damaging e↵ect (discussed in detail in Section 2.8.1) and so a
major mission of cryopreservation scientists is to find the middle ground between ice control
and CPA toxicity[74].
Figure 2.3: Schema of the key events during freezing of cells. Typically, the extracellular
ice is seeded between -1 and -4 °C, and then the cooling process starts. (Taken from Fowler
et al [77])
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The formation of ice both intra- and extra- cellular raises a series of issues. The formation of
extracellular ice causes the cell to dehydrate as it attempts to maintain osmotic equilibrium
with its environment. Intracellular ice formation (IIF) kills cells because of two primary
reasons. First, the ice causes the cell to dehydrate and secondly the cell will be structurally
damaged by the ice crystals[180, 183].
Cryoinjury is a big issue, which cryoprotectants aim to mitigate. These have their own
problems, but by reducing the formation of ice, or at least mitigating it, cell survival can be
increased[74]. This thesis primarily focuses on conventional slow freezing, and it is within
this paradigm that cryoinjury will be explained.
At temperatures below ⇡-0.6°C water within biological systems starts to become thermo-
dynamically unstable and shows preference for its crystalline state. Intracellular ice can be
prevented by a su ciently slow freezing rate (but not too slow) such that as the cell os-
motically dehydrates as it cools. With a slower freezing rate the cytoplasmic water remains
near chemical equilibrium with the outside ice and solution. As shown in Figure 2.2, the
exact optimum for the slow freezing rate varies between cell types, for stem cells a “slow”
freezing rate is approximately -1°C/minute- -2°C/minute. The “inverted-U” phenomenon of
the two-factor hypothesis appears to be a direct function of where and when the ice is formed
in the system and likely due to the two competing mechanisms of intra- and extra-cellular
ice formation with the variation across phenotypes due to cellular size and content. As there
are no apparent heterogeneous nucleators inside the cell, if a cell remains in isolation, ice
would not form inside the cell until it reaches -40°C. Ice however usually does form outside
the cell where heterogeneous nucleators do exist[77, 283].
As ice forms outside the cell the extracellular osmolality increases, this causes the cell to
dehydrate causing damage to the cell[77, 181, 183]. One important source of cellular injury
caused by slow freezing is the increase of electrolytes as the concentration increases by
freezing. This phenomenon know as “solute damage” is perhaps the most often considered
cause of death by slow freezing.
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Cryoprotectants are used to prevent the formation of ice[74, 85] and their mode of action
will be discussed in more detail in Section 2.5.1, briefly however, if ice can be avoided, so can
cellular cryoinjury. But, by raising the concentration of CPAs to necessary levels to entirely
prevent ice causes toxilogical issues.
Were the cell solution be able to be vitrified to a “glassy” state without crystalline ice
formation damage could be prevented. Without crystalline ice formation in pure water the
glass can form at temperatures as low as at -138°C[77] remaining amorphous for far longer
than normally expected with the glass transition temperature (Tg) being approximately -
85°C[170]. E↵orts continue to achieve this- many sugars form glasses easily but do not cross
cell membranes quickly, and so developing technologies to allow this is a key challenge[247].
The formation of ice can entirely be prevented by the use of vitrification protocols using
extremely quick cooling rates (>1000°C/minute[114]). However, the freezing rates required
to vitrify manufacturing level cell volumes are impossible to reach[106].
2.2.2 Why Cryopreserve? Decoupling Production from Delivery
As has been shown, cryopreservation is now a modern science. It is important to establish
why cryopreserve at all and further to define and discuss what benefits are gained by taking
cells or tissue to ultra-low temperatures,
Broadly, the key functions of cryopreservation are product shipment, banking for development
or future use or storage for experimental purposes. Overall, these three core functions of
cryopreservation and storage allow for a key benefit, the ability to decouple production from
delivery.
Cryopreservation allows for storage of products theoretically ad infinitum between production
and delivery to the patient or customer, with appropriate quality control (QC) occurring at
any point between the two, for example. The advantages are clear: one can make a large
batch, under Good Manufacturing Practice (GMP) conditions for example and deliver to
patients as and when required. Prochymal from Mesoblast has up to a two year shelf life
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whilst frozen[33], and even that could be considered pessimistic considering recent work
by Saijo Sumida showing viable recovery and di↵erentiation capacity of bone marrow cells
cryopreserved in 1972[268].
Further when growing up cell banks cell quality can be maintained with products starting
from the e↵ectively the same seed population. So long as cell vials are stored in well topped-
up LN2 they are protected from physical, natural or man-made damage.
As products start to make it to the market and clinic, it is worth touching on the issues
a↵ecting of cryopreservation in its manufacturing or engineering context for cell therapeutics
and this is the focus of Section 2.8.
2.3 Looking to the Animal and Microbiological Kingdoms
The bacterial and animal kingdoms have had a 3billion+ year[59] head start on developing
successful freezing strategies.
In the polar-regions, where sub-zero temperatures are experienced the majority of time, a
surprisingly diverse community of bacteria and archaea exist. These microorganisms are
believed to have expanded from crenarchaeota in high temperature environments to the
cold deep of the polar oceans over 100 million years ago in the mid cretaceous period[61].
Hundreds of species exist in both the pacific and arctic oceans, in marine sediments and
in sea ice, and on both polar tundra. Bacteria operate in such cold temperatures by using
enzymes which are still active below the all-important 0°C where water freezes. The bacteria
also are able to survive without ice crystal nucleation by having developed survivability at
the low temperatures in salty water. These brine networks allow the sea to remain liquid to
-35°C[111]. These factors unfortunately mean that the evolutionary mechanisms developed
by these bacteria and archaea cannot be used in human or other mammalian cells due to
the vastly di↵erent phenotypes experienced. It is however interesting to see that “life” is
possible at low temperatures[61, 111].
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When considering phylogenetics, the study of evolutionary relatedness, of freeze-avoiding
and freeze-tolerant animals it has appeared numerous times across unrelated animals groups
throughout the tree of life- a form of convergent evolution. This allows for numerous inter-
esting freeze survival methods in nature. A few zoological examples will be discussed in the
context any useful lessons to be learnt from these species relevant to the development of a
cell preservation platform. A search of zoological literature shows that there are no extant
mammalian species with the ability to successfully freeze their cells therefore the insect,
reptilian, amphibian and fish groups should be looked at.
Animals that can cope with temperatures below freezing fall into two categories- freeze-
avoiding and freeze-tolerant. Fundamentally, freeze-avoiding animals can keep body fluids in
a liquid states to very low temperatures, there is evidence of arctic insects cooling to -50°C.
Freeze-tolerant animals however defend only the cytoplasmic liquids, allowing ice to form
in their extracellular matrix (ECM) and extra-organ space. Animals with successful freeze
tolerance can endure at least 50% and barnacles have been shown to be viable with over
80% ice content[1, 43, 264]. Evolution is a magnificent process and animals develop through
natural selection and survival advantage. No point on Earth has ever been below -90°C, and
so animals would never naturally evolve tolerance of this level, and so the examples described
below are only partially relevant to a cells preserved in LN2 at -196°C.
As mentioned before, numerous terrestrial insects are freeze-tolerant. An interesting spec-
imen is the banded woolly bear caterpillar Pyrrharctia isabella (see Figure 2.4). It has the
ability to accumulate 200-300mMol glycerol in its hemolymph, the insect equivalent of blood,
a↵ording good survivability at sub-zero temperatures. Arctic groups of these moth larvae are
able to survive much lower temperatures, winter after winter- some up to 14 times before
pupating[153, 154].
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Figure 2.4: The Woolybear Caterpillar Pyrhharctia isabella[97]
There are complications for using this zoological example in human cells, mammals do not
have hemolymph or the ability to naturally produce glycerol, but it allows conclusions to be
drawn. First, that glycerol is a successful cryoprotectant for members of the animal kingdom
justifies its well documented use in bacteria stocks[102]. Second, it is biocompatible and
therefore non-toxic.
Amphibians are, on an evolutionary timescale, a lot closer to humans than insects. Richard
Dawkins states that our common ancestor lived around 340 million years ago in the early
Carboniferous period. [59] Some frogs initiate self-freezing at a high sub-zero temperature,
-2.5°C. They take 24 hours to reach maximum ice content; this gives these amphibians time
to activate cryoprotective measures. Wood Frogs (Rana sylvatica) use glucose as a CPA
distributed from the liver. The high temperature also has an additional physiological reason,
at -4°C, the ice formation rate is too high and the glucose is unable to get out of the liver
where it is made to successfully protect the frogs’ cells. The long freeze time also gives the
frogs plenty of time to make metabolic adjustments and reduce osmotic shock. These points
are important for mammalian cells[155, 263, 264]. The wood frog is also able to experience
up to ⇡55% desiccation. Storey and Storey suggest that there is a relationship between
freeze and dehydration tolerance[264].
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Perhaps the closest species (evolution-wise) to Homo sapiens with cryoprotective abilities are
certain turtles. Richard Dawkins suggests in The Ancestor’s Tale that our common ancestor
lived around 300 million years ago again during the late Carboniferous period [59]. Storey
and Storey[264] suggest, “[their] capacity for freeze-tolerance is quite weakly developed”.
American Painted turtles (Chrysemys picta) can endure up to 50% body water frozen, al-
though Canadian specimens (C. p. bellii) rely on a form of freeze-avoidance. These turtles
were able to accumulate glucose and lactate in their livers and use it as a CPA, similar to
the frog species discussed above[43].
Storey and Storey conclude[264] by suggesting that much is known about cryoprotectant
synthesis in freeze-tolerant animals. There is potential that this knowledge could be used
in the development of a cell preservation platform. It is interesting to note that glycerol
is a widely use cryopreservant in nature, and this knowledge will perhaps be useful when
laboratory research takes place.
2.4 Overview of the Regenerative Medicine and Cell Therapy
Industry
The motivation for this thesis was to develop improved cryopreservation technologies and
techniques for the burgeoning cell therapy industry, which forms a key part of regenerative
medicine. Regenerative medicine has great potential to revolutionise medicine. Improving
both patient life quality and reducing overall healthcare costs has caused significant interest
to be generated, if the application and development of therapies based on living cells with
regenerative properties could change the way medicine is practiced[234].
Werner et al [298] suggest that regenerative medicine is “a paradigm shift in healthcare” as
these treatments are designed to focus on the “underlying causes of disease by repairing,
replacing or regenerating damaged cells”. With the population ageing (there will be 32million
more elderly people by 2030 in the US than there are today) now is as better time as ever to
focus research and commercial development on this shift in the application of medicine. A
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UK House of Lords report from 2013 defines regenerative medicine as “methods to replace or
regenerate human cells, tissues or organs in order to restore or establish normal function”[50].
Cell therapies are just one facet of regenerative medicine, which includes medical products
such as recombinant erythropoietin, growth hormone and bone morphogenic protein and
also gene therapy, tissue engineering and a myriad of medical devices. Mason et al [174]
suggest that cell therapies represent a “fourth pillar” of healthcare- joining pharmaceuticals,
biologics and medical devices and therefore overall regenerative medicine technologies in
e↵ect use all four “pillars” and represents a new branch of medicine like emergency medicine
and gerontology.
Cell therapies, more specifically represent a significant market opportunity, there are cur-
rently 300-700+ companies actively invested in developing these therapies, including global
healthcare leaders such as GSK, Johnson and Johnson and Pfizer. With the creation of the
Cell Therapy Catapult from substantial government support of $110million[177] and with
the announcement of the Catapult’s manufacturing centre in the 2014 budget[37] the UK
is ideally placed to become a leader in cell therapy commercial development[174]. Over the
past few years cell therapies have moved on from being a curiosity led scientific endeavour
to a viable industry. Products have started to pass successfully through clinical trials and
appear on the market, Mesoblast’s “Prochymal” is an allogeneic mesenchymal stem cell-
based therapy treating graft-versus-host disease and is approved for use in Canada and New
Zealand[33]. Dendreon, developed by Provenge and gained market approval in the US in
April 2010, is an autologous prostate cancer vaccine. Based on three treatments with a
reimbursement value of $93,000 it has the possibility of becoming the first blockbuster cell
therapy. Analysts suggested that sales could be in the region of $1-2billion per annum in a
few years after launch[224].
The most recent estimate of the market capitalisation of the cell therapy industry is in excess
of $7billion[177] after strong progress in translation and commercialisation. With more and
more products in development and strong progress in development for unmet medical needs,
the cell therapy and regenerative medicine industries are set to grow and grow[177]. The
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details of the cryopreservation of therapeutically relevant cell types are discussed in Section
2.6.
2.5 Current Methods of Preservation
Broadly speaking, there are two methods by which cells are cryopreserved- conventional slow
freezing and vitrification. This section includes a discussion of each and their advantages
and disadvantages, followed by a description of another less used preservation method:
hypothermic storing or “pausing” cells between approximately 2°C and 35°C[51, 125].
2.5.1 Conventional Slow Freezing
For the purposes of this section, cryopreservation will be described under the paradigm of
in vitro cells taken from stable culture and cryopreserved under widely accepted protocols.
Protocols used in the forthcoming experimental chapters are described in Section 3.7.
After enzymatic detachment cells are suspended in a cryomedium, made up of a CPA and
a vehicle solution, most commonly 10%wt DMSO in FBS. After transferring to cryovials,
or other vessel, the cells are cooled at a predefined rate, passive cooling uses for example
isopropyl alcohol (IPA) or a metal alloy such as in BioCision’s CoolCell (Figure 2.5)[26, 58].
The method of operation of these passive devices is to control the reducing temperature
of the environments where the cryovials are kept linearly due to the physical properties of
the IPA or alloy used. As mentioned in Section 2.2.1 ⇡-0.6°C water shows preference for a
crystalline state and becomes thermodynamically unstable, by controlling the freezing rate
at -1°C/minute for stem cells the highest proportion of cells are viable on thaw (see Figure
2.2)[137]. This process is used quite consistently in life science laboratories across the world
and is regarded as the current standard for the preservation of a variety of therapeutically
relevant adult stem cells [18, 58, 159]. A number of studies have shown that preserving with
a passive device does generate similar cooling rates and recovery on thaw to those used in
controlled rate (i.e. active) freezing methods, although the lack of a record of the procedure
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and raises regulatory questions[103, 122, 211] along with issues of scale due to the chemical
or metallic material used to accurately cool cryovials, the larger CoolCell (Figure 2.5) only
holds up to 30 vials per unit.
Figure 2.5: CoolCell produced by BioCision, USA [26]
The individual steps in the standard process are taken to minimise the nucleation of ice
crystals which, as described in Section 2.2.1, are a major cause of cryoinjury. Cells preserved
with this method such as sperm, oocytes and hESCs commonly yield in excess of 90%
viability on thaw and the process allows for the generation of allogeneic working cell banks
(WCB) and master cell banks (MCB) which can then be used to deliver “o↵ the shelf”
products[107, 147, 151]. Nevertheless, some cell types such as those grown in colonies
e.g. hESCs have had poor survival reported on thaw when preserved with conventional slow
freezing methods[159, 310].
Issues concerning cryopreservation from a more general process perspective are discussed in
Section 2.8 as these issues exist across all preservation processes. Specific concerns with
slow freezing processes however also exist. During slow freezing cells are exposed to cold
temperature above Tg over a longer period than vitrification, which can cause lethal intra-
or extra- cellular ice formation[180] this can then induce osmotic imbalances which in turn
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cause apoptosis on thaw[178]. However for processing the benefits are several, a large
number of vials can be preserved at any one time and these vials can approach densities
required for clinical application, for example the Grant EF600M can hold up to 55 cryovials
per freeze[127]. Prochymal for example uses 15mL bags for delivery: viability in excess of
the FDA’s 70% threshold is consistently achieved[33, 38].
Cryopreservation by means of traditional slow freezing is not an ideal, optimised process for
long term storage and delivery, however it has become an e↵ective standard in the research,
development, production and delivery of cell therapeutics with companies such as ReNeuron
using slow freezing processes [266].
2.5.2 Vitrification
Vitrification is di↵erent to slow freezing in that small clumps of cells are loaded with a
greater concentrations of CPA than slow freezing and then plunged straight in to LN2 such
that both intra- and extra-cellular formation ice is prevented all together: a pseudo solid
“glass” is formed. In this condition, the system has the properties of a solid but the molec-
ular structure of a liquid[122]. Unfortunately due to the requirement of very quick cooling
(>1000°C/minute[114]) only small volumes can be vitrified at a time, usually between 1 and
20µL. The Tg of water is -138°C[77] and to truly vitrify water a cooling rate of 106°C/s is
required[60, 114]- this has not yet been performed with cells. To successfully get clumps of
cells to this glassy state a more modest cooling rate is needed, therefore the mass of cells
that can be preserved is limited, and the concentration of CPAs increased- ⇡4M compared to
slow freezing (10%wt DMSO is 1.28M). This higher CPA concentration decreases ice crystal
nucleation, increases the Tg such that vitrification can occur over much more achievable
cooling rates. Crucially, in vitrification, this is why CPAs are used[77, 106]. It has been
reported that vitrified colonies of non-di↵erentiated hESCs recover to >70%, compared to
<25% for a similarly slow cooled groups [223, 318].
Whilst using vitrification prevents the formation of crystalline ice the state of the art has a
key disadvantage of freezing extremely low volumes; 1-20µL. Even at a high cell density of
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for example 107cells/mL only 200,000 cells could be preserved per sample, several orders of
magnitude below that needed for commercially and clinically successful cell therapies[232].
Nevertheless, as a process vitrification is used primarily in reproductive medicine- oocytes
or IVF embryos where small number of cells are required. There has been some work
performed on scaling up vitrification procedures. Wang et al [294] looked into a vitrification
procedure that would allow for subsequent scaled-up vitrification of hepatocytes. Whilst
unfortunately not specifically looking into volumes higher than the 500µL straw scale this
study developed a model which indicated that a complex series of media would be required,
at high concentrations (>65%) of a sugar solute based CPA. This study also found that using
Ficoll improved quality of hepatocytes on thaw but experienced an unavoidable reduction
in cooling rate due to the nature of heat transfer through a larger volume. The ultimate
issue and concern with this study is the complicated freezing process, the need for high
concentrations of sugars acting as a CPA and limited work on the process at true higher-
scale, nevertheless the study does indicate the possibility of scaling up vitrification. More
relevant to cell therapies, Li et al [158] published research which using a modified cryovial
showed evidence of preservation of hESCs which was both more e cacious and at a similar
scale to a traditional slow freezing method. The cells preserved with their bulk vitrification
method had significantly higher adhesion and growth on thaw. Automated devices do exist
for the vitrification of IVF products, as described by Pyne et al [214], although these were
to preserve just one cell: a fertilised embryo. These studies show that there is some promise
in the use vitrification at a manufacturing level. but a lot more work required to achieve
equivalent scales, automation and e ciency to slow freezing.
2.5.3 Hypothermic Preservation
Another method of cell preservation is hypothermia. This is the preservation of cells, still in
culture but at temperatures much lower than 37°C, which is the physiological temperature of
humans. This is often referred to as “pausing”. In a 2004 review Hunt et al [125] discussed
cells preserved in standard media for short (days to weeks) periods at temperatures of 4°C to
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24°C. This cell pausing decreases ATP synthesis and alters the cell membrane permeability.
There are a number of grades of hypothermia shown Table 2.1.
Hunt et al discussed a variety of culturing methods which are exposed to several degrees of
hypothermia- centrifuge tubes, tissue flasks and bioreactor. Using a recombinant Chinese
Hamster Ovary (CHO) cell line (CHO-DG44) and a human embryonic kidney cell (HEK) line
(HEK293) they showed that cells paused at 17°C experienced over 80% viability, whereas
the control of a non-paused group at 37°C achieved 90% viability. Interestingly a group
of cells paused at 37°C in a centrifuge tube had very poor viability- around 10% less than
those paused at 4°C (30%). Unfortunately this storage can only be for a maximum of
around 3 weeks, much less than the years achieved with cryopreservation. The cells also are
required to be kept in a liquid culture, which whilst not needing feeding and maintenance
is not as flexible as a cryostore due to motion causing media to be disturbed causing the
cells not to have access to the required nutrients. There is promise in this area, but it is
perhaps not useful for the storage and global shipping of human cells, a clear target of this
project. Interestingly, hypothermia is a natural process employed in nature to help animals
survive the winter- hibernation. This is done by lowering the core temperature and reducing
physiological and metabolic activity.
Table 2.1: Levels of Hypothermia[227]
Level of Temperature
Hypothermia Range
Mild 32°C-35°C
Moderate 28°C-32°C
Severe 20°C-28°C
Profound 1°C-20°C
Instead of a cryoprotectant, cells are paused in a hypothermic media of which there are a
number on the market. These tend to have anti-oxidative properties, which help prolong
survival, knowledge however is poor as to how these work[83, 125, 304].
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Robinson et al [227] in a 2013 review proposed that low temperature pausing perhaps holds
the best potential to be used to transport products from the manufacturing site to the patient.
The review also showed that using BioLife solutions’ Hypothermosol-FRS provided for the
best storage of mammalian cell types for up to 48h at 4°C. This would allow transport to the
vast majority of the world’s population. Whilst using 4°C for short term storage may allow
simple transfer of existing manufacturing process, Robinson et al state that using ambient
temperatures would be most beneficial. Using ambient temperatures would remove the need
for temperature controlled devices but these climates vary greatly across the world. The
challenges of hypothermic preservation are similar to that of cryopreservation: maintaining
cellular viability, quality and potency.
Hypothermia does have a lot of promise in short term preservation, its advantages include
no use of toxic cryopreservants and no cryoinjury due to ice crystal formation. However from
a long term perspective only cryopreservation can store cells ad infinitum, Sumida et al [268]
have presented evidence of cells stored for over 40 years.
2.6 Introducing Cell Therapy Relevant Lines and their Cryop-
reservation
For over 50 years stem cells have been used in medical practice. Bone marrow was first trans-
planted by Mathe et al in France in the late 1950s[122] and subsequent studies have revealed
the e cacy of stem cells in this treatment. Autologous skin epidermal cells grown from cul-
ture were successfully used to treat severe burns patients in 1980 for the first time[313].
Their potential is enormous. Stem cell biologists are currently working hard to find therapies
for brain diseases like Huntingdon’s or Alzheimer’s; recently a whole trachea was grown in
vitro[136].
Stem cells are simply defined as cells that can divide and di↵erentiate into di↵erent cell
types and have the ability to self-renew[254]. Broadly, there are two types- hESCs taken
from the inner cell mass of the blastocyst and adult stem cells, cells that exist in the
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tissues of fully developed humans[282] however there is also a third type: human induced
pluritpotent stem cells (hiPSCs); established in 2006 by Takahashi and Yamanaka[270].
HiPSCs are formed from somatic cells which have been introduced to just four specific
gene encoding transcription factors (Oct-4, Sox2, cMyc, and Klf4), this then causes the
cells to be fundamentally identical to hESCs. These three types of stem cells can then
di↵erentiate into the 200+ cells in the human body[8] and with progenitor cells help repair
and replenish the body’s tissues. The cryopreservation of stem cells is an underdeveloped
area of research and it is essential that the biology of stem cells is well understood before
successful cryopreservation can occur[51, 124].
Stem cells’ ability to self renew means they are immortal- they can maintain their undif-
ferentiated state theoretically ad infinitum[254]. Di↵erentiation however is the cells’ ability
to develop new functional abilities, characteristics and morphology, for example a mucous
producing cell or the cone cells of the retina. This specialised function of stem cells is the
reason for the promise that they hold in the cell therapy industry. The previous Section
2.4 showed that a new generation of therapies based on these cells with the function of
regeneration and repair could revolutionise medicine.
2.6.1 Adult Stem Cells
There is great promise in the research into adult stem cells. These are isolated from the
tissue of mature human individuals- as opposed to embryonic stem cells which are extracted
from the inner cell mass of blastocyst stage embryos[254].
A large number of stem cell treatments are allogeneic [179], that is to say derived from
a di↵erent individual from the treated patient. Allogeneic therapies di↵er from autologous
therapies where cells from that patient are either simply transferred in a skin graft for
example or extracted and expanded before re-transplantation. Allogeneic treatments are
usually developed away from the patient and manufactured from banked cell lines; this
means they need to be transported. It is far easier to deliver a frozen package than a living
culture. This is where cryopreservation comes in. For cells to safely make it into patients after
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Figure 2.6: Derivation of a human embryonic stem cell line, and di↵erentiation strategies.
(Taken from Hyslop et al [126])
resuscitation from cryopreservation and retain clinical function they need to be preserved in
a non-toxic and biologically safe medium. Also, stem cell products are likely to be expensive,
and the average treatment may run into the billions of cells[175] therefore, good viability
of more than 90% is highly desirable to keep costs down. Several adult stem cell types
exist, including neural stem cells, endothelial stem cells, olfactory stem cells and testicular
stem cells[254], but the two of most interest from a research and clinical perspective are
haematopoietic and mesenchymal stem cells.
Haematopoetic stem cells (HSCs) are the ultimate progenitor of all blood cells. HSCs possess
the ability to di↵erentiate into, amongst others, erythrocytes, macrophages, platelets, T-cells
and B-cells. These cells are primarily found in bone marrow, but have also been sourced from
umbilical cords and peripheral blood. Their clinical function includes treating patients with
cancers of the bone marrow or blood such as leukaemia or multiple myeloma. The classic
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marker of HSCs is Cluster of Di↵erentiation (CD) 34[95]. Cryopreservation of these cells is
usually performed with DMSO with an albumin based vehicle solution[2, 123]. Abbruzzese
et al found that cryopreservation does not a↵ect viability on thaw- even after almost 10
years of preservation and the e cacy of transplants was not reduced, with Haemoglobin,
granulocyte and platelet recovery occuring after 8-13 days[2].
Human Mesenchymal Stem Cells (hMSCs) are perhaps the most important stem cell type in
the present day. HMSCs are primarily extracted from bone marrow tissue but are found in
various tissues in the body[23] including umbilical cords, placenta, amniotic fluid and tissue
from liver, lung, pancreas and muscle[135]. They are the focus of research both on the
upstream and downstream side as their unique properties and potency grant huge potential
for cell therapies. They are also relatively easy to isolate, are believed to exist in small
populations in various tissues across the human body and primarily di↵erentiate into cell
types of the mesoderm- adipocytes, chondrocyes and osteocytes [23, 34], but also possessed
the ability to di↵erentiate to cells from the endoderm and ectoderm such as liver, neural cells
and cardiomyocytes[130, 309], see also Figure 2.7. Another issue of great interest is the scale-
up of hMSC products, expansion of hMSCs has been shown possible in bioreactors such as
the work by Rafiq et al [218] in 5L vessels. However the scale for a cell therapy for a common
application such as heart failure would require a number of cells in the order of quadrillions;
orders of magnitude higher than what is currently possible in bioreactors[176, 232].
HMSCs clearly hold a lot of promise in the clinical arena; indeed a search of the US Depart-
ment of Health and Human Services’ ClincalTrials.gov provides details on 148[201] separate
active clinical trials, however only Prochymal, treating the indication Graft-versus-Host Dis-
ease (GvHD) is currently approved for human use in Canada and New Zealand.
On the research and development side however there is a lot of controversy related to every-
thing from high-level issues such as the nomenclature, the location of hMSC populations,
and the methods of extraction, to the markers, which indicate the identity of these cells. The
first research into what would eventually be termed mesenchymal stem cells began in 1970
with research from Friedenstein et al [82], here mesenchymal progenitors were isolated and
cultured in vitro, this culminated in IP filings and the establishment of Osiris Therapeutics
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Figure 2.7: Mesenchymal Stem Cell Lineage showing ability to di↵erentiate beyond the as-
sociated tissue type. (Taken from Ore↵o et al [204], MAPC are multipotent adult progenitor
cells)
(now Mesoblast) who would go on to make the first approved hMSC therapy- Prochymal.
Over the late 1990s and 2000s MSC research focused on developing standards of nomencla-
ture and protocols, this culminated in the International Society for Cellular Therapy (ISCT)
publishing in 2006 a series of parameters, which at that time were internationally agreed cri-
teria for these “multipotent mesenchymal stromal cells” known as the “Dominici Criteria”,
they are[65]:
• Adherence to plastic
• Antigen expression: CD105+, CD73+, CD90+, CD45-, CD34-, CD14 or CD1b-,
CD79↵ or CD19-, HLA-DR-
• In vitro di↵erentiation to osteoblasts, adipocytes and chondroblasts demonstrated by
staining in culture
However, these criteria are somewhat lacking when the clinic is considered, given a) the sheer
number of antigens that MSCs are postulated to express (or not) [6] and b) the first and
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third criteria can only be investigated in vitro and leaves no way for the e↵ect in vivo to be
analysed. Indeed over the course of the development of the work in this thesis the definition
of the hMSC accepted by the scientific community has essentially been a moving target.
Papers critical of Dominici criteria have suggested expansions to the 2006 list[22, 23], with
the possibility of expanding into function based on studies from the Galipeau and LeBlanc
research groups[86, 193]. Arnold Caplan who first proposed the name “mesenchymal stem
cells” in 1991[34] suggested a common progenitor for tissue that is of the mesoderm lineage,
that is to say the “classic” three lineages, and the myocardium and endothelium, and that
these progenitors are found in all relevant parts of the body. However, Bianco et al in a
2013 review stated that neither of these points have been proven experimentally, and if they
were to be could only be performed with poorly defined in vitro assays, which do not use
single cells[21].
Further clinical trials are needed to determine the true function and origin of these multipo-
tent cells, before their clinical benefit can be truly realised. Unfortuately there does remain
inconsistencies with understanding hMSCs’ true growth characteristics and di↵erentiation
protocol and the lack of a definitive marker[128, 287]. Further, age plays a significant factor
in the frequency of hMSCs in bone marrow, ranging from 1 in 10,000 cells in newborn babies
to 1 in 2,000,000 in an 80 year old[35, 309]. Despite these factors hMSCs are considered
to be a suitable cell type for a wealth of cell therapy applications because of there easy
of isolation from a range of sources (e.g. bone marrow, adipose tissue and skin)[6], rela-
tive abundance, substantial in vitro growth potential[218], established e cacy[33] and the
lack of ethical concerns that surrounds hESCs with hMSCs being sourced from consenting
donors[12, 128].
Limited work has focused on the long-term e↵ect of cryopreservation on mesenchymal stem
cells after cryopreservation. The key quality attributes are, for now at least, the ISCT
criteria, but also important for cell therapy development are their long-term proliferative
ability. Studies up until now have focused on the a↵ect of DMSO prior to freezing, usually
only at di↵erent concentrations. Liu et al focused on both reduced DMSO concentrations and
alternative cryoprotectants like 1,2-propanediol (PrOH), polyethylene glycol and trehalose in
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a study that only focused on immediate post thaw cell quality attributes. They found that
a the standard formulation 10%wt DMSO in FBS was statistically better (i.e. p<0.05) than
most alternatives tested[162].
A 2011[172] study presented evidence that cryopreservation does not a↵ect the “stemness”
of mesenchymal stem cells, but studies to date have only been performed in canine tissue
although a recent Iranian study found that DMSO essentially catalysed the hepatic di↵eren-
tiation of hMSCs once hepatogenic protocols were utilised[7].
Given that cell therapies will require manufacturing in the order of tens of billions of cells[232],
the requirement for long term di↵erentiation and proliferative ability is ever greater for
hMSCs. There is clear need for process improvements to be made upon cryopreservation,
despite it being a peripheral process it will be essential for the success of mesenchymal stem
cell based therapies.
Recent studies from the Galipeau[86] and LeBlanc[193] research groups has shown that
cryopreservation could cause a reduction in the immune e↵ects of transplanted hMSCs which
were first proposed as a major therapeutic application by LeBlanc et al in 2004[156]. Franc¸ois
et al showed that freshly thawed hMSCs from healthy donors exhibit up-regulated heat-
shock proteins, reduced interferon gamma response to Indoleamine-pyrrole 2,3-dioxygenase
(IDO) up-regulation and compromised T-cell suppression abilities[78]. Moll et al [193] found
that cryopreserved MSCs- compared to fresh cells- showed a trend towards reduced clinical
e cacy in GvHD trials, increased sensitivity (causing lysis) to serum exposure, reduced
immunomodulatory properties and substantial activation of coagulation cascades. Their
clinical study investigated 44 MSC infusions, of which 9 were fresh/early passage- these
treatments had a 100% response rate, compared to frozen cells with only a 50% response
rate. This result however was not statistically significant (p=0.06) as the study was limited by
the number of fresh infusions, although in vitro studies did show the conclusions mentioned
above.
Despite the posited reduction in clinical function, hMSCs have been shown to be remarkably
resilient to cryopreservation. A 2012 study[91] found that frozen hMSCs did not exhibit
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changed marker expression, similar alkaline phosphatase activity once the MSCs were dif-
ferentiated to osteocytes, growth was not compromised and the cells were over 95% viable
after month long cryostorage. The authors did however note reduced viability (to 80.2%)
after storage for 5 months- compared to 99.5% before freezing and 95.4% after one month
storage. The authors suggest that their results show that cryopreserved MSCs are viable for
therapeutic use. Whilst questions of cellular function exist, these have not yet been truly
framed and so the e↵ect that cryopreservation has on MSCs immunological function, let
alone other regenerative properties, remains to be seen.
2.6.2 Embryonic Stem Cells
Embryonic Stem Cells are regarded as pluripotent, not totipotent as they are unable to
di↵erentiate into the placenta. These embryonic stem cells are progenitors of the three germ
layers, which then further di↵erentiate into the progenitors of other stem cells (shown in
Figure 2.6)[126, 296].
Embryonic stem cells were first isolated and derived from donated human blastocysts in
1998 by a Wisconsin based team led by James Thomson. Their seminal 1998 paper[282]
discusses how they successfully isolated 5 karyotypically normal lines. Interestingly, this
paper states that “each of the cell lines were successfully cryopreserved and thawed” with
no further discussion. Numerous other lines have now been derived in various laboratories
across the world particularly in the United States and Sweden. As Thomson et al state
in their abstract “these cell lines should be useful in human developmental biology, drug
discovery, and transplantation medicine”. These human embryonic stem cells express various
markers that characterise their pluripotency- SSEA-3, SSEA-4, TRA-1-60, TRA-1-81 and
alkaline phosphatase further, they also express Oct3/4, Sox2, Klf4 and c-Myc known as the
“Yamanaka Factors” after the development of hiPSCs[270] described below.
The method of the creation of hESC lines is now well understood. As their name suggests
the cells must be taken from embryos, and usually these are from IVF patients. in IVF, a
woman is hormonely stmulated to produce more eggs (oocytes) which are then extracted
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and fertilised in vitro. In IVF between 2 and 7 embryos are created[108], normally parents
only want one child and so the others are either wasted or stored for further use. The parents
are then sometimes o↵ered the choice of the unused embryos being used for research. As
shown in Figure 2.8 the inner cell mass is taken from the embryo at the blastocyst stage,
approximately 4-5 days post-fertilisation, these are then cultured in vitro as hESCs[282].
Figure 2.8: Overview of the process of hESC derivation (Taken and cropped from The
University of Hong Kong Li Ka Shing Faculty of Medicine, Stem Cell and Regenerative
Medicine Consortium website[280])
Given that the isolation of hESCs was just 14 years ago it is perhaps not surprising that
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there are as yet no treatments involving derived from them in current use. A trial which
held perhaps the most promise was the unfortunately now closed trial of Geron’s GRNOPC1
treatment. Embryonic stem cells were di↵erentiated into oligodendrocyte progenitor cells
(OPCs) for the treatment of spinal cord injury, something which a↵ects over 12,000 people
in the United States according to Geron[203]. A search of the US Department of Health’s
“ClinicalTrials.gov” shows that there are just 11 treatments in trials using hESC-derived cells
recruiting patients[200], however, this is surely only going to increase. It has been suggested
that cell based therapies are about 10 years behind monoclonal antibodies, and given that
stem cell products are another step beyond cell therapies, it will be at least two decades
before stem cell based products begin to make it to market, and commonly prescribed to
patients[140].
It is important to note that therapeutically, hESCs are not transplanted per se, cells derived
from hESCs are used- that is to say di↵erentiation is initiated in vitro. Therefore, from a
cryopreservation point of view the storage of hESCs is only needed for research, banking
prior to production and quality control (QC). Nevertheless, no cell therapeutics will use true
hESCs, cells derived from them will be. A few studies exist in the literature related to the
cryopreservation of hESC-derived cells. Kim et al and Chong et al [42, 146] in two sepa-
rate hESC-derived cardiomyocyte studies found that cryopreservation did not a↵ect viability,
identity or function.
The culture of hESCs is dependent on a matrix made of a feeder layer of cells or synthetic
extra cellular matrix. These cells grow in colonies; there is work currently taking place to allow
growth in monolayer, this being essential for scale-up[167, 281, 296]. Given the fact that it
is predicted that between 106 and 109 cells will be needed per patient per treatment and that
many indications have millions of patients[140, 175] not to mention the low di↵erentiation
e ciencies of hESCs (Park et al [207] in an optimisation study achieved <20%), scale up is
an essential step. This also shows a clear need for scalable, safe and e cient storage and
transport.
Research investigating cryopreservation of hESCs acknowledge highly variable recovery rates,
some as low as 0-30%, some as high as 80%[124, 180]. Two of the three methods investigated
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by Li et al [159] show substantial promise, these methods used vitrification and programmable
freezing and recoveries of 94.3% and 55.6% respectively were reported. This paper describes
advancements in hESC cryopreservation but makes no mention of scalability, as mentioned
above, a key hurdle to overcome. It is clear that improving scalable freezing procedures is
essential if hESC derived products are to have any clinical or commercial success, especially
considering the sheer number of cells required for a single patient[175]. All results reported
typically only look at immediate post thaw viability and do not investigate what has happened
to cells after a series of cultures.
There are numerous ethical issues surrounding hESC research, let alone their use in patients.
Given that human embryonic stem cells are isolated from early stage viable embryos and that
technically these embryos could become foetuses and therefore living children, “pro-choice”
style activists protest against any research into hESCs. This activism also extends to adult
stem cells, which is likely due to a lack of scientific understanding as adult stem cells are
from consenting donor patients. The ethical ins and outs of stem cells are not for here, but
it is worth noting them, and acknowledging their existence[254].
The majority of the ethical concerns have been solved by the development of hiPSCs by
Takahashi and Yamanaka in 2006[270]. Despite just 0.1%-1% reprogramming e ciency to
hiPSCs Takahashi and Yamanaka were able to produce cells functionally identical to hESCs
from somatic skin cells by reprogramming them with the retroviral transduction of the four
factors mentioned above: Oct3/4, Sox2, Klf4 and c-Myc.
2.6.3 Other Clinically Relevant Cell Types
There are numerous other cell types that hold therapeutic promise as the cell therapy in-
dustry expands. Forthcoming experimental chapters focus on improving cryopreservation
technologies for hMSCs, to both assess the current state of the art and note any lessons to
be learnt it is worth mentioning the biology and current cryopreservation techniques of two
other key clinically relevant cell types: T-cells and hepatocytes. These two cell types whilst
not stem cells are some of the more important areas of research in cell therapies.
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2.6.3.1 T-Cells
T-Cells are a group of cells from the haematopoietic lineage which, as a type of adult
stem cells, were mentioned in Section 2.6.1. The family of T-Cells is further split into a
number of groups[131], key groups include helper cells which are characterised by expression
of the extra-cellular marker CD4. Helper cells assist other white blood cells in immunologic
processes. Whereas cytotoxic T-cells which are CD4- but do express CD8- destroy infected
and tumour cells. Memory T-cells can be both CD4 and CD8 positive and are antigen
specific and maintain immunity long after an infection. The most interesting group of T-
cells from a cell therapy perspective however are T-regulatory (Treg) cells, they are CD4+
and are further split into FOXP3+ or FOXP3- groups. These cells hold promise as an
immunological suppressor by shutting down T-cell mediated immunity such as GvHD. Treg
cells therefore could be used in therapies to prevent or inhibit GvHD[93]. Tang et al have
shown that infusion of autologous Tregs could hold promise in delaying the onset of Type
I diabetes in children by preserving  -cell function[274]. In more detail, Treg cells also
positive for Foxp3 transcription factor suppress autoimmune inhibition of allograft rejection
and responses to mircobial infection. This regulatory mechanism is operated by cell-contact
depended cytokines such as IL-10[16].
Whilst holding significant potential as a therapeutic, challenges remain in cryopreserving
Tregs. As they are a relatively recent discovery, and their therapeutic potential only starting
to be realised, there are a number of issues in the cryopreservation process. Golab et al
discuss a number of these in a 2013 review[93]. Significant toxicity to DMSO is noted with
exposure for more than 2hrs to >2% DMSO inducing death and compromised function,
although exposure for less than 1hr does not a↵ect viability and function[149]. Concerns
also exist with precisely when Tregs should be frozen: immediately after isolation from
peripheral blood mononuclear cells (PBMCs), or after some ex vivo expansion. The several
studies that Golab et al reviewed showed no standard technique and therefore it is di cult
to draw a valid conclusion. Freezing of PBMCs with the intention of isolation of Tregs on
thaw was also proposed as an option, although a study[239] found that reduction in Treg
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frequency in PBMCs was due to selective cell death as their activated status (expressing
CD25) causes increase susceptibility to apoptosis.
Ultimately, as with all cell therapies, Tregs could be a lot more attractive potential for com-
mercialised cell therapy if they could be e ciently stored and thawed without compromising
biological function. Current knowledge regarding the impact of cryopreservation is limited
and requires work. Tregs however are not the focus of this thesis’ work, but certain im-
portant points can be taken from the literature described here and possibly applied to the
cells used in this thesis. First, a clear time point of toxicity to DMSO was observed by
Kloverpris et al [149], two hour exposure to 2%wt DMSO cryomedium induced cell death
and damaged function. Toxicity of CPAs is discussed in more detail in Section 2.7 and as-
sessed experimentally in Chapter 5 and a bench mark time value for these alternative cells is
useful. Sattui et al [239] made important points on when to cryopreserve, what point in the
cellular processing, it maybe that how the isolation is performed a↵ects the cells. Finally,
with a lack of any standard protocols defining such will be of a clear benefit to these and
other clinically relevant cells.
2.6.3.2 Hepatocytes
Hepatocytes make up almost 80% of the mass of livers[150]. The cells’ function include
protein synthesis and storage, carbohydrate transformation, synthesis of cholesterol, bile
salts and phospholips, and detoxicfication, modification and excretion of exogenous and
endogenous substances. These allow the liver to have its unique capacity to regenerate and
regulate its growth and mass. The capacity of liver regeneration is unusually not due to stem
cells present in this organ but the hepatocytes themselves. After a partial hepatectomy (PH)
approximately 68% of the organ is removed, the removed cells do not grow back, instead
the remaining liver tissue increases in size to compensate recovering to ±10% of the original
size in 1-2months in humans[75].
This incredible ability of hepatocytes make the liver, as Fausto and Campbell say in a 2003
review “one of the best ’practitioners’ of regenerative medicine”[75], making cell therapeutics
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to aid individuals with liver conditions an important challenge that research should be focused
upon. Allogeneic liver cell transplantation (LCT) is used as a bridge to transplantation for
patients waiting for a graft, it is able to correct liver errors that patients’ are born with
by supplying viable hepatocytes. However, despite the clear benefits of LCT, developing a
therapy at scale remains di cult due to the challenges in maintaining hepatocyte function
on thaw has become a surprisingly di cult challenge. The state of the art involves freezing
with University of Wisconsin solution[261] primarily used for organ preservation. A study of
porcine hepatocytes found that the ability of hepatocytes to synthesis proteins, glucose and
associated functions was significantly decreased after cryopreservation and there is also wide
acceptance that urea production is reduced after cryopreservation[40]. In a 2010 review,
Ste´phenne et al [261] say that there is limited understanding of how cryopreservation a↵ects
hepatocytes, but that if specific functions were assessed in combination with a range of
permeating and non-permeating cryoprotectants (discussed in more detail in Section 2.7)
a better determination of the cause of reduced function could be properly tested. Finally,
Ste´phenne et al noted that irreversible cell death is initiated post-cryopreservation due to
impairment of mitochondria.
Another 2010 paper discussed the development of optimised protocols for the freezing and
thawing of hepatocytes. The study investigated a range of parameters in a one-factor-at-
a-time (OFaT) experimental process: cell density, DMSO concentration, DMSO addition
rate, freeze rate and thawing protocol. The standard hepatocyte freezing protocol involved
preserving at a density of 3x106viable cells/mL in a cryomedium of UW solution with 10%wt
DMSO added dropwise. 1.8mL of cell suspension was preserved in 2mL vials or 4.5mL in
5mL vials and cooled with an established controlled rate freezer (CRF) protocol[62] and
then storage at -140°C. Thawing was performed in a 37°C waterbath with gentle agitation.
The optimisation study ultimately found that the 3x106-1x107 viable cells/mL density gave
good viability and that the choice of CPA “did not appear to be a major determinant of
the outcome of cryopreservation”. Considering the concentration of DMSO used; above
17.5%wt or below 7.5%wt caused poor outcome on thaw- higher concentrations causing
toxic e↵ects, lower preventing enough DMSO to enter the cells to positively e↵ect recovery.
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The last pre-freeze factor that had an impact on this study’s results was the rate of addition,
with gradual addition proving more e cacious than single-step. Finally the study found that
a standard thawing protocol was the most e cient way of thawing frozen hepatocytes with
the highest maintained viability, attachment and function, this was also similar to a drop-
wise protocol whereby fresh medium was slowly added over 3minutes after the vial had been
thawed. Despite the advancements that Terry et al made[279], viability and attachment was
still low (52% and 48%) compared to what would ideally be expected of a cell therapy.
With so much promise in cell therapies based on hepatocyte transplantation, it will be
important to improve associated cryopreservation protocols. Key points relevant to the
research in this thesis taken from hepatocyte research include the fact that maintenance of
function is essential to ensure good clinical function. Hepatocytes are notorious for losing
function during cryopreservation and it is important to note that ensuring all cell types
maintain function after cryopreservation should be a key objective in advancing preservation
protools. Also important to note was how small changes in the thawing protocol a↵ects cells
continuing survival and function. Despite Terry et al [279] determining that standard thawing
(37°C waterbath warming) was the best method, that other similar protocols were not as
e↵ective shows the importance of this process which does lack discussion in the literature,
thawing as an issue a↵ecting cryopreservation is discussed in more detail in Section 2.8.2.
2.7 Cryoprotective Agents
Various chemicals are used to cryopreserve cells and tissues. A lot of research has been
performed with di↵erent CPAs for sperm and oocyte preservation[248], as this is essential
for IVF and other banking for human reproduction. The processes here are a lot more mature
than those for other human cells, however the general principle is the same for somatic and
stem cells. The mostly widely used cryoprotectant in life science laboratories tends to be
DMSO, most commonly in a 10%wt solution with either foetal bovine serum or growth
medium [51, 58, 81].
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In a widely cited review, Barry Fuller[85] calls cryoprotectants “the essential antifreezes to
protect life in the frozen state” but that significant gaps exist in science’s understanding of
the mechanisms with in cell bodies and their potential toxicities. Also, there are two faces of
CPAs, they provide protection but there is also unwanted toxicity encountered from osmotic
and chemical bases[85, 269].
For the purposes of slow freezing, broadly, there are two categories of cryoprotectants-
permeating and non-permeating. DMSO, glycerol and PrOH are examples of permenating
CPAs, these are discussed in Sections 2.7.1, 2.7.2 and 2.7.3 and certain non-permeating
CPAs are discussed in Section 2.7.4. Permeating enter the cell membranes and provide their
protective e↵ect here, preventing ice crystal formation. Non-permeating CPAs however are
too large to cross cell membranes and so novel solutions must be used to allow them to
transfer the membrane or used in combination with a permeating CPA. Non-permeating
CPAs work by preventing ice crystal formation in the intracellular space whilst this provides
some protection it is not as e cient as permeating CPAs. The benefit here is that lower
concentrations of potentially toxic CPAs can be used in combination with the non-permeating
CPA[85].
The following is a discussion of the e cacy of the most widely used cryoprotectant, DMSO
along with a discussion of two other oft used permeating cryoprotectants: glycerol and PrOH
before a brief pre´cis of other cryoprotectants[85].
2.7.1 DMSO
DMSO (Me2SO) is an organo-sulphur compound. Its Mr is 78.13 and at room temperature
it is a colourless liquid. It has a density of 1.090g/cm3 and a viscosity of 0.001811mPa.s[44].
As a protective agent it has been widely used for cells as varied as human haematopoietic
stem cells, ovarian follicles in zebra fish, CHO cells and numerous other cell lines[18, 315].
DMSO has been used as a cryopreservative agent since the 1950s [164] and it has been widely
adopted. Protocols tend to advise use at a concentration of around 10%wt[19, 58, 302] and
reviews refer to this concentration as a standard [103, 121].
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Figure 2.9: DMSO Structure
The main benefit and motivation for its use in cryopreservation is the fact that it protects
cells by limiting ice crystal formation as cells are cooled. In a 2000 study, Baudot et al [15]
investigated the way that high concentration aqueous DMSO solutions (40-47.5%wt) freeze.
The study showed that DMSO along with various similar chemicals form stable glasses,
indicating that ice crystals are prevented from forming, vital for successful cryopreservation.
Whilst the DMSO concentrations here are substantially higher than that which would be
used in cryopreservation- higher even than vitrification- this paper shows the important glass
forming tendency of DMSO/water systems. The study also investigated several other widely
used cryoprotectants, including glycerol and PrOH.
Figure 2.10: Plots of Cv as a function of temperature of di↵erent concentrations of DMSO
in water. Line 60 (light blue) is roughly equivalent to 10%wt DMSO in water (60:440
DMSO:Water). (Taken from Mandumpal et al [170])
The mechanism by which DMSO prevents crystalline ice formation is clearly of great interest.
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Mandumpal et al [170] using computational molecular dynamics were able to define the
method by DMSO prevents ice crystal formation. Figure 2.10 shows that as the ratio
of DMSO in water increases, the peak of heat capacity at constant volume (Cv) against
temperature broadens indicating a widening of the glass-transition. This means that the
system has increased thermodynamic stability at this crucial point of cooling, which in turn
causes a stabler glass and thus reduced ice crystal nucleation and therefore reduced formation
of ice which aids the preservation of cells.
Various papers show the e cacy of DMSO as a cryoprotectant for several cell phenotypes.
Several of those discussed here have attempted to improve upon or remove DMSO from the
process, the motivation for this is discussed in Section 2.8.1.
In a 2013 paper, Abbruzzese et al [2] showed that preservation in 5%wt DMSO allowed
CD34+ autologous peripheral blood stem cells to retain high viability- in excess of 97% after
five weeks or 95% after 9-10 years of preservation. The cells also maintained their clinical
e↵ectiveness, with recovery of haemoglobin, granulocytes and platelets after transplantation
despite the 9-10 years of preservation.
A 2009 study investigating the optimisation of the preservation of human dental pulp stem
cells (hDPSCs) found that 1M and 1.5M DMSO preserved cells provided for significantly
higher viability on thaw compared to those preserved in lower DMSO concentrations an
ethylene glycol and propylene glycol[305]. Note 10%wt DMSO is roughly equivalent to
1.28M. In another optimisation study by Freimark et al [81] attempted to systematically
define a DMSO free system for hMSCs. In all the cases in this study where data is available
for a 10%wt DMSO system compared to the attempted optimisations, the performance of
the standard formulation was significantly better, with higher cell viability on thaw and, 24h
and 48h survival rates. Unfortunately this study that limited data is available for the 10%
DMSO system, although that which is available clearly shows that despite the investigators
substantial e↵orts in defining a proline/ectoin system, 10% DMSO is clearly superior, at
least from a hMSC viability and early growth perspective.
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In a paper assessing the toxicity of DMSO[293] a tissue engineered dermal replacement made
of fibroblasts was preserved in various cryomedia including one made up of 10%wt DMSO.
The dermal replacements preserved in 10% DMSO had a viability on thaw in excess of 80%.
Whilst the authors did not conduct a more detailed analysis of cell fate, these data clearly
show that a more advanced tissue engineered cell therapy product, for example, can survive
cryopreservation in a DMSO containing media.
There are dozens of articles published annually using DMSO as a cryoprotectant. Some
merely mention that DMSO is used as a CPA briefly whilst others show the e cacy and
time and again cells preserved in DMSO retain high viability on thaw. It is no surprise then
that DMSO is the most widely used cryoprotectant.
Whilst DMSO is the most widely used cryopreservative agent for the storage of diploid
human cells, the development of a new process may require understanding of other CPAs so
it is worth considering two other cryoprotectants which are used in more mature industries:
bacterial preservation and reproductive medicine. As was shown earlier in Section 2.3 glycerol
is commonly used by animals to enable some level of freeze tolerance or avoidance.
2.7.2 Glycerol
Two widely used alternatives to DMSO are glycerol and PrOH. Glycerol, also known as glyc-
erine and 1,2,3-propanetriol, has a molecular weight of 92.09g/Mol, a viscosity of 0.934Pa.s
and a density of 1.261g/cm3. It freezes at 17.8°C, is non-toxic to humans and appears as a
colourless liquid at room temperature and pressure (RTP)[299].
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Figure 2.11: Glycerol Structure
Glycerol has numerous applications in industry, medicine and biology. Indeed all lipids have
a glycerol backbone, and so it is essential for all fat structures[8]. It is used in bacterial
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cryopreservation and in natural freezing mechanisms employed by insects and amphibians
(see Section 2.3). In industry, it is a widely used lubricant[272]. In medicine, it has been
used as a cough medicine[41].
However it is its cryopreservative properties that are of interest here. It has been used
as a cryopreservant in reproductive medicine; a study by Keros et al shows its promise in
preserving spermatogenic tissue[143]. A study on fowl spermatozoa showed that glycerol was
the least toxic cryopreservant when compared to DMSO and dimethylacetamide although
this study only loaded sperm cells with the CPAs, and did not freeze[286].
John Morris et al [195] have shown that glycerol forms strong H-bonds with water, which
then compete with other water molecules disrupting the production of an ice lattice. This
is its core ability as a CPA, unfortunately, as Morris et al discovered, the viscous properties
of glycerol that cause its downfall as a particularly good CPA. The high viscosity limited
water di↵usion and thus the loss of water from cells by osmosis is restricted. This water loss
is critical to cryopreservation as water in cells can form ice crystals and this causes injuries
from intracellular freezing[195, 197] which was discussed in more detail in Section 2.2.1.
Keros et al [143] found glycerol and PrOH to be moderately successful cryopreservants
when compared to DMSO although they conclude “DMSO. . . proved to maintain the struc-
ture. . . better than PrOH or glycerol”. This was with spermatogenic tissue, although the au-
thors tested for structural normality after cryopreservation, rather than viability or metabolism
[143]. That glycerol is widely used in other life science industries makes it a clear possibility
for a non-toxic alternative to DMSO. The research discussed here does indicate the impor-
tance of molecular properties on the e↵ectiveness of a CPA.
Research investigating glycerol as an alternative CPA for hMSCs has found contrasting
results, Lara Janz et al [129] found that glycerol provided for similar viability and identity of
cryopreserved amniotic fluid stem cells (another possible source of hMSCs), whilst Grein et al
found complete cell death when using glycerol as a CPA for hMSCs[98]. These contrasting
results indicate ambiguity in the use of glycerol but further make it worth investigating as
an alternative to DMSO.
Review of the Literature 44
2.7.3 1,2-Propanediol
PrOH is again a non-toxic, viscous clear liquid (at RTP) it has a molecular weight of 76.09g/-
Mol. It is slightly less dense and viscous than glycerol with densities and viscosities of 1.036
g/cm3 and 0.0404Pa.s respectively[273]. The freezing point of PrOH is -60°C.
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Figure 2.12: 1,2-propanediol Structure
PrOH has been widely used again in the reproductive medicine industry since the 1980s. It
has been used in the preservation of spermatogenic tissue and embryos/blastocysts[72, 143].
Emiliani et al showed that viabilities of >80% could be reached with 4-cell stage embryos[72].
PrOH toxicity was also tested, and after 24 hours of exposure, a loss of just 12% was experi-
enced. Whilst these tests were performed on various early stage embryos/blastocysts, murine
cells were used. This once again shows a clear need for research into the cryopreservation of
human cells and the e cacy of PrOH with reproductive cells makes it worthy of testing as
an alternative to DMSO in the experimental studies in this thesis.
A search of the literature was unable to find any citations of the use of PrOH as a CPA
for hMSCs, but its e cacy with reproductive medicine akin to glycerol establishes it as a
possible alternative to DMSO.
2.7.4 Other CPAs
In his seminal review Barry Fuller[85] talks of how various sugars and alcohols have been
extensively tested for their e cacy as cryoprotectants on a wide variety of cell types including
animal, plant and bacteria cells. The most successful include sucrose and ethanediol and the
three discussed above. Poorer e cacy was observed with amino acids- namely proline, alanine
and glycine, other sugars including glucose and lactose and amides such as acetamide and
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formamide. Hydroxyethylstarch has seen great promise in the preservation of erythrocytes
but due to the high molecular weight is not viable for the preservation of nucleated cells.
A recent study focused on a novel method[247] to improve the e cacy of using the sugar
trehalose as a cryoprotectant. Trehalose has been cited several times as a viable cryoprotec-
tant for human cells[166, 229, 238, 307]. A notable issue with trehalose is that its molecular
size, 343.3g/Mol, causes it to not be readily transferred across cell membranes requiring long
incubation times to ensure equivalent on-thaw viability to that of DMSO-based protocols[4],
however its molecular structure being essentially two ↵-glucose units tied together with an
↵,↵-1,1-glucoside bond gives it an advantage over DMSO as cells can break it down with
enzymes such as trehalase[64, 222]. Sharp et al used an amphipathic polymer, PP-50, to
improve transport of trehalose across the membranes of SAOS-2 human osteosarcoma cells.
Using 25µg/mL PP-50 and 0.2M trehalose, statistically similar viability to a DMSO based
system was observed, these data were also significantly higher than a system absent of PP-
50. Sharp et al went on to note that despite increased processing time a PP-50 based system
could provide for a superior cryopreservation protocol[247]. Nevertheless, current work ob-
serves that slow-freezing in combination with a cryomedium including 10%wt DMSO is the
most viable preservation technology available, this process has issues and concerns as prod-
ucts approach the market. Concerns include the removal of trehalose on thaw, Benaroudj et
al [17] argue that trehalose may aid protect cells from some stress removing it before infusion
to patients will be essential as any toxic a↵ects may not be fully defined or understood.
2.8 Issues A↵ecting Cryopreservation
The experimental work in this thesis focuses on improving the processes by which cell ther-
apeutics will be cryopreserved. As such, here follows a number of key issues a↵ecting
cryopreservation protocols within the context of therapeutically relevant cell types- primarily
mesenchymal stem cells.
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2.8.1 Cryoprotectant Toxicity
There are problems with both of the components of the e↵ective standard cryomedium
10%wt DMSO in FBS, this section focuses on DMSO whereas Section 2.8.3 focuses on the
xenological issues with using bovine sera.
The time at which cells are exposed to DMSO at viable temperatures is kept to a mini-
mum because it is regarded as toxic and this is said to be time, temperature and dosage
dependent[122]. However the mechanism of DMSO toxicity is currently only theoretical. It
seems in a large literature search that the word “toxic” is far too general to truly explain the
issues with this well used cryoprotectant. The di culty comes when defining a specific toxic
e↵ect. DMSO has various uses of interest, aside from as a CPA, it can be used as as a drug
delivery solvent, biomembrane penetrator and as an in vitro di↵erentiation inducer[314]. It
has been reported that DMSO has a relatively low toxicity with a lethal dose, 50% (LD50) of
2.5-8.9g/kg approximately similar to that of alcohol[314]. Concerns for cellular therapeutics
include its di↵erentiation inducing capacity [236] and the possibility of being the cause of
a range of adverse reactions including heart attacks and stroke[55]. Less seriously, but still
concerning are minor e↵ects such as nausea and abdominal cramps seen when patients are
infused with non-washed stem cells for leukaemia treatment. Although by washing out these
toxic e↵ects these can be dissapated: a meta-analysis of various clinical studies found that
by washing the incidence of toxicity to patients can be reduced from 2.1% to 0.3%[302].
However one published hypothesis paper even suggests that DMSO may have a role in re-
ducing malignancy for the application of bone marrow for leukaemia post-transplantation by
inducing di↵erentiation[285], though this remains unsupported by evidence.
These additional functions are perhaps the key to why DMSO is regarded as toxic. It could be
hypothesised that DMSO e↵ectively acts as toxicity “enabler” allowing agents that genuinely
are toxic across the cell membrane. The issue with cell di↵erentiation is also important given
that stem cells are to be investigated. This LD50 value is perhaps not that useful here, that
refers to toxicity to an individual organism, rather than cells.
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Standard protocols often report the need to “work quickly”[58, 145] with DMSO with no
further definition. Some studies have shown varying durations of exposure but none report a
definitive cut o↵ point for a process parameter to ensure good cell viability and proliferation
on thaw.
One study with ovarian follicles of zebrafish (Danio rerio) shows that 1M DMSO causes
a 25% (⇡80%-⇡60%reduction in viability after 5 hours of exposure (a control of 5 hour
exposure to “nothing” i.e. fresh media gives a ⇡70% viability). Increasing this to 3M of
DMSO only gave a viability of ⇡55%. Whilst this indicates a potential cytotoxic e↵ect of
DMSO, it is notable that zebrafish are only a useful bio-model for ovarian tissue but not
other cells[315]. Oocytes however are interesting, as they have overdeveloped cytoplasm and
are therefore very sensitive to low temperatures[11]. Results from a 2010 study[11] (Figure
2.13) show that after exposure of DMSO to CHO cells as an oocyte model for around 3
hours to at concentrations of up to 200mg/mL (approx. 2.5 M) the cell survival was still
well over 90%.
Aye et al [11] left the cells in the cryomedium for 24 hours, this showed only around 10%
survival. However a medium made up with 0.25M concentration DMSO gave a cell survival
after 24 hours of ⇡80%. These results are shown in Figure 2.13. This study, however, only
studied two time points (2hr and 24hr) and both are perhaps far longer than cells would be
exposed to in a normal cryopreservation cycle. For example, if an operator does as some
protocols advise: “work quickly”[145] cells should not be exposed at room temperature for
3 hours, let alone 24 hours. It would be interesting to see values both lower than 3 hours,
and in between 3 and 24 to see what the e↵ects of CPAs are over more process relevant
timescales, i.e. where the cell survival rate drops.
In a classic paper, Hunt et al showed in 2002 the e↵ect of DMSO on CD34+ cells extracted
from umbilical cord blood, whilst only showing the e↵ect of DMSO exposure without freezing,
they did not investigate over-exposure after thawing, and only used time periods up to 60
minutes. They showed that varying the DMSO concentration up to 2.5x the standard
formulation (25%wt) with a normally timed protocol did not have a significant e↵ect on
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Figure 2.13: Cytotoxicity of DMSO to Human Oocytes Triangles are 2hr exposure, Circles
24hr exposure. (Taken from Aye et al [11])
“recovery index” their measure of standardising post-thaw expansion over one passage, as
shown below.
However when over exposure is considered, there is a subtle, but more substantial e↵ect.
Hunt et al [123] exposed the CD34+ cells to a 2°C pre-chilled 25%wt DMSO freeze media.
The authors did not explain the decision for using a why 25%wt concentration as no sig-
nificant di↵erence was found from 5-25%wt- when exposed for 20, 40 and 60 minutes to
this chilled media. Further, no significant di↵erence in recovery index was observed, how-
ever a significant drop was observed in cells exposed to the DMSO cryomedium at 20°C for
60 minutes, as shown below- Figure 2.14. Strangely however the 20°C condition was only
recorded for the 60 minute condition, so it is unknown whether this strong e↵ect (⇡50%
drop) happens at shorter exposure times.
A number of concerns from both clinical and process perspectives exist with DMSO[55]
but cells preserved in DMSO regularly exceed viabilities of 90% on thaw[143, 147, 151].
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(a)
(b)
Figure 2.14: E↵ect of exposure time and temperature on the toxicity of 25%wt DMSO to
CD34+ cells: (A) Change in Recovery index with di↵erent concentrations of DMSO (B)
Change in recovery index with di↵erent temperatures and time exposure to DMSO (Taken
from Hunt et al [123])
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Over time, 10%wt has emerged as a standard in both research and commercially available
products[33, 55, 259]. With scaled-up processes taking hours rather than the minutes to
fill delivery bags or vials [107] defining in more detail the e↵ect on cells after exposure to
DMSO-containing cryomedia for long periods above freezing will be an important process
consideration.
In one of the few papers exploring the post-freeze e↵ect of DMSO on hESC cells, Katkov
et al [138] showed albeit using poorly designed gating, that around 50% of cells are non-
viable and lose the Oct-4 marker, indicatory of self-renewal potential (PI+/Green Fluorescent
Protein A- (GFP-A-)) but after 7-14days in culture these do recover. As Figure 2.15 shows,
gates are free-drawn irregular polygons causing some of the population to be ungated. This
unusual gating strategy makes it unclear how accurate the results are, but they do show there
is at least some e↵ect on the potency of stem cells after freezing with DMSO. However this
paper did not investigate whether this was an e↵ect solely due to DMSO, or just freezing,
known to be harmful to cells.
Earlier in Section 2.7.1 a 2007 paper from Xin Wang and colleagues was cited[293], this paper
details a study investigating the a↵ect of DMSO containing cryomedia on the cell viability
of a tissue engineered dermal implant. In addition to the e cacy of cryopreservation of the
dermal implant the study also looked at the fibroblasts used to make the implant. Whilst
the study purely looked at on-thaw viability, the paper reports a significant drop after 10-30
minutes if concentrations of 15%wt and above. In the most extreme case, almost 100% cell
death is observed in cells exposed to 30%wt DMSO for 30 minutes. This raises questions
for the maximum amount of time that cells can be exposed to DMSO for before detrimental
e↵ects occur.
All read studies into the toxicity of DMSO tend to only investigate the a↵ects after im-
mediate exposure, and do not analyse the long-term a↵ects in in vitro culture, (let alone
in vivo when transplanted to patients) with exposure only prior to freezing. This is clearly
an important area for research, in vitro e↵ects could change the way cells are processed
prior to transplantation and in vivo transplantation of freshly thawed damaged cells into an
inflammatory environment, for example, could make the cells more likely to die. Limited
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Figure 2.15: Change in Oct-4 expression of (A) fresh hESCs and 3, 7 and 14 (B, C, D) days
after thaw. PI is propidium iodide a measure of viability by means of membrane integrity
and GFP is green fluorescent protein used to detect the presence of Oct-4. (Taken from
Katkov et al [138])
work also investigates the cell quality- phenotype, metabolism and in the case of stem cells,
di↵erentiation potential.
2.8.2 Thawing
Thawing is an important step in cryopreservation, the conversion of cells from a frozen, glassy
state where they exist in a stasis, to a viable temperature where on recovery they are able to
proliferate once again. For such a vital step, literature regarding the thawing of cryopreserved
human cell samples is surprisingly limited and therefore an apparent lack of understanding
exists. Part of a thawing protocol available from Life Technologies’ website[276] states:
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1. “Remove the cryovial containing the frozen cells from LN2 storage and immediately
place it into a 37°C water bath.
2. Quickly thaw the cells (<1 minute) by gently swirling the vial in the 37°C water bath
until there is just a small bit of ice left in the vial.
3. Transfer the vial it into a laminar flow hood. Before opening, wipe the outside of the
vial with 70% ethanol.
4. Transfer the desired amount of pre-warmed complete growth medium appropriate for
your cell line dropwise into the centrifuge tube containing the thawed cells.
5. Centrifuge the cell suspension at approximately 200 × g for 5–10 minutes. The actual
centrifugation speed and duration varies depending on the cell type.
6. After the centrifugation, check the clarity of supernatant and visibility of a complete
pellet. Aseptically decant the supernatant without disturbing the cell pellet.
7. Gently resuspend the cells in complete growth medium, and transfer them into the
appropriate culture vessel and into the recommended culture environment.”
This short phrasing clearly shows a number of issues with the process of thawing despite
being from a respected company. The protocol uses unclear words like “quickly”, “gently”
and “a small bit” and this could cause serious variation in products. This is essentially a key
problem with thawing protocols- ambiguity.
As shown in the Life Technologies method, the generally accepted method is to remove cells
from cryostorage and then to place them into a 37°C water bath and wait until almost all
the ice has melted the so called “trace” or “small bit” of ice remains, although protocols
vary on the time taken to reach this state[58, 124, 276].
A visualised protocol by Kent[142] suggests a similar method, but states that one must “swirl
the vial gently and observe the progress of the thaw often”, indeed this protocol advises to
continue operation when “only a small ice crystal remains”. This small ice crystal parameter
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exists in numerous other protocols and given its highly subjective and qualitative nature
should be deprecated[124, 276].
In unpublished data Smith[256] showed that vials in a 37°C water bath take approximately
140 seconds to reach 0°C and then approximately a further 10 seconds per 5°C increase-
giving a further 74 seconds or so to reach 37°C, a total of about 3.5 minutes.
There are a few reports on the comparison of dry to wet thawing. They tend to report little to
no di↵erence in e cacy with respect to cell fate post thaw. For example a paper by Ro¨llig et al
showed no significance for both dry and wet thawing of peripheral blood cells with regards to
viability, apopotosis/necrosis induction and clonogenic potential. They, and others, suggest
however that a dry method may be preferred to ensure compliance with Good Clinical Practice
(GCP) and GMP due to the risk of contamination from microorganisms which may be present
in the water bath environment causing infection of the cellular product[188, 230].
There are a number of controlled rate freezers on the market, and the process of dropping
cells from viable temperatures to -80°C, or below is well understood for the most part, and
freezing is controlled to prevent ice nucleation. There are other devices like the Nalgene
“Mr Frosty” or Panasonic BioScion CoolCell that allow for a controlled rate of 1°C/minute
using IPA or a metal alloy which both have understood thermic parameters. There are a
few controlled thawing devices, however, Asymptote, Cambridge, UK are known to be devel-
oping a VIAThaw device, that will give a “clean, highly repeatable and validated approach
removing all the limitations of traditional water bath systems” [10], additionaly Biocision
have devloped ThawSTAR which also aims to replace insu cient methods by o↵ering a
standardised approach to thawing[25]. Lastly, the Israeli company Pluristem have developed
a bespoke thawing device solely for thawing their PLX cellular product which uses placental
cells, this device allows for “rapid, uniform thawing” of PLX[212]. As these products are
only now approaching market delivery and use proprietary methods, details are limited.
Guan et al [100] using primary skin fibroblasts looked into cell morphology and collagen
morphology after being dealt with -20°C for the application of cryotherapy. The researchers
looked into two warming rates- approximately 5°C/minute up to 20°C and 10°C/minute up to
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37°C. There was a significant di↵erence in cell viability as assessed by trypan blue exclusion
and there was also a significant change in ↵-SMA positive cells. The latter is an important
marker of skin fibroblast quality, indicating that thawing process does have an e↵ect on cell
quality, indeed as the end hold temperatures are di↵erent, it is di cult to truly see if it is the
thawing rate or the hold temperature that has a greater e↵ect. Collagen I and III production
is significantly di↵erent also, with the 20°C group producing more type III and the 37°C more
type I than each other and the control. Whilst these experiments are for the application of
cryotherapy, certain allegories can certainly be taken.
Understanding thawing on a larger-scale than a handful of vials will be desirable for man-
ufacturing delivery, Mesoblast’s Prochymal advises 4 weekly doses of 2x106 cells per kg of
patient body weight- with the product delivered in bags with 1x108 cells in- these should
be thawed in a 37°C waterbath and gently rocked for 3-5 minutes[33]. This process, whilst
viable and approved for clincal use realistically needs more definition.
Thawing however appears to be somewhat better understood or studied when agricultural and
sporting animals are looked at[14]. These animals are regularly impregnated with artificial
insemination (AI) and so preserving sperm is necessary[258]. This is done at ambient,
hypothermic (chilled ⇡4°C) or cryopreserved temperatures[30]. Given the specifics of the
process of AI, only a small volume of semen is required to be frozen at a time, and so it
is usually vitrified, but it is worth comparing and contrasting human cell thawing, as there
maybe something to be learnt from these well understood processes.
Hu et al [119] in 2011, working with blue catfish (Ictalurus furcatus) spermatozoa straws
attempted to establish a commercial scale cryopreservation process. Their “Study IV” looked
into two thawing temperatures (20°C and 40°C) but for 2 di↵erent times- 40sec and 20sec, so
any results are di cult to compare, but they did not show any significant di↵erence. Soler et
al [258] vitrified deer sperm, noting in their introduction that “little is published for. . . thawing
methods for these species”. This investigation also looked at di↵erent di↵erent thawing times
additionally with di↵erent temperatures for the vitrified straws, this is shown in Table 2.2:
Review of the Literature 55
Table 2.2: Thawing Hold Times for Deer Sperm from a study from Soleret al [258]
Temperature (°C) Hold Time (Sec)
70 5
50 8
37 10
Naturally, vitrification is a very di↵erent freezing/thawing method, but comparisons can be
taken. Soler et al found no significant di↵erences with the three methods, except after two
hours incubation, noting that the lower temperature protocols provide better conservation
of sperm motility- an analogous measure of long term cell quality. This is interesting, as
the authors note that any e↵ect on sperm quality is only noted after two hours- immediate
post-thaw analysis showed no significant di↵erence.
Taking all of these factors into consideration, it will be important to define key parameters
for successful thawing which will then allow for the development for a framework of scaled-up
thawing.
2.8.3 The Xeno Issue
A common component in cryomedia, as has already been shown, is FBS, usually making up
the bulk of the freezing medium[58]. Whilst serum free comerciall alternatives, use of this
component in cryopreservation is regarded as problematic[31, 112] On a wider bioprocessing
scale, moving away from animal-sera containing cultures would be advantageous- growth
media tends to include 5-20% FBS[112], for example. Here, briefly discussed are the issues
with using serum in culture and thus establishing a case for serum-free growth- and cryo-
media.
Extraction of sera from cattle is regarded as cruel and unethical [112], and for that sake
alone should be deprecated, but more significantly the e↵ects of transferring xeno-originated
components to patients are not yet fully understood. It is perceived that the US FDA has
an aversion to serum based processes, and this is perhaps the biggest motivation for a move
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towards animal component free alternatives. Nonetheless, the risks associated with FBS are
often mitigated by the development of GMP-grade serum although this adds new burdens
with the limited availability, increased cost and reliance on agricultural infrastructure[31].
There is a notable lack of understanding of how the composition of sera aid both culture
and cryopreservation. Festen[76] in a 2007 review discusses that serum provides growth
and attachment factors that are essential for cell proliferation and maintenance along with
myriad nutrients.
A conference poster from Novozymes shows that it is primarily the albumin present in sera
that aids cells preservation during the dangerous freezing and thawing processes. Studying
CHO and mouse myeloma lines, this investigation found that preserving cells in a cryomedium
made up of recombinant albumin, DMSO and a serum-free medium (SFM) was roughly
comparable to standard FBS/DMSO formulation and a commercially available cryomedium.
The data also showed that similar rates of growth post-thaw and apoptosis were observed in
recombinant albumin/DMSO/SFM preserved cells compared to FBS/DMSO preserved cells.
Recombinant albumin is however expensive, but could prove to be a key component in a
more attractive (from a regulatory perspective) cryopreservation vehicle solutions[63].
Other alternatives exist such as human platelet lysate (hPL), CryoStor produced by BioLife
Solutions and various other commercial, proprietary blends. Comparing these to standard
FBS-based formulations and choosing a successful alternative- from cell health, patient health
and regulatory approval perspectives- will be key in the development of commercially viable
cell therapeutics.
To be viable, an alternative to FBS will need to meet some key objectives. Lalu et al
[152] noting limited study into any adverse e↵ects that may be caused by FBS exposure.
There is limited understanding of the e↵ect of FBS on human cells. An FDA paper[235]
suggested that cells cultured in animal-based solutions can uptake xenoantigens which could
limit their viability and that using FBS for human cell products could substantially a↵ect
their therapeutic potential. Copland and Galipeau suggest that exposure FBS could cause
human cells to become immunogenic [53], indeed Spees et al showed a number of cells
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equivalent to a therapeutic dose exposed to FBS could carry up to 30mg of bovine-sourced
antigens which, if released in vivo could cause the possibility of detrimental e↵ects [53, 260].
The need to move away from animal compounds for therapeutic application is clear.
2.8.4 Scale-Up
When considering scale out and up of slow freezing cryopreservation, research is somewhat
limited. In general, the scale up of the culture of stem cells still remains challenging[144,
148, 296] current research focuses on the culture of stem cells on micro-carriers in bioreactors
[218]. With doses of cell therapies likely to be in the order of hundreds-of-millions rather than
millions and the current state-of-the art in the case of the commercially available Prochymal
product storing around 1.25x108 per cryobag, not enough for a single dose (assuming an
average patient weight of 62kg[290] and a dose of 2x106/kg patient.) Upwards of 5-10
times this may be needed to treat patients with diabetes and heart failure per dose[176],
not to mention the billions needed to be produced and preserved for WCB and MCBs[233].
There is a clear need for a system that preserves cells in the quantities needed both at higher
densities and higher volumes. Research into scale-up growth of cells is still in infancy limiting
the impetus for the development of preservation technologies for the vast size and number
of doses needed to satisfy market demand- for instance heart failure treated with skeletal
myoblasts would need 4-8x108 cells for the 5.2million instances (in the USA alone)- roughly
3.12x1015 cells per anum [176]. A scaled up method of increasing cell density in the cryovial
is possible. Kleman et al in 2008 preserved 2-5x107 cells/mL in 250mL cryobags albeit with
CHO cells[148] if an equivalent density could be achieved with therapeutically relevant cells
the required doses could be easily achieved.
Before getting to delivering vials to patients the matter of filling thousands of vials per
batch must be assessed. Sartorious-Stedim (Royston, UK) produce “Fill-It” to increase the
speed at which banking can be operated[237], this still however limits cell density to around a
1x106-1x107 cells/mL in 1-5mL cryovials and as it essentially speeds up the human controlled
process by mimicking it robotically it is an example of scale-out. Vitrification protocols, as
discussed in Section 2.5.2 are not currently able to exceed the scale of cryovials[158, 294].
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Hediemann et al [107] investigated using 100mL cryobags for preservation of large numbers
of recombinant baby hamster kidney cells, this study primarily focused on the time pre-freeze
to fill delivery vessels at this scale, noting that to prevent detrimental cellular damage (traced
to the toxic e↵ects of the DMSO CPA) this time should be kept below 1.5hrs. The study
also stated that these bags could be filled at approximately 100mL/min indicating that (at
this scale 100mL/dose) <100 doses could be filled per batch, nowhere near the demand
of indications like diabetes or heart failure . There is a clear need for improved scaled-up
cryopreservation processes.
2.8.5 Shipment
Cell therapy companies could site their production facilities across the world. Patients for
the specific indication that a product treats could therefore be on the other side of the planet
therefore products must be shipped to them. In the case of a current similar process- organ
transplant- tissue is kept chilled above freezing and must be delivered to the ideally within
4hrs. Due to di↵erent organs exhibiting di↵erent ischaemic properties, an exception to the
4hr deadline are kidneys which can still be viable up to 18hrs post extraction from the donor
[297]. For cell therapies, whilst building on the knowledge of the mature organ transplant
systems, they represent a change in how viable tissue is delivered to patients. Whilst there
is some development in hypothermic preservation (see Section 2.5.3) cryopreserved products
are seeing the widest development in industry.
Coopman and Medcalf note that cost and transport delays (including through customs)
can be an issue but that controlled temperature systems already exist to transport blood
products [52]. European guidelines for distribution state that it is the responsibility of
the distributor to demonstrate that “medicines have not been exposed to conditions that
may compromise their quality and integrity” and that “products should be transported in
containers that have no adverse e↵ect on the quality of the products, and that o↵er adequate
protection from external influences, including contamination.”[49] Also advised is consistent
and regular monitoring of temperature controlling devices to ensure the quality of products is
maintained (albeit with no clear definition of what quality means in the case of cell therapies).
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Parcell Laboratories (Natick, MA, USA) have proposed thawing product prior to despatch
and shipping at ambient or hypothermic temperatures to avoid issues caused by thawing
performed closer to the patient[300].
Temperature alone may not be the only cause of detrimental e↵ects on cellular products.
Nikolaev et al and Wang and Chen showed that hMSCs stored at hypothermic temperatures
(4°C) and subjected to vibrations mimicking road transport experienced greater viability
reductions after being stored for six days than an equivalent non-stored group[199, 295].
Coopman and Medcalf however do note that in these studies only culture medium rather
than a bespoke hyopthermic medium was used to store the cells and so vibration may be
alleviated by a tailored medium[52].
Another concern that could a↵ect both shipment and length of time exposed to toxic CPAs
(see Section 2.8.1) is particulate testing, as discussed by the ISCT in a paper by Clarke et
al [45] the processing of cellular products could cause unwanted particles to be present in
cryovials shipped to patients. These particulates could include plastic fibres, cell aggregates,
glass, rubber and so on. Clarke et al notes a number of concerns with particulate testing
including threshold of unacceptable particle size, whether or not particulates a↵ect patient
safety, how any testing should be regulated[45], Hourd et al [118] also note the need for
harmonisation of any particulate testing standards. The ultimate methods by which the
presence and nature of particulates is tested and regulated are beyond the scope of this thesis
but the possibility that any testing will increase the time between thawing and application to
patients is. As was previously noted in Section 2.8.1 cells are sensitive to the most commonly
used CPA, DMSO. Those developing techniques by which particulates are tested post thaw
should consider the e↵ect of toxic CPAs.
Ultimately, challenges remain in developing technologies and strategies to delivery cell thera-
pies to patients who could be thousands of miles from the production site. To get products to
patients or customers LN2 shippers exist, but this can be an expensive and di cult method
for shipment due to the size of these shippers. Often products are shipped with dry ice-
frozen CO2- which, if viable, keeps products at around -80°C. Sometimes, cool-packs are
used to chill products to around -20°C[300]. These strategies however are largely viable and
Review of the Literature 60
keep products at the temperatures needed for product viable[213] although regulatory guide-
lines make clear that temperatures should be constantly monitored for any deviation and
with issues like customs and price, perhaps a more e cient system less reliant on external
complications is required.
2.8.6 Variability
Considering just human mesenchymal stem cells, perhaps the most viable, clinically rele-
vant cell type substantial variance is observed from patient to patient and donor site to
donor site[6, 250]. This has serious ramifications for the parameters a↵ecting successful cell
preservation.
Literature which requires the use of cryopreservation, but does not focus on the specifics
of the process tend to use a cryomedium of 10%wt DMSO in serum e↵ectively with a slow
freezing system as a “one-size-fits-all” approach. Protocols for various cell types tend to have
specified growth medium formulations and it is therefore surprising that the same paradigm
does not apply to cryopreservation which as has been previously stated is a peripheral but
vital process in cell therapy commercialisation[220].
2.9 Bridging the gap between literature and the lab- What are
the core issues with the process of cryopreservation and
what can be done to improve them?
Cryopreservation is an imperfect process. It has several issues, which need attention as
cell therapies move towards commercialisation. These issues a↵ect the process parameters,
operator actions and ultimately patient safety. The purpose of this project is to explore a
number of these core issues and attempt to improve upon them. In several places in this
thesis the term “cell health” is used this takes into account a combination of cell viability,
proliferation, metabolism, identity and function. On thaw, in accordance with FDA release
criteria cellular products are required to have an on-thaw viability in excess of 70%[38] in
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literature this is occasionally referred to as recovery on thaw[123], the term “cell health” is
designed to expand and improve on this limited on-thaw measure. Alternatively the term
“cell quality” is used, similarly defined this term is a more nuanced definition of how cells
would perform as a transplanted clinical product. In the experimental chapters of this thesis
three of the issues mentioned above in Section 2.8 were tackled:
• Cryoprotectant Toxicity- This is a key focus of this thesis, as was explored in literature
in Section 2.8.1 and experimentally in Chapter 5, DMSO, the apparent “gold standard”
as discussed, is regarded as toxic to cells, and this is based upon time, temperature
and dosage basis.
• Xenological issues- FBS is an undefined solution, the batch to batch variation could be
harmful to culture processes[116] and regulators are keen to move away from animal
products as their could be unknown xeno-toxlogical issues. In Chapter 6 it is intended
that this be clarified and if needed a defined, non xeno-based alternative proposed.
• Thawing- Thawing is the crucial phase of cryopreservation in which cells are thawed
from cryogenic to biologically active temperatures. Protocols report using 37°C water
baths to thaw the vials at a rate of approximately 60°C/minute. For such an essential
process step, the un-definition is alarming. Some studies have explored basic param-
eters for human cells, including Mancias-Guerre et al who investigated the di↵erence
between wet and dry thawing, as wet thawing is considered unhygienic[169], but do
not fully clarify this important process step. The aim of Chapter 7 is to develop a
better understanding of thawing and improve clarification of the process.
The other issues- scale-up, shipment and variability should be the focus of further work (see
Section 8.3) as these, in the context of laboratory work cannot be controlled or investigated
to an appropriate standard.
Considering this review taken as a whole a series of research questions are proposed that this
thesis can answer.
• How does 10%wt DMSO in FBS fare as a cryopreservation medium?
Review of the Literature 62
• What a↵ect does standard cryopreservation have on cells?
• How long can cells be exposed to DMSO before detrimental a↵ects occur?
• Is there a viable alternative to FBS? If so, is it animal component free, more ethically
sound and not represent a significant investment?
• How can thawing be better defined? Can thawing processes be improved?
Chapter 3
Materials and Methods
3.1 Chemicals, Reagents, Consumables and Equipment
Water used for aqueous solutions, or other experimental purposes was filtered using a MilliQ
ultrafiltration unit (Millipore, UK). Sterilisation of equipment and materials was performed by
either filtration through a 0.22µm filter (Millipore, UK) or by autoclaving at 121°C for 30min
using a Systec VX-95 autoclave (Systec, Germany). A list of all equipment used for this
work is provided in Section 3.12. Unless otherwise noted all reagents were purchased from
Sigma-Aldrich, UK, and consumable equipment were purchased from Scientific Laboratory
Supplies (SLS), UK.
3.2 HOS TE85
3.2.1 Cell Culture and Passsaging
A human osteoblast/osteosarcoma immortalised line- HOS TE85[73]- was used. A vial had
been previously acquired from ATCC and grown up to MCB at passage 44 with 1x106 cells
preserved in 10%wt DMSO in FBS. This was then thawed according to the method given in
Section 3.7.3.
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After culturing for 48-72hrs in a humidified 37°C/5%CO2 incubator, HOS TE85 cells were
usually passaged at 80-90% confluence. Tissue flasks or well plates were removed from
the incubator and washed once with 0.2mL/cm2 PBS(Ca-,Mg-), they were then dosed with
0.04mL/cm2 w,5g/L Trypsin/0.2g/L EDTA (Ethylenediaminetetraacetic acid) and incubated
at 37°C for 3 minutes, and then gently tapped to detach cells.
The cell/trypsin suspension was diluted (1:3) with minimum essential medium (MEM)[69]
with Earl’s Balanced Salt Solution supplemented with 2%wt Non-Essential Amino Acids
(NEAA)[70], 10%wt FBS (South America) and 2mMol L-Glutamine.
Cell samples were taken for analysis, and the suspension was centrifuged at 220 x g for 5
minutes at room temperature, approximately 20 °C (see Appendix B). The supernatant was
aspirated and the cell pellet was then suspended in fresh MEM medium. A new vented-cap
tissue flask or welled-plate was then seeded with 2x104cells/cm2 and 0.2mL/cm2 of medium.
The cells then take 48-72 hours to reach confluence again. Table 3.1 below details various
seeding densities, medium and trypsin volumes used for various culture vessels.
Table 3.1: Volumes of reagents used in the culture of HOS TE85 cells
Culture Cell Culture Medium Trypsin-EDTA Target Cell
Vessel Area Volume Volume Seeding
6-Well Plate 10cm2 2mL 0.4ml 2x105
T25 25cm2 5mL 1ml 5x105
T75 75cm2 15mL 3ml 1.5x106
T175 175cm2 35mL 7ml 3.5x106
T875 (Multi-Flask) 875cm2 175mL 35ml 1x107
3.2.2 Alkaline Phosphatase Assay
An assay was utilised to allow a key phenotypic trait of HOS TE85 cells to be measured.
Osteoblastic cells should express alkaline phosphatase (ALP), and HOS TE85 cell quality
can be quantified by assessing cell ALP activity[48].
Materials and Methods 65
An assay with minor modifications from Sharp’s method [246] was employed, which is based
on the mechanism defined by by Bjerre et al and Modrovich [28, 191]. These assays were
used with hMSCs and as such optimised reduced cell density and incubation times were used.
Samples of HOS TE85 cells were acquired at a concentration of 2.5x106cells/mL in dH2O.
The cell suspension was then subjected to two freeze/thaw cycles in a -20°C freezer to fully
lyse the cells. 100µL samples of the cell lysate were loaded to a 48 well plate. To each well
300µL of a freshly made para-Nitrophenylphosphate (pNPP) working solution was added.
The working solution is made up of 5mg pNPP tablets (pNPP disodium salt hexahydrate) was
added to an aqueous solution of 2.2mMol MgCl2 and 16.7mMol 2-amino-2-methypropanol. 1
tablet is added to 5mL of bu↵er giving a final pNPP concentration ofg 1mg/ml (2.694mMol)
at a pH of 10.3.
The solution was then incubated for 60mins in the dark at room temperature. After incu-
bation 100µL of 3M sodium hydroxide was added to each well to quench enzymatic activity
thus stopping the reaction i.e. the production of p-nitrophenol (pNP) from pNPP.
100µL of the sample was then transferred to an individual well of a 96 well plate and then
spectrophotometrically analysed with a plate reader at 405nM absorbance. A standard curve
was prepared with 0-400µM pNP in the bu↵er, loaded in parallel to samples on the 96-well
plate. A representative standard curve is shown in Figure 3.1.
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Figure 3.1: Representative standard curve for alkaline phosphatase assay. Data are ab-
sorbance at 405nm plotted against know pNP concentration linear regression demonstrates
strong correlation.
3.3 hMSC
3.3.1 Donor Characteristics
Two human mesenchymal stem cell lines were used in these experiments. One cell line
was derived from fresh human bone marrow aspirate (Section 3.3.2) from a donor who had
provided informed consent (Lonza), this line was classified in-house as M7. A second cell line-
M4- was also used for validation experiments; these cells were initially extracted from bone
marrow by Lonza and shipped as P0 mono-nuclear cells. Additional donor characteristics
available are detailed below in Table 3.2.
3.3.2 Extraction from Processed Bone Marrow Aspirate
Chilled fresh bone marrow aspirate (supplemented with 5mMol EDTA) was first filtered with
a 100µm cell strainer to remove any bone fragments then split into two 50mL centrifuge
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Table 3.2: Human Mesenchymal Stem Cell Donor Characteristics based on information
available from vendor (Lonza)
Cell Line Age Biological Gender Race
M4 25 Female Hispanic
M7 21 Male Caucasian
tubes. The strainers and sample tubes are then washed with PBS.
The tubes were then centrifuged at 300 x g for 15 minutes. The plasma supernatant was
aspirated, with 1-2mL of plasma left on top of the bu↵y layer. Each tube of remaining
aspirate was then re-suspended up to 15mL in PBS and centrifuged again at 300 x g for a
further 15 minutes. The plasma layer removal/spinning/suspension was repeated until the
plasma layer was light pink to remove excess EDTA.
Once the plasma layer and excess EDTA was removed, the aspirate solution was topped up
to 30mL with warmed complete Dulbecco’s Modified Eagle’s Medium (DMEM)- (see Sec-
tion 3.3.3). The medium was further supplemented with 1%wt 5000U/mL Pen/Strep (Life
Technologies, UK) in order to deactivate any infectious contaminants potentially contained
in the primary sample.
The bone marrow/DMEM suspension was then seeded in appropriate culture vessels and
stored in a 37°C/5% CO2 humidifed incubator.
Every day for three days, then every third day, excess medium and residual blood was removed
by gentle aspiration followed by addition of 0.2mL/cm2 of supplemented DMEM[189].
3.3.3 Cell Culture and Passaging
hMSCs are an adherent cell type and so culture methods are similar to the previously de-
scribed HOS TE85 cells, di↵erences to Section 3.2.1 above are as follows. The medium used,
as described in 3.3.2, is DMEM (1g/L glucose)[252] supplemented with 10%wt FBS (United
States) and 2mMol Ultraglutamine. When passaging, trypsin/EDTA is again used in the
same volume (0.04mL/cm2) but the cells are left incubating for 4 minutes rather than 3 to
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detach the cells from the culture plastic. Centrifugation is at 220 x g for 5minutes. Cells were
seeded at 5000 cells/cm2 of culture plastic. The passage duration is 7 days (±2days) and a
100% media change occurs on the third day. All counting of hMSCs was performed using
the NucleoCounter® (see Sections 3.4.2 and 3.4.3), di↵erent culture doses are detailed in
Table 3.3.
Table 3.3: Volumes of reagents used in the culture of hMSCs
Culture Cell Culture Mediumi Trypsin-EDTA Max Cell
Vessel Area Volume Volume Seeding
6-Well Plate 10cm2 2mL 0.4ml 5x104
T25 25cm2 5mL 1ml 1.25x105
T75 75cm2 15mL 3ml 3.75x105
T175 175cm2 35mL 7ml 8.75x105
T875 (Multi-Flask) 875cm2 175mL 35ml 4.375x106
3.3.4 Di↵erentiation
Cells at 60-80% confluence in the mid-log growth phase were detached from cell culture
plastic. They were then seeded and treated in three di↵erent ways to assess the cells’ ability
to di↵erentiate into one of the three lineages characteristic of mesenchymal stem cells-
adipogenesis, chondrogenesis and osteogenesis. Sample images from a paper investigating
the scale-up of hMSCs by Rafiq et al [218] are shown in Figure 3.2. All di↵erentiation media
and supplements here were purchased from Life Technologies, UK.
3.3.4.1 Adipogenesis
Cells were seeded into a twelve well plate at 1x104cells/cm2. They were then incubated
for 24 hours in the supplemented DMEM-based growth medium defined above in Section
3.3.3. The medium was then replaced with pre-warmed (37 °C) adipogenesis di↵erentiation
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(a) Adipocytes (b) Chondrocytes (c) Osteocytes
Figure 3.2: Sample images of the di↵erentiation capacity of bone marrow derived human
mesenchymal stem cells [218] depicting (A) Adipogenic, (B) Chondrogenic and (C) Os-
teogenic di↵erentiation. Observed through a 10x objective lens.
medium made up of 9 parts StemPro® adipogenesis di↵erentiation basal medium and 1
part StemPro® adipogenesis Supplement. This medium was then replaced every 3 days.
After 14 days the medium was gently aspirated and the cells rinsed with PBS. The cells
were then fixed with 1mL of a 4%wt formaldehyde solution. An Oil Red O stain was then
made up of 3mg/mL Oil Red O powder in 99%wt isopropanol. This solution was then mixed
3:2 with distilled water and then incubated for 10 minutes, finally the solution was vacuum
filtered.
Wells were then washed with 2mL distilled water. 2mL of 60%wt isopropanol was then added
to each well and then allowed to rest for 5 minutes. The isopropanol was removed and 2mL
of the Oil Red O working solution was added to each well followed by 5minutes incubation
at room temperature.
The Oil Red O solution was then removed and the wells washed with distilled water. The
cells were left in distilled water and then observed under a light microscope. Oil Red O is a
neutral lipid-soluble dye- a lysochrome, and stains lipids and lipoproteins.
3.3.4.2 Chondrogenesis
Cells were first resuspended at a density of 1.6x107 cells/mL. 5µL droplets of this cell solu-
tion were then seeded into a twelve-well plate to form micro-mass cultures. After two hours
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incubation at 37°C and 5% CO2 the wells were carefully layered with 1mL of chondrogenesis
di↵erentiation medium, which is made up of 9 parts StemPro® osteocyte/chondrocyte dif-
ferentiation basal medium and 1 part StemPro® chondrogenesis supplement. This medium
was changed every 3 days.
After 14 days, the di↵erentiated chondrogenic masses were processed for alcian blue staining.
The medium was gently aspirated and the cells rinsed with PBS. They were then fixed with
4%wt paraformaldehyde solution for 30 minutes at room temperature. After fixation, the
cells were rinsed with PBS and then stained with 1%wt Alcian Blue solution in 0.1M HCl for
30 minutes. These wells were then rinsed three times with 0.1M HCl and then neutralised
with distilled water.
The cells were then observed with a light microscope under a 10x objective lens. Alcian Blue
is a polyvalent dye that stains acidic polysaccharides such as glycosaminoglycans (GAGs).
Proteoglycans which have GAG tails are an integral part of the ECM produced by chondro-
cytes.
3.3.4.3 Osteogenesis
Cells were seeded into a twelve-well plate at 5x103cells/cm2. The plates were then incubated
for 24 hours in the supplemented DMEM-based growth media defined above in Section 3.3.3.
The medium was then replaced with pre-warmed adipogenesis di↵erentiation medium made
up of 9 parts StemPro® osteocyte/chondrocyte di↵erentiation basal medium and 1 part
StemPro® osteogenesis supplement. This medium was changed every 3 days.
After 21 days the media was gently aspirated and the wells rinsed with PBS, the cells were
then fixed with 1mL of a 4%wt formaldehyde solution for five minutes. After fixation the
cells were rinsed with PBS and then stained with 1mL 2.5%wt silver nitrate solution for 30
minutes under UV at room temperature. The cells were then washed three times with distilled
water. The di↵erentiating osteocytes deposit calcium and under UV light conditions this is
replaced by silver, which is visualised as black metallic silver deposits under the microscope.
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4%wt Napthol AS-MX Phosphate Alkaline Solution was added to a pre-thawed fast violet
aliquot and protected from light. 1mL of this solution was added to each cell well. The
plate was then incubated for 45 minutes at room temperature in the dark. Following this
the cells are washed three times with distilled water and observed under a light microscope.
Proliferating osteoblasts show alkaline phosphatase (ALP) activity. This activity is greatly
enhanced during in vitro bone formation. The stains described here stains cells red when
AP is present.
3.3.5 hMSC Immunophenotype Marker Detection using Multi-Parameter
Flow Cytometry
Cells are suspended in supplemented DMEM at a density of 5x105/mL and 200µL of this
cell suspension was added to a well of a V bottomed 96-well plate. This was centrifuged at
300g for 5 minutes at room temperature, the supernatant was aspirated, and the cells were
suspended in 200µL of flow cytometry stain bu↵er (R& D Systems, UK). This was again
centrifuged, and the supernatant discarded.
5µL of each antibody was then added to the cell pellets, for gating purposes a well of non-
stained cells was loaded to the 96 well plate; for control purposes, a well of corresponding
isotypes was also created with cells. The antibodies used are shown below in Table 3.4.
Table 3.4: Antibody markers, their fluorescein and associated max emission wavelength for
the multi-parameter flow cytometry assay for determining phenotype of hMSCs
Fluorscein Target Surface Max Emission
Marker Antibody Wavelength
PE-Cy5 CD34 667nm
PE-Cy7 CD73 785nm
APC CD90 578nm
PE CD105 573nm
FITC HLA-DR 519nm
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The plate was then incubated at room temperature, in the dark for 30mins, before being
centrifuged, and washed twice. The samples were re-suspended once more with 200µL of
stain bu↵er and then analysed on the Guava easyCyte flow cytometer (EMD Millipore, UK)
which is equipped with 488nm and 640nm excitation lasers. A minimum of 10,000 events
were recorded for each sample within a gate for singlets based on forward/side scatter, an
example is shown in Figure 3.3. Compensation of spectral-overlap was performed using
anti-mouse Ig- as previously described by Chan et al [39].
Figure 3.3: Example gating for single cells for the hMSC immunophenotype assay.
A gating strategy was used to create 95% confidence levels based upon the isotype controls.
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3.3.6 Cell Culture with Human Platelet Lysate
For some experiments, media made up with hPL under the tradename “Stemulate” (Cook
Medical, USA) instead of FBS was used. Media composition was therefore DMEM, 1g/L
glucose supplemented with 5%wt Stemulate Human Platelet Lysate (No Heparin Required)
and 2mMol Ultraglutamine.
3.4 Cell Number and Viability
Cells in these experiments were counted with three methods, detailed below. A comparability
study, with cell lines HOS TE85 and hMSC-M7 is shown in appendix A
3.4.1 Haemocytometry for cell counting and Trypan Blue Exclusion Method
for viability determination
A 50µL sample of cell suspension was taken and diluted 1:1 with 0.4%wt Trypan Blue
and loaded onto a haemocytometer and observed microscopically with a phase contrast
microscope with a 10x objective lens. Cells are then counted and viability determined using
a methods described by Strober and Altman et al [9, 265]. Briefly, cells in four corner squares
are counted. Trypan blue positive cells are deemed non-viable, as their membrane integrity
has failed, and uptake trypan blue, whereas trypan blue negative cells are deemed viable.
The number of cells in a population was determined as follows:
⇢cell =
sv
4
⇥ 2⇥ 10000 (3.1)
Nc = ⇢cell ⇥ a (3.2)
Where:
• ⇢cell is the cell density (cells/mL)
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• sv is the total number of viable cells in all four squares (i.e. trypan blue negative)
• a is the volume of the culture (mL)
• Nc is the number of viable cells.
The cell population viability was determined as follows
V =
sv
sn + sv
(3.3)
Where:
• V is the population viability (%)
• sn is the total number of non-viable cells (i.e. trypan blue positive)
More details of these calculations are shown in Appendix C.1.1
3.4.2 NucleoCounter NC-100 for cell counting and viability determination
using propidium iodide
The NucleoCounter (ChemoMetec, Denmark) used propidium iodide and fluorescence to
count cells and assess viability. The method allowed for higher throughput than the previously
described haemocytometry method[245].
The NucleoCounter uses a disposable cassette which takes a 60µL sample and stains the
nuclei of lysed cells with propidium iodide (PI). The cells are then passed into a chamber
with known dimensions, exposed to green light at approximately 525nm which causes the
stained nuclei to fluoresce red (>635nm), which is then detected and counted. Two counts
are performed- one for non-viable cells, and another for all cells. These are carried out as
follows.
For the non-viable cells, a 150µL sample of cell suspension was taken, and analysed imme-
diately. Necrotic cells, late apoptotic cells or those with a disrupted membrane take up the
PI and the NucleoCounter then counts this.
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For viable cells, a 50µL sample of cell suspension was taken and then 50µL of reagent A-
PI and a lysis bu↵er, which disrupts cell membranes, stains them with PI, and disaggregates
cell clumps. The solution was then vortexed to mix before 50µL of reagent B is added.
Reagent B is a stabilising bu↵er to raise the pH to optimise the fluorescence and stabilise
the cells’ nuclei. This 150µL sample was then analysed through the NucleoCounter, this
gives a diluted density value of the total cells.
After these steps the two values can be used to calculate the density, cell number and viability
as follows.
Number of viable cells is calculated as follows:
⇢cell = ((Ct ⇥ 3)  Cn)) (3.4)
Nv = ⇢cell ⇥ a (3.5)
Where:
• ⇢cell is the cell density (cells/mL)
• Ct is the total concentration of cells as displayed from the second NucleoCounter test
(cells/mL)
• 3 is from the dilution of the cells with reagents A and B
• Cn is the concentration of non-viable cells (cells/mL)
• Nv is the total number of viable cells
• a is the total volume of cell suspension (mL)
Cell viability is calculated as follows:
Vc =
Ct.3  Cn
Ct.3
(3.6)
Where all values as above except:
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• Vc which is the cell viability (%)
3.4.3 NucleoCounter NC-3000 for cell counting and viability determination
using acridine orange and DAPI
The NC-3000 uses acridine orange (AO) in combination with 4’,6-diamidino-2-phenylindole
(DAPI) to assess cell number and viability. AO is used for total cell detection, and stains all
the cells’ DNA it is excited by light at 502nm emitting green light at 525nm. DAPI, however,
cannot permeate the cell membrane, hence only staining non-viable cells’ DNA, those with
a permeable membrane[173]. The DAPI is excited by ultraviolet light at 358nm and emits
at 461nm fluorescing as blue light.
To operate, as with the NC-100 method, a known volume of cell suspension sample is taken
prior to centrifugation. One of three consumables can then be used to assess cell viability.
These three consumables count the cells in fundamentally the same way.
• A Via-1 Cassette aspirates up the sample and then passes it through a flow path
containing DAPI and AO to stain the cells
• NC-2 and NC-8 slides require dosing first with 5%wt “Solution 13” (Chemometec,
Denmark), which is a water solution containing 30µg/mL AO and 100µg/mL DAPI,
it is additionally dosed with 0.01% Sodium Azide as a biocide.
3.5 Attachment E ciency
Elements of this assay were developed and validated under supervision by the author and in
collaboration with Rosie Jones
After seeding cells were assessed to determine their adherence to culture plastic. One (HOS
TE85 or three (hMSC) hours after seeding cells were enzymatically detached from the culture
plate or flask and then counted. The number of attached cells (Nca) is then compared to
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the known seeding value (Nc0) to determine attachment e ciency. This is calculated as
follows:
⌘a =
Nca
Nc0
(3.7)
3.6 Determining Cell Yield
After a defined period, cells were enzymatically detached from the culture surface and
counted. The value of cells after the defined period (Nct) is compared to known seeding
number (Nc0) to determine cell yield the following is calculated:
Yc =
Nct
Nc0
(3.8)
Where:
• Yc is the yield of cells (%)
• Nct is the total count of cells after the defined period
• Nc0 is the number of cells seeded (i.e. time=0)
Yield can alternatively be counted from the known viable attached cells after one hour. This
allows for determination of yield of viable cells rather than an estimation from seeded cells.
In this case, Nc0 is replaced with Nca determined after the attachment period.
3.7 Cryopreservation
Work described in the forthcoming experimental chapters are often based on changes to the
parameters in these protocols to investigate the cellular e↵ect. Base protocols follow.
Materials and Methods 78
3.7.1 Preservation
Cells were enzymatically detached and resuspended in a cryomedium made up of 10%wt
DMSO and 90%wt FBS. Usually cells were seeded at 1x106 per vial with 1mL of freeze
media.
The filled vials were transferred to a “Mr Frosty” container (Nalgene) filled with IPA, or a
CoolCell (BioScion), which uses alloys to control the cooling rate. The “Mr Frosty”/CoolCell
was cooled in an -80°C freeezr which cools the enviroment the vials reside in at 1°C/minute.
After >4 hours to ensure stable temperature, the vials were transferred to the vapour phase
of a liquid nitrogen cooled cryostore.
3.7.2 Storage
Cells were stored in the vapour phase of a cryostore (Statebourne Cryogenics BioRack 750).
It was always ensured that the cryostore is kept closed with a soft-top lid to prevent the build
up of pressure. The cryostore was only opened to remove cell vials for culture, or to refill
the cryostore with liquid Nitrogen (BOC, UK). The cryostore has a temperature sensor such
that it can be constantly externally monitored, and is topped up with LN2 twice weekly.
So long as there was an appropriate amount of LN2 in the cryostores, cells were preserved
at cryogenic temperatures (<-150°C).
3.7.3 Thawing
Vials are located in the cryostore and quickly taken out and put into a waterbath at 37°C such
that the vial lid was not submerged. It was then left there to thaw. This was usually done
until a ‘trace’ of ice remains- this takes around 3-5 minutes- a thawing rate of approximately
37-63°C/minute.
The freeze medium/cell suspension was diluted 1:1 with prewarmed (37°C) medium in the
cryovial, and then this solution was transferred to a tube with more medium for a final
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cell/CPA suspension-fresh medium ratio of 1:3. The cell suspension was then analysed for
post-thaw viability, centrifuged and seeded to tissue flasks as needed.
3.7.4 Preservation in CellSeal Vials
For certain experiments, vials produced by Cook Medical (USA) were used. These are
hermetically sealed cryovials designed to maintain container closure integrity during use.
Figure 3.4 is a labelled image of the CellSeal vial. To add cells in to the vial, instead of a
pipette being used (as defined in Section 3.7.1) a Luer lock syringe was used to transfer the
fluid in. An RF welder heat sealing device was then used to seal air vent and fill port tubes
before cooling begins. Any additional tubing was trimmed to allow for cryostorage[186, 306].
Figure 3.4: 5mL CellSeal Vial diagram demonstrating key features and functions [306].
On thaw, vials were thawed as normal (Section 3.7.3), to retrieve cells an 18G needle was
inserted into the septum at the bottom at a 45°-60°angle. Recovery from thaw then continues
as described in Section 3.7.3.
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3.7.5 Preservation with Pseudolyte A
For certain experiments it was intended to use Plasmalyte A as a component in a cryomedium.
Unfortunately due to legal restrictions this was unable to be shipped to the UK from American
suppliers and so was made up according to a protocol described by a manufacturer[202]. The
solution is made up as follows: 100mL contains 526mg of Sodium Chloride, 502mg of Sodium
Gluconate, 368mg of Sodium Acetate Trihydrate, 37mg of Potassium Chloride and 30mg of
Magnesium Chloride. Its pH is 7.4. As this is not true Plasmalyte A it was therefore defined
as Pseudolyte A.
3.8 Metabolite Analysis
Analysis of cell metabolite concentration in medium was determined using a bioanalyser
(Nova Biomedical BioProfile FLEX) which uses electrochemistry to determine the presence
of metabolites in media. 1mL medium samples (from feed and passage) are used to analyse
glucose uptake, lactate and ammonium production. Additionally 1mL fresh medium samples
are also assessed to normalise- normal medium composition is ⇡0.9g/L glucose, ⇡0g/L
lactate ⇡0.12mMol/L ammonium.
The bioanalyser using enzyme based bio-sensors compared the readings of the various metabo-
lites to known standards to give a concentration of the metabolite in the medium. These
readings were then converted from concentration (g/L for glucose and lactate, mMol/L for
ammonium) to a per cell value. This was calculated as follows. First to calculate the glucose
taken up, the concentration in fresh media was first must be subtracted from that in the
fresh medium. For ammonium and lactate, any present in the fresh media, determined from
the control, was first subtracted from the concentration in the spent medium. The change in
glucose and lactate concentration was changed to per cell per day consumption/production
as follows:
Mcell =
Cm
103
⇢cell
.1012
Mr
÷ Tc (3.9)
Materials and Methods 81
Where:
• Mcell is the metabolite concentration per cell (pMol/cell.day)
• Cm is the change in metabolite concentrations, either glucose or lacate (g/L)
• 103 this is to convert the concentration to g/mL
• ⇢cell is the cell density (cells/mL)
• 1012 this is to convert to g/pL
• Mr is the relative molecular mass (g/mol) in the case of glucose, this is 180.16 g/mol,
for lactate it is 90.08g/mol
• Tc is the duration of the culture (days)
Ammonium was calculated by the bioanalyser in mMol/L and therefore was calculated on a
per/cell basis as follows:
Acell =
Cap
103
⇢cell
109 ÷ Tc (3.10)
Where symbols are as before, except
• Acell is the ammonium production per cell (nMol/cell)
3.9 Detection of Early Stage Apoptosis using the Annexin V-
Propidum Iodide Flow Cytometry Assay
The protocol used was adapted from a 2011 protocol by Rieger et al [225]. It uses annexin-V
(AV) to determine apoptosis and PI to determine viability with respect to membrane integrity.
The modifications from the Rieger protocol are as follows:
• Unfixed cells were centrifuged for 5 minutes at 200 x g
• Paraformaldehyde fixed cells were centrifuged for 5 minutes at 500 x g
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• 5µL of PI solution instead of 4µL at the same concentration, as 4µL did not produce
an acceptable signal for analysis
Cells were suspended initially in PBS as directed by the protocol. Approximately 2x106 cells
were used per sample. Four controls were also run at each experiment: Untreated- no stain
control, PI only control, AV only control and AV-PI stained control.
This allowed for the flow cytometry method to be properly set up, including gating and gain
settings on the Beckman-Coulter Quanta. The gates and gain settings were set using the
unstained cells such that 95% of cells appeared in the 1st log decade, the cells were gated
for singles using front and side scatter. The flow rate was set to 100 cells/second and at
least 5000 events were analysed.
Two further controls were analysed, two wells were treated as follows:
• Apoptosis was artificially induced with staurosporine (20nMol in 2mL culture medium
for 3 hours at 37°C)
• Necrosis was induced with hydrogen peroxide (1µL of 3%wt H2O2 in 2mL culture
medium for 3 hours at 37°C)
3.10 Kynurenine Assay
To quantify an element of cells’ inflammatory function an assay which determines the level
of IDO activity was utilised. The below method is based on an established method from
Takikawa et al [271].
On the third day of a passage cycle when hMSCs medium is exchanged, the cells are fed with
a medium supplemented with additional components to promote the hMSCs inflammatory
mechanisms. The medium is treated with 10ng/mL of Tumour Necrosis Factor-↵ (TNF-↵)
and Interferon-  (IFN- ) (Life Technologies, UK). Over the next four days of the passage
medium supernatant samples were taken and frozen at -20°C.
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The samples were thawed in a 37°C water bath and 150µL of the supernatant was mixed
with 50µL of 30%wt trichloracetic acid (TCA) and incubated for 15 minutes at 50°C, this
precipitated the protein in the medium aspirate. Fresh medium and water samples are treated
in the same way to normalise the spectrophotometric analysis and act as controls.
These samples were then centrifuged for 5 minutes at 10,000 x g to hydrolyse the N-
formylkynurenine to kynurenine. In a 96 well plate, 75µL of the medium/TCA solution
is then mixed with 75µL freshly made Ehrlich’s reagent (1%wt p-dimethylbenzaldehydeine
in glacial acetic acid).
Absorbance was then read at 492nm on the platereader. To determine the amount of
kynurenine in samples, a standard curve in the range 0-100µL kynurenine standard was
included in each 96-well plate. A sample curve is shown in Figure 3.5.
Figure 3.5: Sample standard curve for kynurenine assay. Data are absorbance at 492nm
plotted against know kynurenine concentration linear regression demonstrates strong corre-
lation.
3.11 Statistics and Calculations
• Statistical tests were performed with SPSS for Windows, v22 (IBM).
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• Where two experimental mean population estimates were compared, t-tests were
used[288].
• Three or more mean population estimates were analysed with a One-way Analysis of
Variance (ANOVA) test, followed by one of two post-hoc tests[288].
– Dunnett’s test is used to compare experiment points to a control.
– Tukey’s test is used to compare experimental points with each other.
• Unless noted, data are expressed graphically as the arithmetic mean of sample values
with error bars representing ± one standard deviation of the mean.
• Ranges (X±Y) are displayed as the mean ± 95% confidence interval based upon the
normal distribution.
• Sample calculations for all measures determined from raw data are displayed in Ap-
pendix C.
3.12 Equipment Suppliers
• Beckman Coulter Inc, UK
– Quanta SC Flow Cytometer
• BioTEK, USA
– ELx800 Plate Reader
• BioCision, USA
– CoolCell
– CoolCell FTS-30
• Chemometec, Denmark
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– NucleoCounter NC-100 automated mammalian cell counter
– ucleoCounter NC-3000 automated cell analysis system
• Eppendorf, UK
– Eppendorf 5804 Centrifuge
• Grant Instruments, UK
– Sub Aqua Pro 2 2L Heated Waterbath
• Merck Millipore, Germany
– guava easyCyte 8HT Benchtop Flow Cytometer
• Nikon Instruments, UK
– Nikon TS-100 inverted microscope
• Nova Biomedical, USA
– BioProfile FLEX Bioanalyser
• Stateborne Cryogenics, UK
– Biorack 750 Cryostore
• Thermo Fisher Scientific UK
– Herasafe KS Class II Biosafety Cabinet
– Heraeus HERAcell 150 CO2 Incubator
– Fisherbrand 18L Heated Waterbath
– Fisher Scientific Revco Elite PLUS -80°C Freezer
Chapter 4
Benchmarking Standard
Cryopreservation Medium
Formulation
Cryopreservation has existed as a process for over half a century. As previously discussed
in Chapter 2, this allows for large numbers of cells to be banked, and kept in storage
theoretically ad infinitum to be thawed as and when they are needed- in practice cells have
been shown to be viable when preserved for at least 40 years[268]. A primary benefit of
this is to decouple production from delivery, but also cells can be stockpiled in banks for
research and clinical purposes. Numerous CPAs and devices have been proposed to improve
cell viability and health on thaw. One process however has become an accepted standard
used widely across the world for numerous cell lines and applications. Cells are preserved in
a cryomedium made up of 10%wt DMSO in FBS.This cell suspension is then slow-frozen
at -1°C/minute to -80°C before transfer to a cryostore preserving the cells in the vapour
phase of liquid nitrogen. After the period of preservation, cryovials are then rapidly thawed
in a 37°C waterbath- approximately 50°C/min, quenched in fresh medium before continuing
culture. This chapter focuses on benchmarking the e cacy of the standard cryopreservation
medium formulation, and what long term e↵ect it has on cells.
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The purpose of this chapter is to introduce the two key cell lines used in this body of
work and to benchmark the e cacy of the most widely used cryoprotective agent, DMSO,
within a standard preservation process. First, varying concentrations of DMSO (0-10%wt)
were assessed for their e cacy in preserving HOS TE85 cells, then 8 di↵erent cryomedia were
investigated- including two DMSO concentrations and two commercial cryoprotectants. The
four best cryoprotectants- as defined by cell viability, attachment and growth over 24hrs-
were subsequently used to preserve cells which were then thawed and cultured for ten serial
passages to determine what sort of long term e↵ect- if any- di↵ering cryomedia have on cell
proliferation and metabolic activity.
HOS TE85 cells were chosen as a model cell line for initial experimentation. They are sarcoma
osteoblast-like cells first isolated in 1975 from a 13year female Caucasian[73]. Whilst these
cells are not strictly medically relevant like mesenchymal stem cells, they are demonstrably
human diploid cells and therefore a much better model for examining process parameters
related to more relevant phenotypes as compared to CHO cells or Zebrafish (Danio rerio)
cells. Additionally, as sarcoma cells, they grow quickly, with stable, robust and most impor-
tantly consistent cultures as they have been immortalised. Consistent growth allows for low
noise from input cultures allowing proper estimates of variable e↵ects caused by cryopreser-
vation. Non-sarcoma osteoblasts are bone progenitor cells they help create the mineralised
bone matrix that forms the skeleton, along with osteoclasts who remove this[8]. The cell
line used in these experiments- HOS TE85 are immortalised, that is to say they will prolif-
erate indefinitely- useful for cell culture research purposes. This immortalisation is because
the cells are cancerous- known as osteosarcoma cells and e↵ectively acts like an untreated
tumour. Whilst this clearly has research benefits, it does raise a series of questions as to
whether they are a good model of real osteoblasts. Clover and Gowen found in a 1994
study that HOS TE85 cells alkaline-phosphatase activity- an important marker of osteoblast
phenotype- is approximately one third of primary osteoblasts[48, 262], this still allows for
quantitative conclusions to be made on the cellular phenotype.
The final phase of this chapter details a baseline characterisation of an hMSC line isolated
from the fresh bone marrow aspirate of a 21 year old male Caucasian. The characterisation
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is followed by a comparison to a frozen group of the same line and the previously analysed
HOS TE85 cells. By comparing fresh hMSCs to frozen hMSCs, changes- if any- caused by
cryopreservation could be assessed. Mesenchymal stem cells, as has been shown (Section
2.6.1) are perhaps the most therapeutically relevant cell line in the burgeoning regenerative
medicine industry, with over 75% of registered trials using them [187], although interna-
tionally only two products based on hMSCs have gained regulatory approval: Prochymal
(Mesoblast Ltd.) and ChondroCelect (TiGenix). The limited information available shows
however that these two products used di↵erent cryopreservation media [33, 259].
4.1 Initial Cell Line and Standard Protocol Characterisation
Cryopreservation experiments have been performed on a wide range of mammalian and
non-mammalian cells in an e↵ort to understand the fundamentals of cryopreservation, from
this understanding of human cell cryopreservation is improved. Often these experiments
have been for the purposes of reproductive medicine; sperm cells and oocytes. To model
diploid cells, other experiments have used various phenotypes from other species, for example
non-mammalian species such as Danio rerio, the zebrafish are used, others use genetically
modified CHO cells, or nude, immune inhibited mice. As previously mentioned 10%wt DMSO
in FBS is the mostly widely used cryomedium formulation.
In this Section, 4.1, the HOS TE85 cell line is characterised for future experimental pur-
poses. The characterisation here is important to be sure of any e↵ect that cryopreservation
experiments have on the cell population. Growth, viability, phenotype and metabolism was
determined.
The second phase of this section is to assess the e cacy of 10%wt DMSO as compared
to lower concentrations- 1-9%wt. The hypothesis here is that at lower concentrations, cell
health i.e. viability on thaw and over the first stages of post-cryopreservation in vitro culture
is severely damaged.
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4.1.1 Overview of Experimental Procedure
A frozen vial of HOS TE85 cells was acquired at Passage 44. This was thawed (Section
3.7.3) and immediately cultured for three stabilisation passages (Section 3.2.1). At passage
48, the cells were cultured for a further 5 passages in three separate flasks and assessed
at passage for cell number and viability (Section 3.4.1) and samples taken for metabolic
analysis (Section 3.8). At passage 53, a sample was taken to investigate baseline alkaline
phosphatase activity (Section 3.2.2) and six identical flasks seeded. At 24hr time points,
two were sacrificed and assessed for growth and viability to determine the growth pattern
over one passage.
Figure 4.1: Overview of Cell Line and Protocol Characterisation and DMSO Concentration
experiment
4.1.2 Cell Line Characteristics
Figure 4.2a shows that the average fold expansion rate that the HOS TE85 cells grew at
is 2.00±0.09/day, indicating a doubling time of 24hrs, within the expected range of HOS
TE85s. The average proportion of cells with integral membranes over the five passages
was 97.6±1.2%, this was regarded as viability and shows the culture is healthy. The data
expressed in Figure 4.2a was derived from five serial passages after three stabilisation passages
post-thaw, hence the start point being day 9.
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(a)
(b)
Figure 4.2: (A) Serial growth and viability of HOS TE85 cells in stable culture over five
serial passages. (B) Daily growth and viability over one passage (3 days) of HOS TE85
cells. Data are the average of two measurements from three experimental replicates. Error
bars are ±SD
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After the fifth serial passage, six identically treated T25s were seeded with the appropriate
number of cells. At 24, 48 and 72hr, two of these flasks were sacrificed and assessed for
viability and growth to allow the growth curve over one passage to be determined. Growth for
these HOS TE85 cells is not linear, Figure 4.2b shows that growth is not evenly distributed
across the passage in fact on day one 17% of the total growth occurs, a further 30% on day
two and 53% on the final third day. For the first 24 hours of stable culture, cells are in the
lag phase, followed by the exponential phase of rapid growth.
Cell viability and growth are good measures of cell health, but do not tell the full story, to
determine the true quality of the cells, phenotype and metabolism was determined.
Cell metabolic activity was determined using the Nova bioanlyser using the method described
in Section 3.8. Glucose was taken up by cells and converted to pyruvate, a process called
Glycolysis, the energy released here was used to produce ATP: the important coenzyme that
carries energy throughout cells[131]. Glycloysis is regarded as one of the more “ancient”
metabolic pathways due to its wide occurrence in almost all living beings[231]. As shown in
Figure 4.3, one of the byproducts of the conversion to pyruvate was lactate, the concentra-
tion of this and remaining glucose in the medium was measured by the Nova bioanalyser.
Analysing spent medium samples showed that over the five baseline passages, individual
cells were found to have taken up an average 2.25±0.27pMol/cell.day glucose and caused a
change in lactate concentration in the medium of on average 3.96±0.47pMol/cell.day lac-
tate. This then produced an average yield of 1.78±0.26mol/mol of lactate from glucose,
below the theoretical maximum yield of 2mol/mol, which is expected of a stable culture as
shown in Figure 4.4[92].
Phenotype was determined after five serial passages. ALP activity is a key part of the HOS
TE85 cells’ phenotype. ALP activity was determined using an assay by which determine the
conversion of para-nitrophenylphosphate (pNPP), which is colourless, to para-nitrophenol
(pNP), which is coloured green/yellow. This conversion was deemed proportional to alkaline
phosphatase activity. ALP activity is indicatory of cells ability to aid the creation of miner-
alised bone tissue as it increases the local concentration of inorganic phosphate and decreases
the concentration of extracellular pyrophosphate, which is an inhibitor of mineralization[94].
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Figure 4.3: Schematic of selected cellular metabolic pathways [113]
It was found that average alkaline phosphatase activity was 1.658±0.09nMol/cell/hour.
Clover and Gowen[48] noted that the HOS TE85 line does exhibit less ALP activity than
would be normally expected in non-sarcoma osteoblasts, but this level is similar to that
observed by Bjerre et al [28].
4.1.3 DMSO Concentration
Vials preserved in 0-10%wt DMSO in FBS were rapidly thawed and then immediately assessed
for cell number and viability, this is shown in Figure 4.5a. Cells preserved in 3-10%wt DMSO
achieved high, statistically similar viabilities on thaw, on average 96.5%. Complete cell death
is observed when no DMSO (100% FBS) is used to cryopreserve cells. The 0%wt, 1%wt and
2%wt DMSO groups were statistically di↵erent (p<0.0001) indicating that the reduction in
viability is unlikely to have been caused by experimental noise, and highly likely to have been
caused by damage from freezing. No attempt was made to seed cells from the vials with cell
material preserved in 100% FBS (0%wt DMSO. Observing this suspension microscopically
showed only cell debris, therefore no further investigation could occur on this cell group.
Figure 4.5b demonstrates that attachment e ciency presents more information about cell
health (defined in Section 2.8) after thaw. Any damage to cells caused by the freezing,
storage and thawing processes may not have caused cell membrane integral failure, indicating
cell death at the point of the earlier viability assessment. Adherence is key to this cellular
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(a)
(b)
Figure 4.4: (A) Glucose Uptake and Lactate Production and (B) Yield of Lactate from
Glucose of HOS TE85 cells over five serial passages. Data are the average of duplicate
measurements from three experimental replicates. Error bars are ±SD
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growth and so is a more robust measure of population health. In the stable HOS TE85
cultures observed in this study, attachment after passage is usually greater than 85%. Cells
preserved in 5-10%wt DMSO form a statistically similar homogeneous subset averaging
77.1%. In the case of attachment it was DMSO concentrations of 4%wt and below that
showed a significant reduction in this measure. The lowest observed attachment e ciency
was with cells earlier preserved in 2%wt DMSO at 28.5±4.4%, cells preserved in 1 and
3%wt/ DMSO were statistically similar to this measure.
The highest 24 hour yield, displayed in Figure 4.5c is observed in cells preserved in 9%wt
DMSO at 171.5±7.4%, this value statistically similar to cells preserved in 7-10%wt DMSO.
The lowest observed yield was with cells preserved in 1%wt DMSO at 59.5±6.8% however
when this is reassessed based on the attachment data- that is to say compared with viable,
attached cells 1hr after seeding- a yield of 133.1±15.2% is seen. This indicates a reduced
growth rate, as cells preserved in 10%wt DMSO yielded 221.4±16.5% compared to the
attached cells of this group.
Looking at all three measures herein investigated, it was shown that overall, 7-9%wt DMSO
allows cells to recover in a way that is statistically similar to 10%wt DMSO. If only viability
had been investigated, it would just be 1%wt and 2%wt concentrations that were regarded
as statistically di↵erent.
As was expected, cells preserved in 100%wt FBS did not recover on thaw and so the powerful
cryopreservative e↵ects of DMSO are clear when even cells preserved in concentrations as
low as 1%wt recover to viabilities close to that of the FDA’s guideline threshold of 70% for
approved cell therapies [38]. However, the other metrics studies show the limited e↵ectiveness
of the often used on-thaw-viability as an accurate measure for cell health given the significant
di↵erences in the later observed attachment and yield values.
Despite the observation that statistically cells preserved with 7%wt DMSO recovered simi-
larly to those preserved with 10%wt DMSO, all further experiments will continue to inves-
tigate the standard formulation. The vast majority of literature is based upon cryomedia
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(a)
(b)
(c)
Figure 4.5: (A) On thaw viability, (B) One hour attachment and (C) 24hour yield of HOS
TE85 cells cryopreserved in 0-10%wt DMSO with FBS. Data are the mean of duplicate
measurements from three independent experiments. Error bars are ±SD. *, ** and ***
represent statistically similar homogenous subsets (p<0.05).
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with concentrations of 10%wt DMSO and to ensure comparability with other studies this
concentration has been used for all forthcoming experiments.
4.2 Cryoprotectant Screening
There are dozens of chemicals used as cryoprotective agents across the life science field, a
number of these were discussed in Section 2.7. Some are used purely in conjunction with
a vehicle solution, others in a blend. As has been previously mentioned the mostly widely
used for mammalian cells is 10%wt DMSO most commonly with Foetal Bovine Serum. This
mixture has been shown to be e cacious with numerous cell lines[18, 103, 121, 315] in
several contexts such as cell banking and shipment (this was also shown in the earlier study
in Section 4.1.3). This however begs the question, how e cient is it compared to various
other CPAs? As was previously argued in Chapter 2 the scientific community understands
issues with using both DMSO and FBS in cryopreservation, and so commercial alternatives to
both exist. This experiment aimed to investigate a wide range of cryoprotective agents and
compare them to the standard formulation and find their e cacy, if there are any candidates
for a better CPA and how commercially developed blends fare in comparison to the standard
formulation.
4.2.1 Overview of Experimental Procedure
Cells from a stable HOS TE85 line culture (Section 3.2.1) were cryopreserved at 1x106cells/mL
(Section 3.7.1). A wide range of CPAs were used usually with FBS as the vehicle solution:
two concentrations of DMSO (5%wt and 10%wt), along with glycerol, PrOH, maltose and
ectoine, all at 10%wt. Finally, two commercial complete cryomedia were investigated: PAA’s
CryoMaxx NT and TNCBio’s XerumFreeZ.
Glycerol and PrOH are widely used cryoprotectants in other sectors of life sciences, such as
for bacteria and sperm preservation, and have additional benefits such as biocompatibility,
as was shown in Section 2.3 glycerol and similar compounds are used by animals such as the
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larvae of the wooly bear moth to aid survival in cold climates. Maltose is a sugar and sugars
have shown some promise as cryoprotectants[85]. Ectoine is a compound found in several
bacterial species. It was investigated as a cryoprotectant as a known function is the ability
to help organisms survive osmotic stress- such as in cryopreservation[98]. CryoMaxx and
XerumFreeZ were investigated as they are commercial blends, and their e cacy promoted by
their respective companies. CryoMaxx NT is both DMSO and serum free, and XerumFreeZ
uses 10%wt DMSO in combination with a proprietary animal component-free vehicle solution.
No further details are available on the formulation of these solutions.
After suspension in one of the eight cryomedia the cells were then passively frozen and stored
in liquid nitrogen for one week before thawing and resuscitation. (Sections 3.7.2 and 3.7.3)
On thaw, cells were analysed for viability using the haemocytometry method (Section 3.4.1).
Cells were then cultured in six well plates. 1hr after seeding, attachment e ciency was
determined (Section 3.5). After 24 hours, the cell yield was determined (Section 3.6) and
images captured to assess morphology. Samples were also taken to determine any changes
in cell phenotype by assessing alkaline-phosphatase activity (Section 3.2.2).
Cells were frozen in the di↵erent cryoprotectants in triplicate, and each measurement was
completed in duplicate.
Figure 4.6: Overview of CPA screen experiment
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4.2.2 On Thaw Viability
After removal from cryostorage and warming, cells were quickly assessed for viability on
thaw by means of assessing membrane integrity. Cells had been previously cryopreserved at
1x106cells/mL in cryomedia made up of 10%wt CPA and 90% FBS (5%wt/95%wt in the
case of 5%wt DMSO), as shown in Figure 4.7a. The maximum observed viability was from
10%wt DMSO at 96.1±0.7%. The lowest observed viability on thaw was with ectoine at
51.8±5.5%. Cell viability (i.e. membrane integrity) was most compromised when ectoine
and maltose were used as CPAs. The on thaw viabilities for cells preserved with ectoine and
maltose were lower than the FDA’s recommended threshold of 70% for cell therapeutics[38].
Further, the PrOH preserved population’s viability 95% confidence interval (72.7±3.1%)
shows that there is a high probability that using this CPA would cause population damage
below that of the minimum acceptable viability for release by the FDA. The impact of this
has not been fully assessed. For an allogeneic therapy where a bank from a single donor
is developed this average population viability close to the 70% threshold would prevent
acceptable delivery, but for an autologous product there would be some process uncertainty
with some patients’ dose being above the viability threshold and some below.
One reason for the lower viabilities observed on thaw for maltose and ectoine is perhaps
due to the size of the molecules. Maltose has a molar mass of 342.30g/mol, and ectoine,
142.16g/mol compared to 78.13/g/mol, 92.09g/mol, and 76.09g/mol for DMSO, glycerol
and PrOH respectively. The larger size could cause di culties permeating the cells’ mem-
branes, and it is well known that non-permeating cryoprotectants are less e↵ective than
permeating molecules[184]. However, the population investigated here is too small- and bi-
ased towards possible successful CPAs to determine whether or not there is a limit or a trend
for the molecular size/e cacy relationship. Sugars like maltose which were mentioned in
Section 2.7.4 have shown e cacy as cryoprotectants[85], but require either longer equilibra-
tion periods to allow the molecules to cross the cell membrane or additional components to
facilitate this, for example amphipathic polymers allowing transition of the sugar Trehalose
across the cell membrane [217, 246]
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(b)
Figure 4.7: (A) Viability on thaw and (B) 1 hour attachment e ciency of HOS TE85
cells preserved in 8 di↵erent cryoprotective agents. Data are the average of duplicate
measurements from three independent experiments. Error bars represent ± SD. * represents
statistically significant di↵erence from the control, DMSO 10% (p<0.05).
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The populations preserved in commercial cryomedia revived at 94.1±1.1% and 89.1±3.7%-
CryoMaxx and XerumFreeZ similar to that of the 10%wt DMSO standard. CryoMaxx is
DMSO free, and whilst it does provide similar viability on thaw to DMSO, its e cacy as
compared to DMSO should not be defined until other metrics have been analysed.
Viability was measured immediately on thaw, inferring that it was the actual process of
cryopreservation rather than complications post-thaw that caused the damage and death to
the cells. This death caused by means of physical injury from ice crystals that the CPA was
unable to prevent, is the main cause of death in cells from cryopreservation[77, 180, 183],
this was previously discussed in Section 2.2.1. Osmotic or cytotoxic complications would
cause the cell damage after seeding and a↵ect the cells attachment e ciency, as discussed
in Section 4.2.3 below.
4.2.3 Attachment E ciency
One hour after seeding the cell populations were assessed for attachment e ciency. Attach-
ment e ciency data are shown in Figure 4.7b and as shown cells exposed to either 5%wt
(80.9±14.7%) or 10%wt (82.9±8.4%) retained the ability to attach.
The cell populations with the poorest attachments were previously preserved with maltose
(18.2±6.2%) and ectoine (9.1±2.1%). Low attachment indicates severe damage to the cells
during freezing and thawing. Cells preserved with ectoine and maltose had substantially
lower attachment compared to the on-thaw viability than the other populations. Cells with
intact membranes on thaw are ultimately becoming non-viable after on hour. These discrep-
ancies between perceived viability and actual viability (i.e. on-thaw viability vs. attachment
e ciency) could be caused by solute toxicity, or pH excursion not causing membrane damage
and eventually apoptosis or necrosis in the period of approximately five minutes between thaw
and measurement, but ultimately killing the cells in the hour after seeding. This di↵erence
is important as it shows a need to develop improved release criteria for cell therapeutics.
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Attachment of cells preserved in the commercial cryomedia was moderately successful: Cry-
oMaxx at 77.9±5.6% and XerumFreeZ at 52.5±10.0%. The CryoMaxx result was statisti-
cally similar to DMSO 10%wt in FBS indicating that a proprietary blend absent of DMSO
has been developed with similar e cacy on thaw to the standard formulation. The impor-
tance of the vehicle solution is indicated by the significantly lower attachment e ciency
observed in the XerumFreeZ preserved cells, this cryomedium does contain 10%wt DMSO
but a synthetic vehicle solution. A lower number of cells attaching could have been caused
by the cells being starved of nutrients that are present in the FBS during the cryopreservation
process[116]. Some of the cell population appears viable with intact membranes but due to
damage caused by cryopreservation are then unable to attach and proliferate after one hour
in normal culture conditions.
4.2.4 24 Hour Yield
After 24 hours in culture, a population of HOS TE85 cells would be expected to double in
number approximately once- 2.00±0.09 fold expansions/day; this was previously shown in
Section 4.1.2. The yield of cells after 24 hours can be determined in two di↵erent ways.
Absolute yield is calculated by comparing the cell number after 24 hours to the initial seeding
number 200,000 in the case of six-well plates. Alternatively the yield can be calculated using
the previously determined number of attached cells and as such the yield from the viable
population and whether or not these cells proliferate.
For yield based on the initial seeding number, similar trends were observed (Figure 4.8a)
to on thaw viability and attachment. The lowest yield was observed in cells preserved in
ectoine at 11.2±2.1%, with 10%wt DMSO the highest at 172±35.3%. The DMSO 10%wt
yield is equivalent to 1.72 fold expansions per day, indicating that even with this good
cryopreservation method, cell growth was slowed immediately post thaw or there was cell
death in tandem with proliferation giving a lower apparent value for fold expansion.
When however, the yield is calculated based on the cells that had attached, it can be seen
how much damage cryopreservation did to cells in the presence of maltose and ectoine. The
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yield from the cells viable enough to attach after thaw was just 119.2±21.6% for maltose and
122.9±17.4% for ectoine. The yields from the cells preserved in DMSO, Glycerol, PrOH and
XerumFreeZ ranged from 170.7% to 253.8%. The XerumFreeZ value was higher than what
would be expected after 24 hours in a normal culture- 235% although the non-significant
increase is likely due to seeding variation or method variability rather than any cellular e↵ects.
The two measures of yield allow for di↵ering interpretations of the data. One is interesting
from a process perspective, i.e. during manufacture, on-line cell counting would be di cult
and so predictions of yield can only be made from known seeding numbers. Nevertheless,
the yield-from-attached value is interesting from a biological perspective. For example the
Ectoine preserved cells had a yield-from-seeding of 11.2%, and then a yield-from-attached
of 122.9% (based on an earlier attachment value of 9.1%). This shows that despite some
cells attaching, they grow less e ciently than would otherwise be expected.
4.2.5 Phenotype
After 24 hours in culture, harvested cells were analysed for alkaline phosphatase activity
(Section 3.2.2). The earlier baseline control (Section 4.1.2) showed that HOS TE85 from
the pre-freeze culture were expected to have an ALP activity of 1.66±0.09pMol/cell.hour.
Any reduction in this activity was regarded as a detrimental change in the cells’ phenotype
with respect to function. Reduction in ALP expression was regarded as undesirable as ALP is
partly responsible for bone growth, this being lowered would prevent non-sarcoma osteoblasts
from functioning properly.
It was estimated that both of the cell populations preserved in DMSO expressed 1.64±0.22
pMol/cell.hour and 1.57±0.08 pMol/cell.hour (5%wt and 10%wt). The most drastic change
in phenotype was from cells preserved with ectoine and maltose at 1.00±0.08 pMol/cell.hour
and 0.72±0.02pMol/cell.hour respectively, this is shown in Figure 4.8b.
The other four cryoprotectants all showed changed ALP activity ranging from 1.08pMol/cell-
1.57pMol/cell. These data show the importance of selecting an e cient CPA. Cells are
extremely sensitive, but can survive extreme temperatures by using e↵ective cryomedia.
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(a)
(b)
Figure 4.8: (A) 24 hour yield of HOS TE85 cells seeded at 10,000cells/cm2 and yield
from cells attached after 1hr in six well plates and (B) Alkaline Phosphatase Activity of
HOS TE85 cells after 24 hours in culture after cryopreservation in 8 di↵erent cryoprotective
agents. Data are the average of two measurements from three independent experiments.
Error bars represent ±SD. * represents statistically significant di↵erence from the control,
DMSO 10% (p<0.05).
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(a) Stable Culture (b) DMSO 5% (c) DMSO 10%
(d) Glycerol (e) 1,2-propanediol (f) Maltose
(g) Ectoine (h) CryoMaxx (i) XerumFreeZ
Figure 4.9: Photomicrographs of HOS TE85 cells in (A) stable culture, and after cryopreser-
vation in cryomedia containing (B) 5%wt DMSO, (C) 10%wt DMSO, (D) 10%wt Glycerol,
(E) 10%wt 1,2-propanediol, (F) 10%wt Maltose, (G) 10%wt Ectoine, (H) CryoMaxx and
(I) XerumFreeZ and cultured for 24hrs. Observed through a 10x objective lens. Scale bar
represents 0.1mm.
Using a poor CPA, such as ectoine caused significant detrimental changes in cell phenotype,
and thus cell quality. The data here show how important choosing an e cient cryoprotective
agent is in combination with a vehicle solution and other process characteristics to prevent
adverse changes in viability, growth and phenotype.
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4.2.6 Morphology
After 24 hours post thaw cell morphology was assessed photomicrographically using a light
microscope with a 10x objective lens, representative images are shown in Figure 4.9. Whilst
this is not a quantitative measure of cell health it is worth noting- with the background of
the previously gathered data- what the cells looked like after 24 hours in culture after the
di↵erent cryomedia have been removed. Observing cells like this can show drastic changes
in cell size and shape and also whether cultures had debris in them or if there were non-
attached cells. It is clear that the ectoine preserved cells were severely damaged, with little
more than debris observed. The two cell populations preserved in 5%wt and 10%wt DMSO
showed morphology and cell numbers similar to the control confluent population.
The cells preserved in DMSO, glycerol, PrOH and the two commercial CPAs showed a
morphology equivalent to that of the control group (Figures 4.9b, 4.9c, 4.9d and 4.9e)
albeit with a lower number of cells. The images of cells preserved in maltose and ectoine
(Figures 4.9g and 4.9f) showed floating cells, smaller adhered cells and cell debris indicating
substantial damage. These images all correlated with the 24 hour yield data.
4.2.7 Concluding Discussion
These data show the e cacy of the standard formulation of 10%wt DMSO in FBS. With the
process parameters tested here, cells preserved in 10%wt DMSO recovered with the highest
viability and attachment, the best growth rates and the least change in phenotype when
compared to the control.
This result, whilst not unexpected, does show how important the correct selection of CPA
is. Glycerol and PrOH are widely used molecules in other sectors of life sciences- bacteria
and CHO preservation, but the lower e cacy shown here as compared to DMSO reiterates
the need for each species- if not each cell phenotype- to have a defined cryopreservation
process. Xu et al [312] showed in 2014 how hiPSCs and hESCs di↵er in recovery when they
investigated the cryopreservation of these cell types with DMSO, glycerol and PrOH, noting
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significantly di↵erent values of recovery on thaw with di↵erent CPAs. They also noted a
range of membrane permeabilities across the cell types investigated indicating important
biophysical di↵erences proposing this as a hypothesis for di↵erent recoveries on thaw.
10%wt DMSO was ranked the highest in all but one of the metrics investigated herein (Table
4.1), only 24hr yield from attached cells preserved in XerumFreeZ was higher. Maltose and
Ectoine are ranked 7th and 8th in all seven metrics. Sugars like maltose however have shown
some promise as cryoprotectants[85], but the larger size of the molecule prevents the mass
transfer across the cytoplasmic membrane in the 5 minutes that these cells were given at
room temperature to equilibrate.
Table 4.1: CPA Screen Results Ranking
Viability 1hr 24hr Yield 24hr Yield
CPA on Thaw Attachment from from ALP
E ciency Seeding Attached
DMSO 5% 2nd 2nd 2nd 4th 2nd
DMSO 10% 1st 1st 1st 2nd 1st
Glycerol 5th 5th 5th 3rd 3rd
PrOH 6th 3rd 4th 5th 6th
Maltose 7th 7th 7th 8th 7th
Ectoine 8th 8th 8th 7th 8th
CryoMaxx 3rd 4th 6th 6th 5th
XerumFreeZ 4th 6th 3rd 1st 4th
When these data were analysed for statistically significant di↵erences from the DMSO 10%wt
control, only the lower DMSO concentration- 5% was statistically similar according to the
Dunnett’s post-hoc ANOVA test[288]. All other cryoprotectants studied were statistically
di↵erent for at least one metric. Additionally, all significant di↵erences were lower than
that of the DMSO 10% preserved populations. Alkaline-Phosphatase activity, a means by
which phenotypic expression was determined is significantly di↵erent in PrOH, maltose and
ectoine indicating these cryoprotectants do not maintain cell quality during cryopreservation.
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24hr yield from seeding is significantly di↵erent from the cells preserved in 10%wt DMSO
in all populations except the cells preserved in PrOH and 5%wt DMSO, however when the
yield from attached cells is considered, the maltose, ectoine and CryoMaxx preserved cells
are significantly di↵erent. This suggests that in the other groups the cells that survive the
cryopreservation event go on to proliferate in a way similar to that of the 10%wt DMSO
formulation despite sometimes significant reductions in on thaw viability and attachment
e ciency.
When the data gathered from this experiment and the earlier DMSO concentration exper-
iment are considered, it is clear that the 10%wt DMSO in FBS is an acceptable standard
for cryopreservation of human cells. Additionally, other process parameters are standardised
around this 10%wt DMSO standard method such as 1°C/minute freezing rate, 10% CPA
concentration, however studies exploring DMSO-free cryopreservation often use these same
parameters to allow for simple technology-transfer. Cells preserved in 10%wt DMSO comes
have the highest on-thaw viability, attachment e ciency, 24hr yield and phenotype when
compared to cells preserved with pure FBS, lower DMSO concentrations and various alter-
native cryoprotectants. For the other seven cryomedia investigated, at least one of the five
metrics is significantly detrimentally altered. However these experiments only looked at the
short term e↵ect of cryopreservation- 24 hours later; work in the next experiment, Section
4.3, establishes what e↵ect cryopreservation has on the long term fate of cells.
4.3 Long Term E↵ect of Cryopreservation
The purpose of this experiment was to determine cell fate long after resuscitation from cryop-
reservation. From the earlier cryoprotectant screen, it was found that the two concentrations
of DMSO: 5%wt and 10%wt along with 10%wt Glycerol and PrOH were, with respect to
on thaw viability, 1hr attachment and 24hr yield the four most e cient non-commercial
cryoprotectants, and worthy of investigating further. These three cryoprotectants have also
been previously investigated together for a number of cell types[143, 311, 312].
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For the first phase of this investigation, as discussed in Sections 4.1 and 4.2, just the 24
hour yield was investigated, however for these experiments, growth over one passage, and
longer, over ten serial passages was investigated.
The long term e↵ect of cryopreservation, from both a biological and manufacturing per-
spective is important. Here, long term e↵ect was defined as culturing cells for a number
of passages beyond what cells would normally be processed on thaw prior to in vivo trans-
plantation, in this section 10 serial passages were studied. It is usually assumed that on
resuscitation, cells act normally and are biologically identical to what they were prior to
freezing thus there is no e↵ect on long term cell fate. However a significant change in
cells proliferative ability and metabolic profile could prevent as many cells being grown for
banking or therapeutic doses or indicate wider issues with cell health. To manufacture large
cell numbers for therapeutics cells may be required to be grown for substantial periods and
so an understanding of any changes in cell fate is important. Studies typically only look at
immediate post thaw viability and it is hypothesised that this does not give the full picture.
The function of this study is to investigate if preservation with the di↵erent CPAs a↵ected
cells in additional ways that the earlier screen did not indicate[11, 143, 162]. Whilst there is
no clear definition of “normal” cell activity and growth, cells are not biologically identical,
various factors of cell life were investigated and analysed and compared both before and after
freezing.
4.3.1 Overview of Experimental Procedure
Cells from a stable HOS TE85 line culture were cryopreserved at 1x106cells/mL (Section
3.7.1). Cells were preserved in FBS mixed with either DMSO (5 or 10%wt) Glycerol or
PrOH (both at 10%wt).
Cells were preserved in the gas phase of liquid nitrogen for one week before thawing, resusci-
tation and seeding (Sections 3.7.3 and 3.2.1). On thaw, the cells were analysed for viability
(Section 3.4) before being cultured in T-flasks (Section 3.2.1). On the first passage, cells
were analysed for alkaline-phosphatase activity (Section 3.2.2). The cells were then cultured
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for a further nine serial passages. At each passage cells were analysed for growth, viability
and metabolism (Sections 3.4 and 3.8).
Cells were frozen in the di↵erent cryoprotectants in triplicate and each measurement was
completed in duplicate.
Figure 4.10: Overview of Long Term E↵ect of Cryopreservation experiment
4.3.2 Viability on Thaw
First, the previously determined viability data was extracted for the cryoprotectants used
and analysed further- Figure 4.11a. Both DMSO concentrations achieved high viabilities,
5%wt at 95.6±3.0%, 10% at 96.1±3.8%. Glycerol was lower at 84.9±5.2%, whilst PrOH
was significantly lower at 74.9±2.3%. Statistical analysis using ANOVA followed by Tukey’s
post hoc test shows that the DMSO concentrations and Glycerol are a statistically similar
homogenous subset.
Viability was also determined at each passage (Figure 4.11b) and with very few exceptions
at every serial passage viability was greater than 90% indicating quick recovery on thaw, as
would be expected from this robust cell line. Further this shows that any damage to the cells
caused by cryopreservation inducing a reduction in viability (measured as membrane integrity)
only occurred in the first passage post-thaw. This is promising for cell bank growth, as it
shows that cells growth capacity was not a↵ected by cryopreservation at this early post-thaw
stage.
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(a)
(b)
Figure 4.11: Viability of HOS TE85 cells (A) on thaw and (B) over 10 serial passages
after cryopreservation in four di↵erent cryomedia. Data represent duplicates from three
experimental replicates. Error bars represent standard deviation. * represents a statistically
similar homogenous subset (significance p<0.05).
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4.3.3 Growth
Over the first passage (see Figure 4.12a) the fold expansion rate was slowed in cells preserved
in Glycerol and PrOH when compared to the cell populations preserved in DMSO. Both cell
populations preserved in DMSO have a growth rate in passage one close or higher than that
of the average, whereas glycerol and PrOH populations grew a lot slower in passage 1 than
the rest of the experiment. The lowered growth rates in the glycerol and PrOH preserved
populations are demonstrated to have been significantly lower when assessed statistically
than the overall growth rate.
There was a quick return in all four groups to baseline-like growth rates (2.00±0.09 fold
expansions/day). Indeed, after one passage, ANOVA reported no significant di↵erence.
Considering the cumulative growth patterns (Figure 4.13) almost identical gradients of the
four growth curves was observed after the fourth passage. Any early fluctuations perhaps
caused by complications from cryopreservation are eliminated by the third passage on thaw.
This di↵erence is another argument for moving away from using post-thaw viability as a test
for release: the cells growth profile may have been altered by cryopreservation. The early
stage losses in the populations preserved with glycerol and PrOH however did not cause a
significant drop in total cell expansions over the 10 passages.
4.3.4 Metabolism
Samples were taken at each passage to assess metabolic activity (Figure 4.14) and from
this the change in metabolite concentrations calculated. The data, displayed in Figure 4.14
show the cells took up glucose and ultimately converted or metabolised most of this to
lactate. It can be seen on the first passage, that a lot more glucose was taken up by
the cells preserved with PrOH, 3.05pMol/cell.day, indeed all four populations had glucose
consumptions outside two standard deviations (i.e. 95% of the normal distribution) of the
previously gathered baseline (4.4). Environmental di↵erences during the cryopreservation
process could have caused a change in glucose uptake, for example, Kaur et al [139] have
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(a)
(b)
Figure 4.12: Fold Expansion Rate of HOS TE85 cells (A) over one passage and (B) over 10
serial passages after cryopreservation in four di↵erent cryomedia. Data represent duplicate
measurements from three experimental replicates. Error bars represent ±SD.
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(a)
(b)
Figure 4.13: Growth of HOS TE85 cells. (A) Fold Expansion Rate over 10 serial pas-
sages and (B) Cumulative Fold Expansions over 10 serial passages after cryopreservation in
four di↵erent cryomedia. Data represent duplicate measurements from three experimental
replicates. Error bars represent ±SD
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discussed that extracellular pH is a major regulator of metabolism in chondrocytes and
that “[t]he changes in the physiochemical environment can also modulate the metabolic
response”. PrOH, as has already been shown caused a higher reduction in viability than
DMSO or Glycerol and additional damage to this cell population was observed further with
increased metabolic stress on the first passage after freezing and the next passage with
glucose uptake and lactate production lying outside the 2xSD range. After the third passage,
the metabolism of the PrOH preserved cells was largely in line with the three other groups
indicating a return to normal activity. After the first passage the vast majority of data points
across all four groups were within two standard deviations of the baseline- the range 1.62-
3.47pMol/cell.day indicating it was the e↵ect of cryopreservation that caused the stress,
regardless of the type of cryoprotectant. That a few points laid outside the baseline±2xSD
is likely due to experimental variance rather than any change in cell activity.
The lactate production results showed no substantial response to freezing except PrOH,
which had higher lactate production. However, the vast majority of data points were within
one standard deviation of the previously gathered baseline data indicating a quick return to
good cell health (see Section 2.8) on thaw.
There was a clear e↵ect observed due to the increased lactate production immediately post
thaw on PrOH-preserved cells. Table 4.2 shows the significantly increased total average
net population uptake of glucose and production of lactate was significantly higher for the
PrOH-preserved cells. This was despite the metabolic activity returning to near-baseline
levels after the early passages, as shown above in Table 4.2.
Metabolic yield of lactate from glucose as shown in Figure 4.15 is an additional metric for
determining cell health. Whilst a cell population may be taking up more glucose than usual,
it may be producing less lactate causing a lower metabolic yield, meaning the cell population
is not significantly stressed. This is perhaps a better measure of cell metabolic health. With
glucose having a molecular weight of 180.016g/mol and lacate 90.08g/mol, cells have a
theoretical maximum yield of lactate from glucose of 2mol/mol[92]. A yield any higher than
this maximum indicates the population requiring an additional source of energy, and this has
been previously hypothesised[218] to be glutamine, present in the medium these cells were
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(a)
(b)
Figure 4.14: (A) Glucose uptake and (B) Lactate production rates of HOS TE85 cells
over ten serial passages after cryopreservation in four di↵erent cryoprotective agents. Data
represent the mean of two duplicate measurements from three independent experiments.
Error bars represent ±SD. Also shown is the average yield from the baseline ±2x SD
previously displayed in 4.4
Benchmarking Standard Cryopreservation Medium Formulation 116
grown in at 2mMol. That the cells required additional sources of energy potentially indicates
stress. In the results from this experiment, several early stage data points were above this
maximum, but after the fourth passage the yields for all four groups fell below it. After the
fourth passage, the metabolic yields of the cell populations recovered to close to that of the
previously observed baseline characteristics: 1.78mol/mol. The increased metabolic yield
showed that the cells needed to use another metabolic pathway to allow them to process
the removal of toxic CPAs or more general recovery from pH excursion, solute toxicity and
osmotic shock- amongst other issues- caused by the cryopreservation process.
Table 4.2: Net population average of the total cumulative glucose uptake and lactate
production of HOS TE85 cells after cryopreservation in cryomedia containing four di↵erent
CPAs over 10 in vitro serial passages. Data are the mean of duplicate measurements
from three independent experiments ±SD. * indicates a statistically significant di↵erence
(p<0.05).
Total Cumulative Total Cumulative
CPA Glucose Uptake/Cell Lactate Production/Cell
(pMol/cell) (pMol/cell)
DMSO 5% 48.67±1.76 94.63±2.75
DMSO 10% 44.10±1.74 81.30±5.03
Glycerol 48.18±2.20 88.15±2.31
PrOH 54.18±2.70* 100.82±2.11*
4.3.5 Concluding Discussion
When considering the earlier screen results (Section 4.2) along with the data gathered from
these ten serial passages it is important to note what the di↵erent e↵ects cryopreservation
had on short and long term culture. The e↵ects of cryopreservation could have repercussions
on how cell health is determined on thaw in cell therapies. Whilst cell populations were shown
to be significantly damaged with reduced attachment for example they do quickly recover
to stable culture levels.
Whilst experiments in Chapter 5 investigate the purported toxicity of DMSO the e cacy of
using it at a 10%wt concetration in FBS as a cryomedium is clear. Cells recovered to stable
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Figure 4.15: Metabolic yield of lactate from glucose of HOS TE85 cells over ten serial
passages after cryopreservation in four di↵erent cryoprotective agents. Data represent the
mean of two duplicate measurements from three independent experiments. Error bars
represent ±SD. Also shown is the average yield from the baseline ±SD previously displayed
in Figure 4.4
culture levels within 1-2 passages, and there was no long term e↵ect on glucose-lactate
metabolism. A similar result was seen with cells preserved with the lower concentration of
5%wt DMSO.
Cells preserved in glycerol did appear to grow slower on the first passage after thawing but
they recovered to stable culture levels after 2 passages. It was only where cells preserved
with PrOH that any significant e↵ect was observed. Whilst growth and viability recovered
to stable culture levels within 2 passages, comparing the total cumulative glucose uptake
and lactate production over the ten passages showed a significant change in the metabolic
profile.
Looking at the experiments in Sections 4.1, 4.2 and 4.3 it was seen that DMSO 10%wt in
FBS is a worthy standard formulation even when long term in vitro health is considered.
There is limited literature looking into the long-term fate of cells after cryopreservation,
studies tend to merely look at the early fate, over 1 passage or less[11, 123]. Indeed, some
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studies look at what e↵ect long-term storage at cryo-temperatures has on cell populations
as opposed to long term culture after a period of cryostorage, for example Sumida et al [268]
have presented data recently on the recovery of cells preserved for over 40 years. The present
study has however shown that whilst cells recovered quickly to normal viability and growth
rates, the metabolism was a↵ected as cells recover from cryopreservation. As such, they
were possibly required to utilise an additional source of energy to proliferate successfully.
Nevertheless, HOS TE85s are not therapeutically relevant. It is hoped that the results herein
gathered are comparable to a more therapeutically relevant cell phenotype and thus clinical
application. An example of therapeutically relevant cells are human mesenchymal stem cells.
4.4 Benchmarking Mesenchymal Stem Cells- Comparing Frozen
to Fresh
HMSCs are a clinically and commercially relevant cell phenotype[23, 218]. As previously
discussed in Section 2.6.1 there are over 1,000 therapies using hMSCs in active clinical
trials. In this experimental phase, hMSCs were extracted from primary bone marrow tissue
in house for use as a working cell line for future experiments.
Primary tissue was selected for these experiments, this allowed for the true e↵ect of any
cryopreservation experiments to be understood. Alternatively a frozen vial of a commercially
available hMSC line could have been selected but as this would have involved an additional
cryopreservation cycle the e↵ect of how primary cells behave in culture and respond to
subsequent cell preservation could not be fully defined. In addition, as few reagents as
possible were used when processing the cells, such that anything used in vitro was entirely
planned, and understood. Whilst initial additional extensive processing was performed here,
the e↵ect of cryopreservation was more confidently assessed as the full fate of the cells from
extraction was completely understood. However, it is important to consider the baseline
characteristics of an hMSC line before further optimisation or process transfer can occur and
characterise how a single freezing episode a↵ects cell quality and health.
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In this section, how cryopreserved cells di↵er from their primary counterparts and whether
cryopreservation a↵ected hMSC morphology was investigated. By cryopreserving using the
standard formulation of 10%wt DMSO in FBS, whether or not immediate phenotypic and
metabolic e↵ect occurred was investigated.
4.4.1 Overview of Experimental Procedure
Figure 4.16: Overview of hMSC benchmarking experimental procdure
A vial of bone marrow aspirate was extracted from the iliac crest of the pelvis of a donor
who was then shipped from the United States.
Approximately 30mL of bone marrow aspirate was delivered and processed using density
separation without any other reagents, e.g. Ficoll. Cells were then established in culture
with daily 100% medium exchanges on the first three days, followed by medium changes
every 3 days (P0) (3.3.2). The cells were observed daily and after 14 days deemed confluent
and were passaged (P1). At this point, some vials were preserved. After a further 7 days
the cells were again passaged (P2) and a working cell bank created. Cultures of the primary
cells were kept active for further passages. A series of the P2 frozen vials were thawed and
cultured for further serial passages. Additionally at passage 3, 14 identical flasks were seeded
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(a) Day 4 (b) Day 6 (c) Day 8
(d) Day 10 (e) Day 12 (f) Day 14
Figure 4.17: Development of human mesenchymal stem cell-like cells in monolayer culture
after density separation from fresh human bone marrow aspirate over a period of 14 days.
Representative images from 10x phase contrast microscope in two di↵erent tissue flasks.
Scale bar represents 0.1mm.
and sacrificed at 24hr time points, up to 168hrs, with growth and viability assessed. Also,
cells were analysed at passages 3, 6 and 9 by flow cytometry to assess the expression of
extra-cellular phenotypic markers. Lastly populations of hMSCs were cultured in lineage-
specific di↵erentiation media to ascertain whether they had the capacity to di↵erentiate
down adipogenic, chondrogenic and osteogenic pathways.
4.4.2 Colony Development and Morphology
Few cells were initially observed microscopically, but on the fifth day after initial processing
small groups of cells started to be seen. Eventually 8 colonies were examined daily although
at least 50 were observed prior to P1. Representative images are shown in Figure 4.17.
There are a few points here worth noting. First, on day 5 other mononuclear cell types
were still observable such as the granulocytes or other white blood cells, which don’t adhere
and were eventually- during later medium changes- removed. HMSCs make up the vast
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majority of anchorage dependent cells within bone marrow aspirate[257], and so removing
medium containing suspended cells is an early way to separate and select the candidate MSC
population.
It is also clear over time that larger colonies developed and the classic long parallel groups
of cells indicatory of MSCs were observed. The long striated morphology typical for hMSCs
was first noticeable on day 12 as the cells started to approach confluence.
4.4.3 Baseline Characteristics of Selected hMSC Line
Given the heterogeneous nature of fresh bone marrow aspirate, it was impossible to generate
an accurate count of hMSC cells which would eventually adhere and become the working
population. The shipped vial of bone marrow indicated that there was 30mL of aspirate at a
total density of 3.41x108cells/mL. This was made up of primarily red blood cells, with small
populations of white blood cells, granulocytes, progenitor cells and a small population of
mesenchymal stem cells. Xu et al [309] suggest that approximately 0.001%-0.01% of bone
marrow aspirate are adheren, and therefore likely hMSC candidates and the midpoint of this
range was used to estimate the initial cell count as follows:
3.41x108cells/mL 0.005% 30mL
Total Estimated Cell x Estimated x Estimated Volume of
Density in Aspirate MSC Density Aspirate
This gave an initial estimate for the number hMSCs in the aspirate at 5.12x105. This value
was then used to estimate the growth from P0 to P1 and is shown in Figure 4.18a. The
following therefore shows the growth over five passages after the initial extraction. The first
growth data point is based on the estimate defined above, also cell viability is also initially
estimated to be 100%.
It was decided that for all experiments with hMSCs and additional HOS TE85 experiments,
the NucleoCounter® would be used. Though the trypan blue method is a relatively reliable
method for cell counting, although it does su↵er from a series of shortcomings including
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(b)
Figure 4.18: (A) Daily fold expansion rate and viability of primary human mesenchymal
stem cell-like cells extracted from fresh human bone marrow aspirated and isolated using
plastic adherence and density isolation over six serial passages. Data points for passages 1
and 2 based on estimates of hMSCs in bone marrow aspirate in the absence of the ability to
accurately count cells. (B) Daily cell viability and number over one passage (passage 4) of
hMSCs. Data are derived from the mean of duplicate measurements of three independent
cultures from the same donor. Error bars are ±SD.
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user variability, tool variability and sample errors, the NucleoCounter as shown by Shah et
al [245] reduces this variability. Additionally, data in Appendix A detail the similarity and
comparability between the three counting methods used in this body of work.
Based on the initial estimate above and the count at passage 1, the initial growth rate
was determined to be 0.55±0.02fold expansions/day. Over the next 4 passages this ranged
from 0.48-0.77, with an average rate of 0.61±0.01fold expansions/day. When viability was
considered the population was stable ranging between 95.3%-98.9%.
Metabolism is as previously discussed in Section 4.3.4, a good measure of cell activity
and health. Metabolic activity was determined at feed and passage during the baseline
characterisation. From this glucose uptake, lactate production and yield of lactate from
glucose was determined, this is shown in Figure 4.19. Here the average glucose consump-
tion was observed to have been 8.91±0.45pMol/cell.day and the lactate production was
15.75±0.62pMol/cell.day. These values were higher than the previously acquired data from
the osteoblasts (4.1.2), but in line with the literature [67]. Overall, the rates of glucose
uptake and lactate production gave an average value for the cellular yield of lactate from
glucose to be 1.79±0.07mol/mol, similar to that of the osteoblasts and showing that the
cells were operating normally and most likely not reliant on additional energy sources such as
glutamine or amino acids[92]. It is important to note here that these hMSCs were cultured
in a way where they require a medium exchange midway through the culture period, usually
Day 3. Not only does this serve to replenish glucose and other nutrients, but also allowed
for the removal of waste products such as lactate, accumulation of which was detrimental
to cell health at high concentrations[105].
Finally, it is important to define that these cells were indeed human mesenchymal stem
cells. As previously discussed in Section 2.6.1, there are three key criteria[65]. The first is
adherence to tissue culture plastic in standard conditions, which has been previously noted
in Section 4.4.2. The second criterion is immunophenotypic expression of a series of extra
cellular markers- three that  95% population should express, and five that 2% should
express. The five colour assay described in Section 3.3.5 assesses the three positive markers
and two negative markers[65]. After 3, 6 and 9 passages the multi-parameter flow cytometry
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(a)
(b)
Figure 4.19: (A) Glucose Uptake and Lactate Production and (B) Yield of Lactate from
Glucose of bone marrow derived mesenchymal stem cells over five serial passages. Data are
the average of duplicate measurements from three experimental replicates. Error bars are
± SD
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(a) CD73 95.7% Positive (b) CD90 96.6% Positive (c) CD105 95.4% Positive
(d) CD34 99.5% Negative (e) HLA-DR 99.2% Negative
Figure 4.20: Representative histograms of expression of individual extracellular markers
conjugated to fluorescent antibodies analysed by flow cytometry from duplicate measure-
ments from three independent cultures of bone marrow derived human mesencyhmal stem
cells.Based on  5000 events.
assay for phenotype analysis was performed to determine the baseline phenotype of these
fresh cells prior to any cryopreservation, Figure 4.20 shows sample histograms at passage
three showing cells meeting the second ISCT criterion. A multi-parameter gating strategy
was applied (Figure 4.21[39] to determine the proportion of cells expressing all five markers,
in line with the ISCT criteria, this is shown in Table 4.3.
This shows that the cells met the ISCT parameters for all five investigated markers at
passages 3, 6 and 9, indicating hMSC phenotype in line with the ISCT standards.
The final criterion from the ISCT hMSC parameters set down in 2006 is the ability to di↵er-
entiate down the three typical lineages characteristic of hMSCs[65]. To meet the criterion
hMSCs must have been observed to have di↵erentiated to adipocytes, chondrocytes and
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Figure 4.21: Representative multiparameter gating strategyo f individual extracellular mark-
ers conjugated to fluorescent antibodies analysed by flow cytometry from duplicate mea-
surements from three independent cultures of bone marrow derived human mesencyhmal
stem cells.Based on  5000 events.
osteocytes and stained accordingly. hMSCs at passage three were separated into three dif-
ferent groups and treated with lineage-specific di↵erentiation media. After three weeks the
cells were stained appropriately and di↵erentiation was observed, representative images are
shown in 4.22.
The adipo di↵erentiated cells clearly had lipids within the cell membrane, stained red by the
Oil Red O stain. The chondro di↵erentiated cells produced proteoglycans with GAG tails, an
integral part of the ECM. These GAGs were stained blue by the alcian blue dye. The osteo
di↵erentiated cells have been dual stained. The calcium produced by the ossifying cells was
reduced under ultra-violet light and replaced with silver from the silver nitrate; it is this that
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Table 4.3: Multiparameter expression of CD73+, CD90+, CD105+, CD34- and HLA-DR-
at passages 3, 6 and 9 of primary bone marrow derived human mesenchymal stem cells.
Based on  5000 events Data represent the mean of duplicate measurements from three
independent cultures from the same donor ± 95% confidence interval.
Passage Multiparameter
Number Expression
3 98.2±0.9%
6 98.3±1.0%
9 95.6±1.1%
(a) Adipocytes (b) Chondrocytes (c) Osteocytes
Figure 4.22: Di↵erentiation capacity of bone marrow derived human mesenchymal stem cells
after passaging depicting (A) Adipogenic, (B) Chondrogenic and (C) Osteogenic di↵erenti-
ation. Observed through a 10x objective lens. Scale bar represents 0.1mm. Representative
images of six repeats.
was visualised as black. Further, alkaline phosphatase activity was stained by the Naphthol
Alkaline substrate; the cells were stained red, indicating AP activity.
4.4.4 Comparison of Fresh and Frozen hMSCs, and HOS TE85 cells
Three vials of the 1x106 hMSCs preserved in 10%wt DMSO in FBS from the P2 MCB were
thawed and cultured for five serial passages to see what e↵ect (if any) freezing had on growth
when compared to the non-frozen primary baseline. It is important to establish that the any
freezing event performed for experimental cell banking requirements does not change the
cells in any detrimental way. Further, the characteristics of this cell line will be compared
with HOS TE85; the other cell line used in this body of work.
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First the growth rate over five serial passages was compared with the fresh group, and relevant
equivalent data from previously gathered from the HOS TE85 cell line- cells preserved in
10%wt DMSO in FBS. Figures 4.23 and 4.24 show that the viability, growth metabolism and
phenotype of the frozen and fresh groups was comparable. The HOS TE85 cells proliferate
substantially quicker, but had comparable viability and metabolic yield. The three studied
groups’ viability are all similar across the five passages investigated, ranging from 93.8%-
98.9% (‘frozen’ P3, ‘fresh’ P2, respectively). The two hMSC groups’ were similar to each
other with an overall average of 1.81mol/mol, indicating again that one freezing event
does not a↵ect the cells’ metabolic profile, with respect to glucose-to-lactate conversion.
This yield value was similar to the previously gathered HOS TE85 value (Section 4.1.2) of
1.78mol/mol, these data also showed that HOS TE85 for at least viability and metabolism
were a worthy model cell type. Lastly, comparing the phenotype of the fresh and frozen hMSC
across passages 3, 6 and 9 showed that freezing using the standard cryomedium formulation
and preservation protocol did not significantly alter the cells’ phenotypic identity.
Given the observed ability to adhere and express (or not, in the case of negative markers)
five of the right ISCT markers it can be e↵ectively confirmed that these cells were indeed
hMSCs. The primary growth and metabolism results are useful as they can be compared to
any future experimentation with these cells to see if any e↵ect was observed away from the
primary baseline. These mesenchymal stem cells are a lot more clinically relevant than the
HOS TE85 cells therefore work performed on them will gives more relevant results as the de-
velopment, transport and shipment ofcommercial cell therapies is considered. Nevertheless,
HOS TE85 are an adequate model cell line and allowed for quick throughput experiments to
be designed. The growth rate of the primary cells remains mainly constant throughout the
first 8 passages after extraction, before starting to slow down. This is in line with another
published study[317] and indicates a reduction in di↵erentiation potential to the osteogenic
and chondrocyte lineages. It is clear from Figure4.23 that osteoblasts grew a lot quicker
than mesenchymal stem cells up to 4 times faster. This is no surprise given the carcinoma
nature of HOS TE85 cells. The di↵erence in growth rate from the frozen and primary hMSC
lines is subtler and there was no significant di↵erence when comparing the growth of the
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(a)
(b)
Figure 4.23: Comparison of (A) Cumulative Fold Expansions and (B) Viability over five
serial passages of a primary group of hMSCs (‘fresh’), a group of hMSCs cryopreserved and
revived at passage 2 (‘frozen’), and a group of frozen HOS TE85 cells. Fresh Day 14 data
estimated. Data are the mean of two duplicate measurements from three separate cultures
of the same donor (hMSCs)/three independent experiments (HOS TE85). Error bars are
±SD.
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(b)
Figure 4.24: (A) Metabolic yield and (B) Immunophenotype expression of extracellular
markers of primary hMSCs (‘fresh’) and a group cryopreserved and revived at passage two
(‘frozen’). Data are the mean of two duplicate measurements from three independent
cultures from the same donor. Error bars are ±SD.
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frozen and primary lines.
4.5 Concluding Discussion- A viable benchmark?
The data herein show that 10%wt DMSO in FBS is a viable standard cryopreservation
solution. With both HOS TE85 cells and clinically relevant hMSCs it has been shown that
cells are successfully preserved in this cryomedium and recover to high viability with no
significant e↵ect on cells proliferative activity, phenotypic identity or metabolism. Dozens of
parameters that may or may not a↵ect successful freezing exist- cooling rate, cell density,
temperature of storage environment to name but a few- but in the context of 1°C/minute
slow freezing and the cell densities used here, the 10%wt DMSO in FBS formulation is worthy
of its status as the preservation medium of choice in the life science research industry.
The results in this chapter however have shown that choosing an insu cient cryoprotectant
can significantly a↵ect cell viability, proliferation, metabolism and phenotype. This could
have serious consequences for process development.
Nonetheless, the function of this chapter is to develop the baseline characteristics of the cell
lines used over the next chapters and to characterise the a↵ect of standard cryopreservation
on them, the data in the previous sections demonstrates this.
Chapter 5
DMSO Toxicity
DMSO has been used as a cryoprotectant since the 1950s[164] however, it has been shown
that DMSO can be in toxic to living human cells [11, 74, 123, 315], as discussed in Section
2.8.1. DMSO may facilitate the penetration of other molecules, including toxins across cell
membranes or act as a di↵erentiation enabler[311]. Ultimately, these toxic e↵ects are not a
serious issue for cell lines used in research or therapeutic protein production- e.g. bacteria,
yeast, CHOs, but as cell therapies hit the market where the cell forms the basis of the
product it becomes undesirable to transplant cells that are dead or have a detrimentally
changed function and/or a possible toxin into patients. Whilst DMSO has a relatively low
LD50 in mice, similar to that of ethanol [314], it was shown[55] that there is evidence of
adverse e↵ects on patients, including inducing strokes, heart attacks and haemorrhages after
cryopreserved bone marrow was used as a treatment after preservation in 10%wt DMSO.
As scale up of human cell culture in bioreactors is considered [218] and the large numbers
of cells that are needed for therapeutics, there is a need to define the maximum duration
that cells should be exposed to DMSO and at what concentration it is safe. Prochymal is
an approved cell therapy in New Zealand and Canada for treating graft versus host diseases,
and requires a dose of 2x106 fully functional hMSCs per kg of patient weight [33]. Assuming
an average human weight of 62kg [290], at least 1.24x108 cells will be needed for each dose.
This is beyond the capability of current cryovials with a maximum volume of 5mL and as such
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cryobags which could potentially hold up to the litre scale will be required to safely preserve
cell therapy doses. Prochymal for example is frozen in 15mL bags with 10%wt DMSO with
25%wt human serum albumin in Plasma-Lyte A, and ChondroCelect is frozen in CryoStor10
(BioLife Solutions, USA)[259]. Also, it has been reported that for recombinant baby hamster
kidney (rBHK) cells, cryopreservation bags must be filled in a time not exceeding two hours
to prevent adverse e↵ects from DMSO such as an increase in apoptotic activity or viability
reduction [107]. This period is a lot longer than normal human cell cryopreservation protocols
(⇡10 minutes) and so it is important to determine a maximum exposure time to DMSO.
It is also important to consider large-scale GMP processes [161] which will have additional
hold-ups to allow for QC analytics. Further, when we consider clinical applications, where
there may be a delay between thawing and delivering cells to patient, therefore defining the
tolerance limits of such a delay will allow for a safer, and potentially improved treatment
e cacy.
As has been previously highlighted in Section 2.8.1, little work has been published related to
the e↵ect of DMSO on therapeutically relevant human cell lines. Hunt et al [123] published
a study in 2003 showing that the “recovery index”- a measure of viability from membrane
integrity and colony-forming-ability after thaw- of CD34 positive cells can be reduced by as
much as 50% when exposed to 25%wt DMSO for up to an hour prior to freezing. Katkov et
al [138] showed that hESC cells lose around 50% expression of the vital Oct-4 marker after
even standard cryopreservation exposure to DMSO, indicating that cell quality is a↵ected by
exposure to DMSO. Aye et al [11] used CHO cells as an oocyte model and showed that after
3 hours cells exposed to 20%wt DMSO were still over 90% viable, but after 24 hours this is
reduced to just 10%. Further, there is limited published data related to the long-term e↵ect
of DMSO on cells, that is to say after multiple in vitro passages. It is therefore proposed that
exposure to DMSO could have a significant detrimental e↵ect on cell quality, especially with
regards to phenotype. In this chapter a thorough investigation was undertaken on the e↵ect
of DMSO by exposing HOS TE85 cells and hMSCs to the DMSO-containing cryomedia for
varying amounts of time i) without, ii) prior to, and iii) after employing standard freezing
protocols. The intention was to define a process parameter for the maximum time period
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that cells can be exposed to DMSO before a substantial reduction in viability and adverse
changes in phenotype or metabolism. These adverse changes could be a serious complication
in the production of the next stage of biotherapeutics, as the case with cell therapies, the cell
is the product, and will be injected into patients. As DMSO has been used in preservation
systems at clinically relevant scales- e.g. Prochymal, prolonged exposure risks compromising
product quality. As such, results are discussed in terms of the risk to product quality because
any change in cell function could have a serious impact on patient health, any change in cell
function could have a serious impact on patient health.
5.1 Overview of Experimental Procedure
Figure 5.1: DMSO toxicity experiment overview schematic
As shown in Figure 5.1 three experimental processes were investigated and performed with
two di↵erent cell types: HOS TE85 and hMSC-M7. For the HOS TE85 groups a vial contain-
ing 1x106 cells was thawed and cultured for three preliminary passages before experimental
work was performed. For the hMSCs cells were grown from fresh bone marrow aspirate and
experimental work began at the third passage.
For the Just Exposure group, cells were exposed to a cryomedium made up of 10%wt
DMSO in FBS for 15, 30, 60 and 120 minutes, centrifuged (220g), resuspended in fresh
medium, analysed and then counted. After an hour(HOS TE85)/three hours(hMSC), the
cells were analysed for attachment e ciency. At confluence they were analysed for viability,
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growth rate, phenotype (using an alkaline-phosphatase assay for HOS TE85 cells and multi-
parameter flow cytometry for the hMSCs) and metabolism, they were then cultured for five
serial passages.
The Exposure + Freeze group was exposed as before to the DMSO cryomedium but then
frozen and thawed as normal, followed by the same analysis.
The Freeze + Exposure group was cultured, frozen and thawed, but instead of the cells being
seeded to cultured plastic on completion of the ice melting, the cells were left standing in
the DMSO cryomedium in a 37°C waterbath for the 15, 30, 60 and 120 minute time periods,
before the same analysis as before took place.
In the case of the Just Exposed group, an unexposed control was used, in the case of the
frozen groups, a normally frozen (i.e. as fast as possible) protocol was observed for the
control “Limited Exposure” group- this is shown on charts as non-exposed, but exposure is
likely closer to 2 minutes before the cooling process started, additionally traditional thawing
takes approximately 4 minutes in a waterbath. As has been previously shown in Section 4.2,
attempting to thaw cells without DMSO (or other cryoprotectant), i.e. 100% FBS causes
complete cell death.
All runs were completed in triplicate, and all measurements in duplicate.
The overexposure was designed to simulate three things: generation of large numbers of cryo
vials for cell banking, in the case of scaled up processes (e.g. in bags), the time to fill systems
which may be in the order of hours and finally, operator error- or protocol recommendations
in the case of leaving cells exposed prior- and post- freeze or issues in tech transfer to
clinical application a↵ecting exposure time. For example, users of Prochymal are advised
that thawed product is usable for up to five hours at room temperature after that[33].
5.1.1 At Exposure Viability and 1hr Attachment E ciency
Cells were exposed to DMSO as described in Section 5.1, viability was measured either
immediately after exposure, or in the case of the Exposure + Freeze groups, immediately
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after thaw. The viability of the HOS-TE85 cell populations as assessed by membrane integrity
using Trypan blue exclusion (Section 3.4.1) decreased after two hours by between 0 and 27%,
(Figure 5.2a).
There were significant drops in viability from the non-exposed controls in the cells exposed
to DMSO for 120minutes in all three studies. Additionally the 60 minute Freeze + Exposure
was significantly di↵erent from the non-exposed control. In the most extreme case (Freeze +
Exposure, 120minutes) viability dropped to 71.9±5.5%. Therefore there is a high probability
that HOS TE85 cells exposed to DMSO for longer than an hour will fall below the FDA’s
release threshold of 70% viability[38], but on average, the population was above this required
level.
Cells exposed prior to freezing (Just Exposure, Exposure + Freeze) for two hours only had
drops in viability of 8% and 6% respectively. This indicates that any more substantial
damage to the cells’ membrane integrity (and thus on-thaw viability) required cells to be
first in the fragile state post thaw before the DMSO could significantly a↵ect the cells’
membrane integrity.
However, as has been previously shown in Section 4.2, viability may not be the best measure
on thaw for determining the health of cells or indeed the ultimate product quality in ongoing
culture due to di↵erences between perceived and actual viability. Attachment e ciency
was determined here one hour after thaw, this is shown in Figure 5.2b. Normal one hour
attachment was >85%, but data here shows that both freezing and DMSO exposure has
an e↵ect on this variable. Significant reductions in cell adhesion were observed in the Just
Exposure 120 minute group, and the 60 and 120 minute Exposure + Freeze group. That
no Exposure + Freeze groups were statistically di↵erent compared to the control indicates
that cellular adhesion to tissue-culture plastic is only reduced- in these scenarios- when
immediately preceded by long DMSO exposure. Pal et al [206]. have previously noted
unquantified abnormal cell attachment of stem cells after DMSO exposure for 24-48 hours at
low concentrations of 0.01%wt, 0.1%wt and 1%wt. It could be postulated that the cells are
drawing up DMSO in such a high concentration that a wash in medium after centrifugation
does not elute it out. Attachment may be more than just a secondary measure of viability.
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(a)
(b)
Figure 5.2: (A) Viability with respect to membrane integrity and (B) attachment e ciency
of HOS TE85 cells after exposure to DMSO before and after cryopreservation for up to
120mins. Data are the mean ± SD derived from two duplicates from three independent
experiments. * represents a statistically significant di↵erence from the respective non-
overexposed control (p<0.05).
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Transplanted cells may need to engraft to the host to have a clinical e↵ect and so reduced
attachment caused by DMSO exposure may lower the quality and thus medical e cacy.
Subsequent comparison of the Exposure + Freeze and Freeze + Exposure group to data
from a stable culture (i.e the Just Exposure control) also shown in Figure 5.2b showed
no significant reductions in viability or attachment, demonstrate that the significant drops
mentioned above are likely due to a combination of DMSO exposure and a freeze/thaw cycle.
An additional study shown in Appendix D also confirms that the nature of the experiment
(i.e. keeping cells in a vial rather than a culture flask) does not induce any additional damage
to the cells, findings here showed that cells left in growth medium both without and with a
freezing step did not exhibit reduced viability, attachment or yield after being held for two
hours in a way similar to the present experiment.
5.1.2 Short and Long Term Growth and Viability
Cells were initially cultured for one passage after exposure/thaw. Statistical analysis showed
that there was no significant e↵ect of any DMSO treatments on HOS-TE85 cells. The
non-frozen control underwent 2.58±0.48 fold expansions/day, whereas the cells just exposed
for 120 minutes grew at a rate of 1.92±0.48 fold expansions/day. The lowest growth rate
was observed (Figure 5.3a) in the Exposure + Freeze 120 minute group, at 1.62±0.17 fold
expansions/day. However, when the frozen groups (including “non-overexposed” controls)
were compared to data from stable culture significant reductions in growth rate on thaw were
observed. This indicated that any reduction in growth rate was not due to DMSO toxicity,
but purely due to the overall e↵ect of cryopreservation as a whole such as ice crystal damage
and osmotic imbalances. Slowed growth on thaw has been previously shown in Section 4.1.3
so it is of note that even two hours exposure after freeze did not significantly reduce HOS
TE85 cells proliferative ability any more than a standard cryopreservation cycle did.
Viability was also assessed at the first passage. Viabilities here ranged from 97.9±0.2% to
92.4±3.6% as shown in Figure 5.3b. Statistical analysis shows that the viabilities here, 48
hours later (i.e. one passage post thaw) mirror that of the on-thaw results; all six 60 and 120
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minute exposure groups are statistically di↵erent from both the non-overexposed controls
and data from an established culture. This indicates that whilst there was no substantial
e↵ect on growth after normal cryopreservation in DMSO, overexposure to DMSO did cause
a significant e↵ect on viability in the early stages of an on-going culture.
Also considered was longer term growth and viability over five passages. Long term growth
is important from a manufacturing perspective as cells may need to be grown up from a
master cell bank vial. Slowed long term growth may result in either a longer growth period
or more cells required at the initial thaw both increasing the cost of the therapy.
Figure 5.4a shows that over the 5 passages, there was no significant di↵erence in cumulative
fold expansions between the non-overexposed controls and the over exposed groups. It has
previously been shown (Section 4.3) that cells quickly recover to “normal” growth rates.
However when comparing the 10 frozen groups to the non-frozen control a significant re-
duction in total fold expansions was seen in every investigated frozen population, indicating
that freezing alone causes reduced growth rates on the first passage. From a manufacturing
perspective, it will be important to consider the reduced growth capacity of cells when devel-
oping, for example, a working cell bank from a master cell bank. Further, from a therapeutic
perspective that the cells have reduced proliferative capacity could a↵ect their clinical e↵ect
if for example their function in a treatment is to regenerate tissue.
Viability was also assessed over the five passages (Figure 5.4b) and whilst statistical analysis
of the means shows no di↵erence, there appears to have been a systemic increase in variability
of viability as exposure time increased. All average values of viability over the cultures were
greater than 93%. Indeed correlating the total range against the exposure time- Table 5.1
show regressions (R2 values) higher than 0.94 for the Just Exposure and Freeze + Exposure
groups. The Exposure + Freeze group, however does not correlate strongly- R2= 0.491. This
increased range seen only in the cells cultured immediately after exposure could be caused by
some DMSO remaining in the system throughout culture, or more major underlying e↵ects
in the cell population a↵ecting viability.
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(b)
Figure 5.3: (A) Daily fold expansion rate and (B) viability over one passage of HOS TE85
after exposure to DMSO before and after cryopreservation for up to 120mins. Data derived
from two duplicates from three independent experiments. Error bars represent standard
deviation.
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(a)
(b)
Figure 5.4: (A) Total Fold Expansions and (B) Viability box-and-whisker plot of HOS TE85
cells over five passages after exposure to DMSO before and after cryopreservation for up to
120mins. Data derived from two duplicates from three independent experiments. For (A)
Error bars represent standard deviation, for (B) bars represent the range, circles the mean
and bars the 1st, 2nd and 3rd quartile.
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Table 5.1: Regressions of range of viability (y) vs. DMSO exposure time (x) of HOS TE85
cells after exposure to a DMSO cryomedium before and after cryopreservation for up to
120mins. Data derived from two duplicates from three independent experiments.
Viability Range vs. Regression
Experiment Exposure Regression (R2) Equation
Just Exposure 0.942 y=0.013x+4.30
Exposure + Freeze 0.491 y=0.051x+4.5
Freeze + Exposure 0.943 y=0.095x+4.02
5.1.3 Metabolism
Medium aspirate was analysed for metabolites at each passage. The key pathway of glycolysis
was assessed, this is the conversion of glucose in the medium to pyruvate which can then
form lactate.
It has previously been shown in Section 4.1.2 that HOS TE85 cells in stable culture take up,
on average, 2.25±0.27pMol/cell.day of glucose from the medium. This is then metabolised
to 3.96±0.47pMol/cell.day of lactate. DMSO exposure changes the cells metabolism, sig-
nificantly after 60-120 minutes. It has previously been shown that freezing cells changes
metabolic activity (Section 4.3). Figure 5.5 shows that cells merely frozen (i.e non-overexposed)
took up significantly more glucose on the first passage- 3.23±0.36pMol/cell.day and pro-
duced a slightly higher amount of lactate at 5.97±0.65pMol/cell.day. DMSO exposure
however significantly changes this on the first passage post-thaw/exposure. In the most ex-
treme case, (Freeze + 120minutes Exposure) cells took up 6.29±0.37pMol/cell.day glucose
and produced 15.24±0.4pMol/cell.day. This possibly shows that the cells are requiring a
lot more energy to process any biological damage for example: pH stress caused by DMSO
exposure, or merely to push the DMSO taken up by the cells outside of their membranes. In-
deed, as Table 5.2 shows, after the first passage, cells quickly recover to a metabolic activity
similar to that of the baseline.
Any changes in the cells’ yield of lactate from glucose was also considered, this is shown
in Figure 5.6. For the HOS TE85 cells, a control value of lactate yield from glucose was
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(a)
(b)
Figure 5.5: (A) Glucose Consumption and (B) Lactate Production of HOS TE85 cells over
one passage after exposure to DMSO before and after cryopreservation for up to 120mins.
Data are the mean ± SD derived from two duplicates from three independent experiments.
* represents a statistically significant di↵erence from the respective non-overexposed control
(p<0.05).
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Table 5.2: Average glucose uptake (pMol/cell.day), lactate production (pMol/cell.day) and
yield of lactate from glucose (mol/mol) of HOS TE85 cells over passages 2-5 post thaw
after exposure to DMSO either without, before, or after cryopreservation. Data derived
from duplicate measurements from three independent experiments, shown ±SD.
Exposure Just Exposure
Time (mins) Glucose Lactate Yield
Non Exp 2.53±0.41 3.42±0.75 1.84±0.16
15 2.81±0.32 3.82±0.63 1.87±0.13
30 2.78±0.52 3.55±0.67 1.75±0.12
60 2.81±0.58 3.76±0.98 1.83±0.22
120 2.61±0.72 4.08±1.21 1.62±0.39
Exposure Exposure + Freeze
Time (mins) Glucose Lactate Yield
Non Overexp 2.67±0.30 3.75±0.57 1.80±0.04
15 2.62±0.60 3.85±0.89 1.90±0.07
30 2.85±0.49 4.05±0.68 2.07±0.13
60 2.92±0.57 3.89±0.66 2.11±0.09
120 2.87±0.68 3.63±0.89 1.87±0.08
Exposure Freeze + Exposure
Time (mins) Glucose Lactate Yield
Non Overexp 2.67±0.30 3.75±0.57 1.80±0.04
15 2.48±1.35 3.24±0.97 1.88±0.36
30 2.34±1.10 3.60±0.79 2.07±0.36
60 2.73±0.44 3.33±0.31 1.91±0.63
120 2.73±0.42 3.62±0.23 1.70±0.09
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Figure 5.6: Metabolic yield of lactate from glucose of HOS TE85 cells over one passage
after exposure to DMSO before and after cryopreservation for up to 120mins. Data are the
mean ± SD derived from two duplicates from three independent experiments. * represents
a statistically significant di↵erence from the respective non-overexposed control (p<0.05).
been observed to be 1.78±0.36mol/mol. The Exposure + Freeze 60 minute and Freeze +
Exposure 60 and 120 minute groups were significantly higher than this. The highest value
was 2.43±0.14mol/mol. This indicates that only after prolonged exposure to DMSO, in
combination with freezing do cells require an additional source of energy as this value is
above the theoretical maximum yield of 2mol/mol[92]. The remaining populations from the
other exposure scenarios were below the maximum theoretical yield indicating that although
in some cases more glucose was consumed and more lactate produced, these less exposed
cells were not in a state where they required additional energy sources. Again, after this
first passage, cells from all fifteen di↵erent exposure scenarios recovered to metabolic activity
similar to that of the baseline cells as shown in Table 5.2. Whilst quick recovery is good, from
a manufacturing perspective, the early stage increases in metabolic activity could indicate
further damage to the cell population that this study has not yet shown.
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5.1.4 Phenotype
After one passage, the HOS-TE85 cells were analysed for detrimental e↵ect on the cells’ alka-
line phosphatase (ALP) activity which is regarded as a key part of HOS TE85 cells’ phenotype
(Figure 5.7). While HOS TE85s are osteosarcoma cells and not true osteoblasts; the baseline
experiments (Section 4.1) still show expression of ALP in culture (1.658±0.09pMol/cell.hour).
ALP activity is indicatory of a cell’s ability to aid the creation of mineralised bone tissue as it
increases the local concentration of inorganic phosphate and decreases the concentration of
extracellular pyrophosphate, which is an inhibitor of mineralization[94]. The unfrozen con-
trol had an ALP activity of 1.821±0.08nMol/cell/hour. Cells from the frozen control have
a slightly reduced activity at 1.62±0.12nMol/cell/hour, although this is not statistically
di↵erent.
Figure 5.7: Phenotype data derived from alkaline phosphatase activity of HOS TE85 cells
after exposure to DMSO before and after cryopreservation for up to 120mins. Data derived
from duplicate measurements from three independent experiments. Error bars represent
±SD. * represents a statistically significant di↵erence from the respective non-overexposed
control (p<0.05).
Cells exposed to DMSO for at least one hour all had significantly reduced ALP activity
thus a↵ecting the osteoblastic phenotype as shown in Figure 5.7. A reduced expression of
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ALP has previously been noted in pancreatic cells after exposure to DMSO[185]. That the
just exposure 60 and 120 minute groups were statistically similar to the two frozen groups
would appear to indicate that it was purely DMSO overexposure rather than a combination
with freezing that caused detrimental phenotypic changes. Further confirming that DMSO
is culpable for the reduced ALP activity is that there was no significant di↵erent between
experiments at the same time points. Whilst recovery of ALP activity has been demonstrated
in bacterial cells through biochemical cues such as adenosine triphosphate (ATP)[90], these
cells retained the reduced ALP activity through at least one passage post-thaw. As cells are
likely to be delivered to patients within hours rather than days post thaw, the detrimental
e↵ects on phenotype are likely to have an impact on therapeutic delivery should this result
correlate to more therapeutically relevant cells.
Once again, this shows the ine↵ectiveness of the 70% viability on thaw threshold FDA
criterion[38]. All six 60 and 120 minute groups had average viabilities in excess of this
threshold, but had significantly reduced alkaline phosphatase expression.
5.1.5 Apoptosis
Long-term exposure to DMSO may cause induction of apoptosis, or even necrosis. An AV-PI
assay was used to determine the nature of this induction (Section 3.9). AV attaches to the
negatively charged phospholipid phosphatidylserine which is normally located on the inner
leaflet of the lipid bilayer that makes up the cell membrane, but this is flipped in early stage
apoptotic cells [131]. PI stains cell nuclei passing through compromised cell membranes and
therefore is a marker of late stage apoptosis and necrosis[225]. A control group of cells from
a stable culture were shown (Figure 5.8a) to be approximately 6.1±0.87% pre-apoptotic
using this assay.
It has previously been shown that normal freezing tends to increase apoptosis in population
of a number of cell phenotypes[171, 310] and in the case of these HOS TE85 cells the
frozen control was 30.98±1.61% pre-apoptotic statistically similar to cells exposed to DMSO
for 15-60 minutes using the Freeze + Exposure scenario. Figure 5.8b shows that all five
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Figure 5.8: (A) Flow Cytometry Histogram of HOS TE85 cells in stable culture assessed
using an Annexin-V/PI assay showing little pre-apoptotic cells. (B) Cells in pre-apoptosis
on thaw after over-exposure to DMSO containing cryomedium before freezing. Data are
the mean of duplicate measurements of three independent experiments ±SD and based
on 10,000 ±500 events, gated for singlets. * represents a statistically similar homogenous
subset (p<0.05).
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frozen groups were statistically di↵erent to the non-frozen control. The cells exposed for
120 minutes had a slightly higher proportion of apoptotic cells at 36.31±1.55%, this was
significantly di↵erent (p=0.02) to the non-overexposed control.
These results indicate that there was limited additional activation of the apoptosis cascade
caused by 120minutes of DMSO overexposure- roughly a 17% increase.
5.2 hMSC
5.2.1 At Exposure Viability and 1hr Attachment E ciency
As with the HOS TE85 cells, viability of hMSCs was assessed immediately on thaw or after
exposure (Figure 5.9a). The most significant reduction in viability was when cells were
overexposed to the DMSO cryomedium for 2 hours after thawing. This resulted in a viability
of 74.1±4.0%. The only other significant reduction from the non-overexposed controls was
observed in the Just Exposure 120 minute group at 92.8±0.8%. In the other exposed groups
viabilities ranged from 89.3% to 97.3%, indicating that below two hour exposure has virtually
no e↵ect on cell viability, in line with the HOS TE85 cells.
When however data from the frozen groups was compared to that from stable culture (i.e.
cells that have never been exposed to DMSO), notable changes in viability are observed. The
baseline experiments in Section 4.4 showed an average viability of 96.2±1.4%, significantly
lower viability was observed in all of the exposed Exposure + Freeze groups and the 60 and
120 minute Freeze + Exposure group. As previously seen in the HOS TE85 cells, this shows
that DMSO exposure on its own did not cause drops in viability, it was a combination of
exposure and cryopreservation causing significantly lowered viability on thaw.
Attachment was observed three hours after culturing in tissue flasks. Attachment at low-
passage of the non-frozen control was shown to be 81.6±6.0% and the frozen control to
be 83.2±6.7%. This demonstrated that as-fast-as-possible normal cryopreservation had no
e↵ect on cells ability to adhere to culture plastic on thaw. The reductions shown in Figure
5.9 were therefore assumed to be due to overexposure to DMSO and not a function of
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Figure 5.9: (A) Viability with respect to membrane integrity and (B) attachment e ciency
of bone marrow derived hMSCs after exposure to DMSO before and after cryopreservation
for up to 120mins. Data are the mean ± SD derived from two duplicates from three inde-
pendent experiments. * represents a statistically significant di↵erence from the respective
non-overexposed control (p<0.05).
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the cryopreservation process. In the most extreme case (Freeze + Exposure, 120 minutes),
attachment was reduced to just 52.7±9.1%, this significant reduction in cell adherence
showed that whilst a population appears over 70% viable, just over half of those cells attach
and are thus able to proliferate. One hour over exposure had significant e↵ects on cell
attachment in both frozen groups, which all had on thaw viabilities substantially higher than
the 70% release threshold. This was in contrast to the HOS TE85 group, where none of the
Exposure + Freeze group were statistically lower than the non-overexposed control. Tissue
plastic adhesion is the first hMSC criterion defined by Dominici et al in 2006[65]. The results
here appear to illustrate that whilst cells are above the FDA’s viability threshold for release, a
significant minority of cells in the population would not be considered mesenchymal stem cells
on thaw and so might not bestow their therapeutic benefit should they be transplanted into
patients. The fact that data from Appendix D showed that merely holding cells for substantial
durations does not a↵ect cell viability, attachment or yield has previously been noted. Whilst
the data in Appendix D are from HOS TE85 cells, these findings in combination with the
present experiment suggest that should cells be washed post-thaw they would continue to
be viable for at least two hours prior to transplantation potentially easing clinical transfer.
5.2.2 Short and Long Term Growth and Viability
The hMSCs also showed a downward trend in growth with increasing exposure time over the
first passage (Figure 5.10a), in all three experimental regimes. However, statistical analysis
shows that only the 60 and 120 minute Exposure + Freeze groups were significantly di↵erent
from the non-exposed control. This increased e↵ect on the Exposure + Freeze group e↵ect
is likely due to the fact that hMSCs react more strongly to environmental changes than HOS
TE85s. The drastic reduction in growth rate during the first passage after thaw could become
an important consideration should cryopreserved vials of hMSCs be needed for growing the
large number of cells for working banks and therapeutic doses. A 50% reduction in growth
rate will require twice the number of vials, or twice the culture time to reach therapeutic levels
i.e. >1x109 cells [232]. This could increase costs by doubling the amount of manufacturing
campaigns to satisfy the same market demand.
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Figure 5.10: Growth (A) over one passage (displayed as a rate) and (B) five passages
(displayed as total fold expansions) of bone marrow derived hMSCs after exposure to DMSO
before and after cryopreservation for up to 120mins. Data are the mean ±SD derived from
two duplicates from three independent experiments. * represents a statistically significant
di↵erence from the respective non-overexposed control (p<0.05). (C) Normalised data of
attachment e ciency and total fold expansions over five serial passages of hMSC cells after
exposure to a DMSO containing cryomedium and then washing for up to 120 mins.
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For long term growth, a five serial passage experiment with the Just Exposure group was
conducted as shown in Figure 5.10b. A significant reduction in total growth over the five pas-
sages was observed in the 120minute group- 11.40±0.51 fold expansions versus 14.39±0.58
fold expansions for the frozen control.
Culture of hMSCs takes a substantial amount of time, typical seeding at a density of
5000cells/cm2 takes 5-7 days to reach confluence[163, 244]. Consequently a 5 passage
experiment may take well over a month, which in a manufacturing process would be too
long a period over which to accurately determine long term growth e ciency. Mitchell et
al [190]previously noted that adherence of human embryonic stem cells has “the highest sen-
sitivity [of studied factors] to long-term recovery in response to process variation”. One hour
attachment under these conditions could therefore reflect the longer term growth potential
for these cell lines.
Data from the five serial passages were gathered for the Just Exposure group of hMSCs and
normalised to the previously gathered attachment data, shown in Figure 5.10c. Comparing
these normalised values shows an average error of just 1.63% This shows that that cell
attachment after three hours is strongly correlated with long-term expansion potential of
this mesenchymal stem cell population. Mechanistically, this is explained by cells needing to
be adherent to replicate. Fewer cells adhering means a smaller seed population and long-term
expansion potential is determined by the initial seed population and subsequent expansion
rate. As expansion time increases, the impact of the size of the seed population size is
amplified. Therefore, the correlation between seed population and expansion potential will
be maintained ad infinitum and will be more important the greater the duration of expansion.
In tissue plastic culture, cells are often disposed of at passages, but in scaled up processes,
with bioreactors, culture area is increased with perhaps an addition of microcarriers, and
so a smaller seed population would a↵ect ultimate cell number. Further analysis with the
previously acquired HOS TE85 data (not shown) showed that this correlation is also true
for this cell line with a average error of just 6.3%. This allows for a much quicker analysis
process- weeks compared to hours for determining the long term e↵ect on cell proliferation
and this surrogate marker also allows for an e cient estimate of expansion potential.
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5.2.3 Metabolism
Medium samples were collected at both passage and freeze and in combination with the cell
growth values the values of glucose consumption and lactate production were calculated on
a per cell basis. Additionally, the yield of lactate from glucose was calculated.
First observing glucose consumption (Figure 5.11a), a significant increase is observed in all
three populations over-exposed to DMSO for two hours, and the 60 minute Just Exposure
group. The peak glucose consumption is in the 120minute Freeze + Exposure group at
17.45±2.15pMol/cell.day, double that of cells that have not been cryopreserved at all, and
62.2% higher than the non-overexposed control group. There is a clear trend of increased
glucose consumption as DMSO containing cryomedium exposure is increased- with regression
values, R2, around 0.8 for all three experimental groups- indicating that what caused the
increased glucose consumption did not plateau, for example.
The lactate results (Figure 5.11b) were somewhat similar to the glucose results, with signifi-
cant increases observed in all three 60 and 120minute groups. The peak here being again in
the 120minute Freeze + Exposure group at 54.58±5.00pMol/cell.day- over 3.4 times higher
than non-frozen cells and almost 2.7 times higher than the non-overexposed group. Again,
there is strong correlation with exposure time. This indicates that the cells were highly
stressed and when considered with the yield data (Figure 5.12) where values in excess of
the 2mol/mol threshold[92] were observed in all but the Just Exposure 15, 30 and 60minute
groups. These high yield values indicated that populations are likely reliant on additional
energy sources in the medium- glutamine for example. Most values here were below 2.5mol/-
mol, it was only both 120minute groups and the 60minute Freeze + Exposure group that
exceed 3mol/mol, this shows that these cell populations were strongly reliant on additional
energy sources to recover from the damage caused by a combination of cryopreservation and
DMSO exposure.
It is likely that the a detrimental change in metabolic activity was a key cause of the reduced
growth rate. It has previously been shown that a build up of lactate and other waste products
can be detrimental to cell health[218] and with the increased lactate production observed
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Figure 5.11: (A) Glucose Consumption and (B) Lactate Production of bone marrow derived
hMSCs over one passage after exposure to DMSO before and after cryopreservation for up
to 120mins. Data are the mean ±SD derived from two duplicates from three independent
experiments. * represents a statistically significant di↵erence from the respective non-
overexposed control (p<0.05).
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here, it is unsurprising that expansion was slowed on thaw. Slowed growth caused by higher
lactate concentrations has previously been observed by Ozturk et al [205] in murine cells.
Figure 5.12: Metabolic yield of lactate from glucose of bone marrow derived hMSCs over
one passage after exposure to DMSO before and after cryopreservation for up to 120mins.
Data are the mean ± SD derived from two duplicates from three independent experiments.
* represents a statistically significant di↵erence from the respective non-overexposed control
(p<0.05).
From a therapeutic perspective, questions must be raised as to the cells’ health and quality if
such ine cient metabolism is promoted after long exposure to DMSO. As has previously been
mentioned, Mesoblast state that Prochymal “must be infused within 5 hours from thaw”
and the protocol does not include a washing step that would remove all of the DMSO, only a
3:5 dilution step which would still leave a concentration of around 4%, perhaps still enough
to cause the detrimental e↵ects here observed[33].
5.2.4 Phenotype
To determine the phenotype of the hMSCs the multi-parameter flow cytometry assay was
employed. This was performed one passage post thaw/exposure and so the data are presented
with confidence that it was not an e↵ect of the presence of DMSO in the cells. The expression
DMSO Toxicity 157
of five antibodies was investigated; the co-expression of these is shown in Figure 5.13 this was
calculated using the method previously described in Section 4.4.3 and Figure 4.21. Results
from the non-frozen control showed an average co-expression of 97.9±1.3% and cells from
the frozen control showed an average co-expression of 94.9±4.3%. The ISCT criteria are
developed only for single-marker expression and as such do not advise on the required co-
expression level[65]. Multiplying the criteria thresholds together (i.e. 95% x 95% x 95% x
98% x 98%) gave a threshold of 82.3%. For these data, any populations with co-expression
of the five markers below 82.3% the single parameter expression of the markers were observed
to deduce what caused the multi-parameter value to fall below the threshold.
Figure 5.13: Multiparameter expression of CD73+, CD90+, CD105+, CD34- and HLA-
DR- of bone marrow derived hMSCs one passage after DMSO expsoure and either without,
before, or after cryopreservation. Data are the mean of duplicate measurements from
three independent experiments ±SD. Based on  5000 events. * represents a statistically
significant di↵erence from the respective non-overexposed control (p<0.05).
Considering first significant phenotype changes from the control groups, there were changes
across all three groups as DMSO exposure time increases, significantly in the three 120minute
groups, and the 60minute Exposure + Freeze and Freeze + Exposure groups. In the most
extreme case, co-expression was just 68.3±2.6%.
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Therefore, exposure of over an hour to DMSO has a substantial e↵ect on the hMSC phe-
notype after the cryopreservation process. The change in expression possibly indicated the
promotion of hMSC di↵erentiation by DMSO, this could be further verified by conducting
quantitiave di↵erentiation analysis for example. Di↵erentiation promotion caused by DMSO
exposure has been previously described by Pal et al [206]. As previously mentioned Katkov
et al [138] also reported a change in phenotype upon prolonged exposure to DMSO with a
reduction in Oct-4 expression in hESC cells. In all cases, the reduction in overall phenotype
co-expression is caused by a substantial down-regulation of CD73 expression- one of the key
positive markers and responsible for part of the immunological properties of hMSCs. For
example, the 120minute Freeze + Exposure group has a CD73 expression of 77.3±4.0%, a
sample histogram with a sample control group is shown in Figure 5.14. The significant down
regulation could be responsible for additional cellular changes. CD73 or 5’-nucleotidase is
an enzyme which is responsible for certain immunological functions[5]. The reduction in
CD73 expression could signify a change in function caused by DMSO over-exposure and
cryopreservation. Wang et al [292] showed that CD73 helps control graft-versus-host disease
(GvHD) in a murine model. The consequences of a down regulation demonstrated here could
be even more severe- blocking CD73 caused a patient’s GvHD to deteriorate. Prochymal
is approved to treat GvHD, and there is considerable global interest in this application for
hMSC therapy [226].
5.3 Confirming the Tolerance
The data from Sections 5.1 and 5.2 showed that to prevent detrimental e↵ects on viability,
attachment, growth, metabolism and phenotype, exposure to medium containing DMSO
should be kept to below 1 hour most importantly post-thaw. This could have ramifications
for scaled-up processes, it taking periods exceeding this to fill cryobags[107], or to process
large numbers of vials both before and after cryopreservation. Additionally, at a clinical site,
medical sta↵ will need to be aware of tight parameters related to the thawing of therapeutics;
thawed doses needing to be used within the hour may a↵ect clinical procedures.
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Figure 5.14: Sample histogram of CD73 expression of bone marrow derived hMSCs one
passage post thaw, either with or without 120minute DMSO overexposure. Based on
 5000 events. Gating is based on the 120minute group.
To validate the tolerance of cells of up to 1 hour exposure, additional analysis was performed
to confirm this parameter and to investigate if there were any additional e↵ects on cell quality
and function. Three separate experimental procedures were conducted:
• Confirming that the temperature of exposure does not have an e↵ect on cell health on
thaw.
• Expanding the analytical toolbox used to define this parameter to investigate whether
the cells had been a↵ected in additional ways and possibly discerning the reasons
behind the drop in cell health and quality.
• It was also determined whether these findings were unique to this MSC line. It was
important to assess if similar results occurred in a cell line derived from a di↵erent
donor.
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5.3.1 Temperature of Exposure Environment
Some cryopreservation protocols note the importance of the temperature at which cells are
exposed to DMSO during the cryopreservation process[121, 123, 124]. Often it is advised
to use a combination of chilled (4°C) room temperature (⇡20°C), or 37°C environments to
improve cell health on thaw. The previous data are all based on over-exposing cryovials
containing cells in the environment where the standard cryopreservation protocols suggest:
when freezing, at room temperature and when thawing, in a 37°C water-bath.
To confirm the findings of the previous experiment HOS TE85 cells were exposed to DMSO in
three di↵erent environments- in a 4°C fridge, in the lab safety hood, at room temperature and
in a 37°C water bath. Cells were exposed to DMSO for two hours in the three environments,
washed and analysed (Just Exposure) or frozen as normal and then thawed and kept in the
three environments for two hours, washed and then analysed (Exposure + Freeze). The cell
populations were then assessed for at exposure viability, 1hr attachment, and 24 hours later,
yield. Temperature validation of these environments are shown in Appendix B.
First looking at at-exposure viability, the data show that there was no significant di↵erence
between the three environments. The viabilities of all three just exposure groups were
between 89% and 91%, and all three Exposure + Freeze groups between 70% and 74%.
Whilst these data are from a separate experiment, they are also not statistically di↵erent
from the results from the earlier experiment described in Section 5.1.1.
Looking at the attachment e ciency data showed no significant di↵erence in the Just Ex-
posure group, 70-71% of the cells just exposed without freezing to the DMSO cryomedium
attaching after one hour. The results from Exposure + Freeze groups show a lowered but
non-statistically significant reduction (4°C p=0.065, RT p=0.055) in cell adhesion after one
hour compared to the 37°C control. 64.4±5.1% of cell population in the control environment
(37°C) attached after one hour whereas 57.6±2.5% and 57.4±3.5% of the cells thawed in
the fridge and bench-top respectively attached after one hour.
The cells were cultured as normal in a 37°C incubator for 24hours and then assessed for
growth over that period. Again, there was no statistical di↵erence in either the just exposed,
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Figure 5.15: (A) At Exposure viability, (B) 1hr attachment and (C) 24hr yield of cells
exposed to a DMSO containing medium for two hours in three di↵erent environments,
washed and cultured, or frozen, and thawed in three di↵erent environments for two hours.
Data are the mean of two duplicate measurements from three independent experiments ±
SD.
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or the exposure + freeze groups exposed to DMSO in the three di↵erent environments.
The yield from the just exposure group ranged from 161-176% and from 150-159% in the
exposure + freeze group.
Finally, to confirm that it is primarily DMSO exposure and cryopreservation that causes
reduced cell health and not being kept in suspension, cells were kept, at room temperature
in fresh medium, in a non-culture plastic vessel. At the start and after two hours they
were assessed for viability and there was no significant di↵erence. These data are shown in
Appendix D.
Overall these results demonstrate that the reduced viability, attachment and growth rates
observed in the cell populations in the earlier experiments was caused by DMSO exposure
above freezing during the cryopreservation process and very similar e↵ects occur at di↵er-
ent exposure environment temperatures. The data from this experiment showed that the
temperature of the exposure environment has no additional significant e↵ect on the viabil-
ity, attachment and proliferation of the cells on thaw. Studies do not tend to investigate
what di↵erent thawing temperatures have on cell proliferation post thaw sometimes rely-
ing on chilled washing medium with the belief that this will prevent further toxic e↵ects
of DMSO[123]. A 2012 study from Ramachandran et al [219] found that resuscitation of
peripheral blood mononuclear cells (PBMCs) using ice chilled medium and cells at a similar
temperature was not significantly di↵erent to cells thawed at 37°C, noting that “exposure
to DMSO [for up to 30 minutes was] a low risk step during the thawing process”[219].
5.3.2 Additional Analysis
To further establish the tolerance to DMSO of less than an hour, additional analysis was
conducted. Vials of hMSCs were preserved, as normal, and cells over-exposed (i.e. Freeze
+ Exposure) to a time point above and below the hour limit- 30 minutes and 120 minutes
along with a non-over exposed control group. In all above studies, two hour over-exposure
post-freeze caused the most damage to cells, and indeed in all studied metrics significantly
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di↵erent than the non-overexposed control, whereas 30 minute exposure was statistically
similar to the non-overexposed control.
5.3.2.1 Cell Size
First cell size over the course of one passage was analysed. DMSO has been shown in the
literature to cause cell swelling[216]. HMSCs range in size from 8-50µm[89]. Ge et al [89]
separated these into a small fraction (average diameter of 17.9µm) which did not cause
any complications to patients with stroke and into a larger population (average diameter
30.4µm) which did cause an increase of vascular obstructions[89]. These hMSCs at passage
from stable culture have a diameter of 17-18µm, changing as the cells grow and split.
Table 5.3: Average cell diameter of human mesenchymal stem cells over one passage post-
thaw after normal thawing, 30 and 120 minute overexposure. Data are the mean of dupli-
cate measurements from three independent experiments ± 95% confidence interval. The
analytical device’s range is 0-20µm, anything above is displayed as >20µm
Cell Size (µm)
Exposure Time Day 0 (Thaw) Day 3 (Feed) Day 7 (Passage)
Non Overexposed 18.5±0.6 16.2±0.3 17.9±0.7
30mintues 18.7±0.5 16.2±0.6 17.5±0.5
120minutes >20 15.8±0.3 17.6±0.5
On thaw, the non-overexposed, and 30minute exposure cells had diameters of 18.5±0.6µm
and 18.7±0.5µm respectively, the cells swelled slightly from the cryopreservation process-
Table 5.3. This average size is very close to that observed by Ge et al [89] in their small
fraction. The cells overexposed to DMSO however were outside the analytical range of the
instrument used: they had swollen to at least 20µm in all samples, indicating that long
exposure to DMSO containing freeze medium caused significant swelling and therefore could
represent that these cells could cause, for example, vascular obstructions.
The results at feed and passage, shown in Table 5.3 show two key points- the non-overexposed
and overexposed groups were statistically similar at both time points. The measurement at
feed is smaller likely due to the cells in a G1 growth phase, just after mitosis. That the three
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groups were similar at the two time points shows that any swelling caused by DMSO over-
exposure was quickly alleviated and did not further complicate cell viability or proliferation in
later culture. The swelling could have been caused by the increased osmolality of a DMSO
containing freeze medium but fact that the swelling is alleviated within three days post thaw
indicates that any damage is not permanent.
5.3.2.2 IDO Expression and Function
IDO is a key enzyme in humans. It catalyses the degradation of L-tryptophan- an essential
amino-acid to N-formylkynurenine, starting the kynurenine pathway. This pathway is believed
to be critical for the immune response of stem cells[56]. It has been shown that hMSCs
migrate to inflammation sites and demonstrate substantial immunomodulatory e↵ects by
regulating the local immune response[36].
Tryptophan is one of 9 essential amino acids the human body is unable to synthesise and
so must be consumed through diet, for example. For the ex vivo culture of the hMSCs
investigated here, it is present in common DMEM formulations[252]. By exposing hMSCs
to IFN-  and TNF-↵ IDO activity can be induced in vitro[132]. IFN-  is the most potent
activator of tryptophan and thus the kynurenine pathway, with TNF-↵ less so but still an
activator.
Tryptophan
IDO   ! Formylkynurenine  ! Kynurenine (5.1)
There has been a move in the cell therapy industry to move towards hMSCs as an immuno-
logical therapy after a study showed treatments with hMSCs had a surprising and substantial
immunosuppressive e↵ect[156]. However, it has been proposed that cryopreservation causes
reduced immunomodulatory e↵ects in cryopreservation, and showing if DMSO overexposure,
in combination with cryopreservation exacerbates this [193]. The previous studies herein,
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focused on the quality and identity of hMSCs, although it is crucial for hMSC therapy com-
mercialisation for any changes in function caused by engineering of the therapies, including
in cryopreservation.
Human mesenchymal stem cells were frozen and thawed; one group cultured immediately,
two other exposed to the DMSO containing cryomedium for thirty minutes and two hours in
a 37°C water bath. After three days in culture the cells were cultured in a medium containing
IFN-  and TNF-↵ as described in Section 3.10 to induce IDO activity. Over the next four
days, medium aspirate samples were taken and then assessed for N-formylkynurenine content.
The process in the assay described in Section 3.10 hydrolyses this to kynurenine, which can
then- after reacting with Ehrlich’s reagent- can be colourimetrically assessed. Based on cell
numbers, the concentration in the medium can then be determined on a per-cell basis.
Figure 5.16: Kynurenine activity of bone marrow derived cells after being cultured in a
cytokine spiked medium three days after thaw and overexposure to a DMSO containing
cryomedium for up to two hours. Data are the mean of duplicate measurements from three
independent experiments ±SD. * represents a statistically significant di↵erence from the
respective non-overexposed control (p<0.05).
Figure 5.16 shows that two hour over exposure to DMSO caused significantly lower IDO
activity over the 4 days post feed. Cells appeared to have IDO activity on days 1 and 2
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then reaching peak activity which remains constant over the rest of the passage. With
regards to DMSO exposure on Day 1, there is no statistical di↵erence between those cells
overexposed and those not (p=0.60), on the remaining days, the 30minute exposed group
was statistically similar; reaching a peak of 0.432±0.430nMol/cell (on day 2) compared to
0.453±0.045nMol/cell (on day 4). The 120minute group however reaches a peak around
29% lower than that of the non-exposed group: 0.351±0.020nMol/cell (on day 2)
Further, earlier analysis in Section 5.2.4 showed that there was significant down-regulation in
CD73 expression. Any changes in kynurenine expression could be the fault of down regulation
of this extra-cellular marker.
The therapeutic role of hMSCs is still under debate and whether the immunomodulatory
function is relevant to clinical application remains to be seen. Nevertheless, that two hour
DMSO overexposure caused significantly lower IDO activity, not seen in 30 minute exposure,
shows again that developing new techniques and assays to determine release criteria is crucial.
Also, it shows that overexposure did have an additional e↵ect on IDO expression compared
to freezing alone.
5.3.2.3 Di↵erentiation
The non-exposed and 120 minute groups were subjected to di↵erentiation protocols. Cells
were cultured in di↵erent lineage-specific media to investigate whether or not after long-
term DMSO exposure cells could still di↵erentiate down the tri-lineage typical of human
mesenchymal stem cells. Figure 5.17 shows that the capacity to di↵erentiate was not lost
despite the overexposure and the significant change in cell phenotype previously shown in
Section 5.2.4.
5.3.2.4 NH4+ Metabolic Pathway
It has previously been noted (Section 5.2.3) that exposure to DMSO caused the metabolism
to change in the hMSCs, likely the fault of DMSO overexposure. The yield of lactate
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(a) Adipocytes (b) Chondrocytes (c) Osteocytes
Figure 5.17: Di↵erentiation capacity of bone marrow derived human mesenchymal stem
cells after two hour exposure to DMSO containing cryomedium after thawing depicting (A)
Adipogenic, (B) Chondrogenic and (C) Osteogenic di↵erentiation. Observed through a 10x
objective lens. Scale bar represents 0.1mm. Representative images of four repeats.
from glucose in most cases above 60minute exposure is beyond the 2mol/mol theoretical
limit. It was proposed that the increased yield is caused by the use of additional energy
sources in the growth medium- likely glutamine. As part of the Kreb’s cycle, the non-
essential amino acid glutamine- which was added to the medium at a 2mMol concentration
(Section 3.3.3) was deaminated to glutamate, thus producing ammonium as a waste product.
Ultimately, the glutamine was converted to pyruvate in a process called glutaminolysis.
Pyruvate was thus next converted to lactate or alanine, or was completely oxidised by the
Kreb’s cycle[92, 242, 243]. Figure 4.3 shown earlier includes this metabolic pathway. It was
by this mechanism that the increased metabolic yield was hypothesised to have increased by
DMSO over-exposure.
The Nova bioanalyser also measured ammonium content in medium aspirate (Section 3.8).
Medium samples were tested at feed and passage and in combination with the earlier growth
data (Section 5.2.2) the per-cell ammonium production determined.
All three groups had statistically similar per-cell ammonium production of between 2.03-
2.16pMol/cell.day over the seven days, as shown in Figure 5.18. However observing the
data at feed on day 3 the cumulative consumption of the 120minute group was significantly
higher than the non-overexposed control group, 4.0±0.1pMol/cell versus 2.3±0.2pMol/cell.
The 30minute group however was similar to the non-overexposed group. This increased am-
monium production early on was likely have been the cause of increased lactate production,
through the Kreb’s cycle. Glutamine is a non-essential amino acid and these data show that
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Figure 5.18: Cumulative NH4+ production of bone marrow derived human mesenchymal
stem cells after up to two hour over-exposure to DMSO containing cryomedium after thaw-
ing. Data are the mean of duplicate measurements from three independent experiments
±SD. * represents a statistically significant di↵erence from the respective non-overexposed
control (p<0.05).
the cells were reliant on additional energy sources to recover from DMSO over-exposure
over the first few days on-thaw. However, glucose concentration is not a limiting factor-
there is still glucose present at both feed and passage and so the cells were perhaps respond-
ing to DMSO over-exposure and supplementing glycolysis by activating their glutaminolysis
pathways.
5.3.3 Additional Cell Line
All mesenchymal stem cell donors are di↵erent. Each grow at slightly di↵erent rates, and
react to stimuli in varying ways[250, 251]. All previous hMSC work has been performed
on one line (hereon M7), from one donor, and whilst significant important e↵ects have
been noted on cell identity and quality, it was essential to repeat key experiments with an
additional hMSC line, from a di↵erent donor (hereon M4).
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Vials of hMSCs from this second donor were frozen at P6 and thawed. Some were thawed as
normal, others were exposed to DMSO for two-hours. Cells were then assessed for viability
and attachment, cultured for one passage and then analysed for growth, metabolite flux and
phenotype. Data from these experiments were then compared to data from M7.
5.3.3.1 On Thaw Viability and Attachment
Considering first on thaw viability, experimental data showed that the M4 cells respond in a
very similar way to cryopreservation after two hour DMSO exposure. Both the control and
overexposed groups were statistically similar to the equivalent M7 results.
Attachment e ciency was also considered. Here, non-overexposed cells from both lines were
statistically similar. In the 120 minute group however, the M7 and M4 cells were statistically
di↵erent- at 54.87±4.70% for M7 and 63.88±2.21% for M4. However, the M4 attachment
was statistically lower than the non-exposed group, showing that whilst the attachment here
is slightly higher, DMSO exposure does cause significantly lower attachment in both cell
lines.
5.3.3.2 Short Term Growth and Viability
After thaw, the cells were cultured for one passage. At passage they were assessed for viability
and number and from this their daily fold expansion rate determined, this is shown in Figure
5.20. Both cell lines grew at a statistically similar rate and the populations were similarly
viable after one passage in culture post thaw. The M7 line grew at a rate of 0.34±0.04fold
expansions/day and the M4 line at 0.31±0.02fold expansions/day.
5.3.3.3 Cells Metabolic and Phenotypic Response
The M4 cell line has a similar metabolic response- an increased yield of lactate from glucose
after 120minute over-exposure to DMSO- 1.95±0.26mol/mol to 2.89±0.58mol/mol. These
DMSO Toxicity 170
(a)
(b)
Figure 5.19: (A) On Thaw Viability and (B) 3hr Attachment E ciency of two bone marrow
derived hMSC lines from independent donors after exposure to DMSO containing cry-
omedium for two hours on thaw. Data are the mean of duplicate measurements from three
independent experiments ±SD. * and ** represent statistically similar homogenous subsets
(p<0.05).
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Figure 5.20: Daily fold expansion rate of two lines of bone marrow derived hMSCs one
passage post-thaw with or without 120minute DMSO over-exposure. Data are the mean
of duplicate measurements from three independent experiments ±SD. * and ** represent
statistically similar homogenous subsets (p<0.05).
data are statistically similar to the previously gathered results from M7, and shown in Figure
5.21a. Further the per-cell glucose uptake and lactate production are shown in Table 5.4.
Table 5.4: Change in metabolite concentrations in pMol/cell.day of of two lines of bone mar-
row derived hMSCs one passage post-thaw with or without 120minute DMSO over-exposure.
Data are the mean of duplicate measurements from three independent experiments ±SD.
Non-Overexposed 120minutes
Metabolite M7 M4 M7 M4
Glucose Uptake 10.75±2.10 10.32±0.86 17.45±2.69 13.17±3.14
Lactate Production 20.381±0.41 19.97±2.07 54.58±5.00 37.12±6.70
Ammonium Production 2.90±0.18 3.09±0.28 2.66±0.15 3.20±0.33
M4’s glycolysis after 120minute DMSO exposure was statistically di↵erent to M7’s. This
is another example of donor-donor variability. Glucose uptake and lactate production were
significantly higher in M7, but still significantly higher than the control group. This shows
DMSO Toxicity 172
that whilst the response was di↵erent across cell lines, the ultimate result- changed yield
of lactate from glucose, and reliance on glutmaine remains similar. Comparing phenotypic
changes in the M4 line after 120minute post-cryopreservation DMSO exposure to the M7
line, a very similar response was seen. As shown in Figure 5.21b, the non-over exposed group
had co-expression of 95.82±3.82% and the 120minute exposed group had co-expression of
74.42±9.00%. These results are statistically di↵erent, but similar to the respective M4
result. Again the major drop in overall co-expression was due to a down regulation in CD73
expression.
Overall, these data show that the M4 line reacted to DMSO over-exposure in a very similar
way to M7. In some cases the responses were di↵erent- M4 had a significantly higher
attachment e ciency, and lower glycolysis rates. Donor-donor variability is a known concern
in the development of cell therapeutics[250]. However, in every case, where DMSO over-
expsoure caused a significant e↵ect on M7, a significant e↵ect also occurred in M4. Whilst
these data are from only two hMSC populations, the earlier “one hour” parameter can be
concluded to be valid.
5.4 Concluding Discussion- What does a one hour parameter
mean?
Clinically relevant cells should not be kept exposed to DMSO, above freezing, for longer
than one hour to prevent detrimental e↵ects on cell viability, growth, identity, metabolism
and function.
Herein, it has been shown that DMSO has an as yet unexplained, but significant e↵ect
on several cell metrics when cells are exposed for periods longer than would be normally
expected in vitro. It was hypothesised however that this could have been due to DMSO
remaining in the cells after exposure for more than an hour, to investigate this an assay
using Suspended Ion Flow Tube Mass Spectrometry (SIFT-MS) was employed. Preliminary
data are shown in Appendix E, briefly however the data appear to show that this is indeed true
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Figure 5.21: (A) Metabolic Yield of Lactate from Glucose and (B) Multiparameter ex-
pression of CD73+, CD90+, CD105+, CD34- and HLA-DR- of two lines of bone marrow
derived hMSCs one passage post-thaw with or without 120minute DMSO over-exposure.
Based on  5000 events. Data are the mean of duplicate measurements from three in-
dependent experiments ±SD. * and ** represent statistically similar homogenous subsets
(p<0.05).
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and even after washing DMSO remains in the cells. Nevertheless, in the main experiments
substantial changes in cellular adhesion and identity were observed in both HOS TE85 cells
and bone marrow derived hMSCs. The detrimental changes in the hMSCs raised questions of
their therapeutic function and it was shown that they had reduced immunological function,
defined by means of IDO expression. From a processing perspective, cell growth was slowed
on thawed potentially increasing the time required to process cells.
The ultimate impact of the significant e↵ects on the cells is the requirement for changes to
cell therapy manufacturing and therapeutic processes. In cell therapies viable cells are trans-
planted into patients, there they either aid regeneration of tissue, or as has been suggested
by Caplan, act as a “drugstore” for injury with the ability to establish a regenerative micro-
environment that regulates the immune response at the injury site and secretes bioactive
molecules[36]. Detrimental changes in cellular identity and function could cause a loss or
change in therapeutic function, raising questions as to what patients are being treated with-
is it an expensive placebo? Additionally and repeatedly shown was the di↵erence between
perceived and actual viability. Cells with reported viabilities on thaw higher than the FDA’s
release criterion of >70%[38] went on to grow slower, have significantly changed metabolic
profiles and fail to meet ISCT identity criteria.
Therapeutics, requiring >109 cells per dose [232] will require a much higher number of cells
than can be currently processed within single cryovials, GMP grade large vials or cryobags
will need to be used. Therefore the cell-cryoprotectant exposure time will necessarily need to
increase, the work presented here has shown that that to ensure no change in phenotype in
the cell types investigated, this period must be kept to below one hour but there may need
to be bespoke investigations for each cell line used. This may drastically reduce the scale
at which cell therapies can be manufactured. The maximum number of doses that could be
produced is around 60 per hour, enough, in the case of Prochymal to treat 15 patients. [107].
As such, tackling the issue of DMSO toxicity, by providing alternatives such as proline[81]
or non-permeable sugars like Trehalose in combination with permeabilising polymers[246],
proprietary cryoprotective media which are formed from a blend of cryoprotectants such as
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CryoMaxx which was investigated in Section 4.2 or negating the issue by improving delivery
technologies will be important for the commercialisation of cell therapies.
Chapter 6
The Xeno Issue
The previous chapters primarily focused on the CPA, for the most part DMSO, however the
other key component of a cryomedium, the vehicle solution is of interest as well. Here the
vehicle solution is defined what makes up the majority of a cryomedium, as suggested by
common cryopreservation protocols the most widely used is fetal bovine serum (also used
in the growth medium). As has been previously discussed in Section 2.8.3, there are a wide
range of drawbacks in using FBS including batch/batch variation, xenotoxicity and regulatory
needs.
Moving away from FBS will require an alternative formulation to meet some key objectives
to be viable. As was shown in chapter 4, cells preserved in an FBS based cryomedium recover
with good cell population viability on thaw in excess of 95% with equivalent cell quality to
an unfrozen group. It is desirable to remove bovine serum-based reagents from all parts of
the process: isolation, expansion, cryopreservation and down-stream processing. A review by
Lalu et al looking into the safety of clinical trials using hMSCs found that 27 of 36 used FBS,
5 used human serum and a further 4 did not list the source and further that FBS is used in
a vast majority of clinical cell culture protocols (75%) [152]. They also highly criticised the
use of FBS saying that “only one study specifically monitored for potential adverse events
associated with its use”, essentially the scientific community does not know the true e↵ect of
using FBS for clinical therapeutics, a paper from the US FDA suggested that cell products
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using animal-based solutions can take up xenological compounds which could limit their
viability and these include but are not limited to prions, bovine diarrhoea, antibody reaction,
reduced e cacy and changed immune response. The authors concluded that “continued
use of FBS for culture of human cell products for therapeutic intent, as is currently the
case for mesenchymal stem cells, may jeopardize engraftment, whereas its removal may
a↵ord a more favorable outcome” [235]. A review from Copland and Galipeau suggests
that exposure to the xenogenic FBS could cause human cells to become immunogenic [53],
this was demonstrated by Spees et al showing that around 1x108 hMSCs- equivalent to a
therapeutic dose- exposed to FBS in culture carry up to 30mg of bovine-sourced antigens,
and that in vivo these antigens could be released evoking a potentially detrimental cellular
e↵ect [53, 260]. The need to move away from animal compounds for therapeutic application
is clear. Copland and Galipeau suggest that even autologous transplanted MSCs could be
quickly rejected by the host which would then develop natural antibodies which would then
prevent any future cell therpaies being applied where FBS xenoantigens are present[53].
The alternative will also need to be a↵ordable. The FBS used in these experiments costs ap-
proximately £261 for 500mL (i.e £0.52/mL) (the cost of DMSO is negligible) whereas CryoS-
torCS10 from BioLife solutions, a complete cryomedium costs around £215 for 100mL[277],
(i.e. £2.15/mL) over four times the price. Serum Free Media such as StemPro cost the
equivalent of £0.40/mL wheras FBS supplemented DMEM costs around £0.08/mL , again
far cheaper. For commercial as well as clinical application, an alternative vehicle solution
will need to be at an appropriate price point. It should be noted, however, that economies
of scale would most likely reduce the cost of these more expensive media as production
increases.
In this chapter first a wide range of vehicle solutions were screened, and then a candidate
for further analysis meeting the previously defined objectives was selected- human platelet
lysate. What follows is then detailed analysis of utilising human platelet lysate as an alternate
cryopreservation vehicle solution in combination with it as a culture supplement.
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6.1 Vehicle Solution Screen
6.1.1 Overview of Experimental Procedure
Human mesenchymal stem cells in a stable, mid-passage (6) culture were frozen in ten
di↵erent cryomedia made up, unless noted as 90%wt vehicle solution with 10%wt DMSO:
• 100%wt FBS
• FBS
• Stemulate (pooled human platelet lysate)
• DMEM Growth Medium (i.e. 10%wt FBS)
• 90%wt Hypothermosol FRS
• Pseudolyte A with 5%wt human serum albumin (hSA)
• 100% Hypothermosol FRS
• 100% Pseudolyte A with 5%wt hSA
• 100% XerumFreeZ
• 100% Sigma-Aldrich Cell Freezing Solution
The wide range of vehicle solutions included FBS as a control, pooled human platelet lysate,
two defined solutions used as vehicles and two commercial cryomedia, the first known to be
entirely animal product free (XerumFreeZ), the other a commercial blend of growth medium,
serum and DMSO (Sigma). Some have been investigated at 100% to investigate if there
are any solutions where a CPA is not at all required. Hypothermosol is very similar to the
CryoStor series of cryomedia, used in the preservation of the Prochymal[33]. Plasmalyte
A in combination with albumin has been investigated as a cryopreservation vehicle solution
for haematopoietic stem cells and so any application to mesenchymal stem cells is worth
investigating accordingly Pseudolyte A (see Section 3.7.5), the identical formulation used
for Prochymal was utilised here[20, 303].
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Vials were frozen, stored for one week and thawed, as described in Section 3.7, and then
analysed for on-thaw viability (Section 3.4.3), 3hr attachment (Section 3.5) and 72hr yield
(Section 3.6). All measurements were then calculated in duplicate from three independent
experiments.
6.1.2 Vehicle Solution Screen- On Thaw Viability, 3hr Attachment and 72hr
Yield
Vials were thawed and cell viability immediately assessed, these data are shown in Figure
6.1a. Cells preserved in pure FBS experienced complete cell death and so were disposed of. In
other cryomedia cell viabilities on thaw ranged from 26.24±8.52% (pure hSA/Pseudolyte A)
to 93.63±1.15% (XerumFreeZ). Cells preserved in the control standard formulation solution
(10%wt DMSO in FBS) recovered to 87.63±7.26% (this result is statistically similar to the
previously gathered baseline, Section 4.4). Cells preserved in FBS, hPL, Pseudolyte/hSA,
Hypothermosol all with DMSO, and XerumFreez had a statistically similar viability on thaw.
Whilst cells preserved in pure hSA/Pseudolyte A had a very low viability, cells preserved
in pure Hypothermosol FRS (i.e. no CPA) did recover to 75.47±3.68%. A relatively high
viability on thaw with Hypothermosol appears to indicate that its makeup- which includes
sugars[117] known to have some e cacy as a CPA[85]- allowed cell survival through the
cryopreservation process. Whilst in most cases an additional CPA is absolutely essential, the
proprietary make-up of this medium absent of a CPA allowed cells to survive.
Cells were then cultured in FBS supplemented DMEM in six-well plates, and after 3 hours,
one well for each sample was sacrificed and cells analysed for adhesion. The highest at-
tachment e ciency based on seeding number, as shown in Figure 6.1b, was with the cells
preserved in 90% Stemulate, at 84.93±7.59%. The few cells that had survived preserva-
tion in pure hSA/Pseudolyte A failed to attach successfully: here with an e ciency of just
12.08±6.51%. Other attachment e ciencies ranged from 53-84% with an ANOVA+Tukey
test showing that cells preserved with 90%wt Stemulate, the Sigma Cell Freezing Solution
and XerumFreez had statistically similar attachment compared to the cells preserved in 90%
FBS. The attachment result for the pure Hypothermosol preserved cells is surprising given its
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(a)
(b)
(c)
Figure 6.1: (A) On Thaw Viability, (B) 3hr Attachment E ciency and (C) 72hr Yield of
bone marrow derived hMSCs after cryopreservation in 8 di↵erent cryomedia. Where DMSO
used as a CPA, it is at 10%wt. Data are the mean of duplicate measurements from three
independent experiments ±SD. *, ** and *** represent statistically similar homogenous
subsets (p<0.05).
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make-up. The earlier CPA screen (Section 4.2) found that Maltose preserved HOS TE85 cells
had a relatively high viability on thaw, but catastrophic attachment one hour later, again it
appears the the formula of Hypothermosol improves cell attachment on thaw despite poorer
cryopreservation e cacy.
Considering also yield after 72hours, Figure 6.1c shows that a peak was observed in the
standard formulation of FBS with 10%wt DMSO at 180.94±14.30%. The cells preserved
in hSA/Pseudolyte, DMEM, Hypothermosol, hPL (all with DMSO) and XerumFreez had
statistically similar yields compared to FBS with DMSO.
Lastly, the FDA release criteria of 70% viability on thaw[38] would be valid for all but
cells preserved in DMEM with DMSO and pure hSA/Pseudolyte, but cells preserved in
Hypothermosol (with and without DMSO) and hSA/Pseudolyte also have poor attachment
on thaw. Again a study in this thesis has shown that the e↵ectiveness of this release criteria
for clinical scale therapeutics is flawed.
6.1.3 Selecting a candidate for further investigation
As has previously been shown, the only three vehicle solutions recovering cells to statistically
similar levels as FBS with DMSO in all three screened metrics were the Sigma Freezing
Solution, XerumFreez and Stemulate. This was all calculated using ANOVA+Tukey tests.
That these four disparate freezing solutions showed that successful cryopreservation can
be achieved with entirely di↵erent vehicle solutions shows that there are multiple ways to
successfully preserve these hMSCs. All of these cryomedia were supplemented with 10%wt
DMSO and it has previously been shown in Chapter 5 that keeping exposure to below 1hour
will help ensure good cell quality. It is important to note however that the selection of vehicle
solution is still important. The results from hSA/Pseudolyte and Hypothermosol preserved
cells show that even certain commercially used formulations do not work with this hMSC
line.
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Table 6.1: Advantages and Disadvantages of three alternative vehicle solutions
Advantages Disadvantages
Sigma Freezing Solution
+ Available as a complete
(i.e with DMSO) solution,
not needed to be mixed in-
house.
- Essentially commercially
brewed DMSO in FBS cry-
omedium, does not solve is-
sues from FBS and no ability
to tweak CPA as needed
- More expensive than in-
house DMSO in FBS
- Not defined, contents not
fully understood
Stemulate + Human based, therefore
no xenotoxilogical issues
- Biologic based, therefore
possibility of toxins
+ Large batch size- limited
batch/batch variance
- Mode of action, like FBS,
not fully understood
+ Can be used as a cul-
ture supplement, therefore
no adaption or changes to
current protocols
+ Not reliant on one
manufacturer- always sup-
ply of platelet lysate
+ CPA can be loaded as
necessary
XerumFreeZ
+ Serum and Animal Prod-
uct Free
- Contents not described by
manufacturer
+ Entirely defined (al-
though proprietary)
- Likely to be significantly
more expensive than FBS
based solutions.
+ Supplied complete - Supplied complete, so no
ability to tweak CPA as
needed.
However, Stemulate, XerumFreez and the Sigma freezing solution have advantages and
disadvantages as compared to FBS. Further, this study only looked at a freeze rate of -
1°C/minute and with 10%wt DMSO, alternatives to these could have resulted in certain
other vehicle solutions being more useful- Hypothermsiol with its sugar components could
have worked better if given long to equilibrate. Nevertheless, to select a viable alternative
the strength and weaknesses of each in the context of an alternative to FBS and for cell
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therapy use must be evaluated, as shown in Table 6.1.
Taking this all into consideration, Stemulate, Cook Medical’s brandname for pooled human
platelet lysate was selected for deeper analysis as an alternative to FBS. Human platelet
lysate is discussed in detail below in Section 6.2. Despite still being biologically originated
being from humans no xenotoxilogical issues will be observed and hPL can be used in both
cryopreservation and culture media making the tech-transfer from FBS to hPL simpler than
the other suggested supplements or media.
6.2 Human Platelet Lysate as an Alternative Vehicle Solution
The data gathered above in Section 6.1, showed that human platelet lysate has the possibility
of being a viable alternate vehicle solution. In this Section hPL as both a cryopreservation
vehicle solution and a supplement in culture will be assessed. The aim here however is not to
improve cell growth capacity or viability, but rather to show good comparability and therefore
a simple process or tech transfer to hPL.
Human platelet lysate has been argued as an alternative to FBS for culture supplementation
for some time now with studies dating back to the 1980s[24], although the first application
to clinically relevant cells like hMSCs was not until 2005[68]. Human platelet lysate is
manufactured by separating platelet-rich plasma (PRP) from the other fractions of donated
human blood. The PRP is then frozen/thawed at around -30°C to lyse the platelets, this
solution can then be used as the hPL culture supplement[68, 109, 240, 249].
hPL is known to be made up of similar components as FBS such as a wide range of growth
factors, although it lacks albumin and fibronectin [278] however the lack of these factors
has been shown not to cause any a↵ect on cells proliferative capacity when cultured in hPL
supplemented media.
Media supplemented with human platelet lysate have been repeatedly shown to allow human
cells to proliferate at equivalent or faster rates compared to those supplemented with FBS,
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whilst maintaining identity[24, 68, 109, 221]. Some papers suggest a reduction in hMSCs’
immunological function but there is no consensus in the literature[3, 53, 134].
Whilst human platelet lysate is derived solely from donated human blood it does require
heparin to prevent coagulation, this is primarily porcine derived and thus defeats any at-
tempt to move away from animal-derived components. Hemeda et al [110] reported that
at least 0.024mg/mL of low-molecular-weight heparin is required to prevent coagulation al-
though processes exist to remove the need for heparin such as Cook Medical’s proprietary
filtration process. Mojica-Henshaw et al [192] report a method of essentially mixing platelet
lysate plasma with calcium chloride and allowing this mixture to coagulate, a non coagu-
lated fraction of this mixture was then used as “platelet lysate serum”. The Cook hPL or
“Stemulate” used below is available in heparin requiring and non-heparin requiring formula-
tions. The non-heparin requiring formulation has been filtered using a proprietary method
removing coagulants although as reported by Mojica-Henshaw et al [192] this process may
remove some of the components enabling cell proliferation.
Use of hPL in cryopreservation is a more recent development. It has been suggested that
replacing FBS with hPL gives normal >90% viability on thaw[275]. It will be important to
define any a↵ect on cells other than on-thaw viability and whether subsequent culture in
hPL a↵ects cells’ proliferation, metabolism or identity.
6.2.1 hPL as a Culture Supplement and Cryo Vehicle Solution
Human mesenchymal stem cells were grown to a mid-stage passage (6) in DMEM sup-
plemented with 10%wt FBS and then frozen at 5x105cells/mL in 1mL of two di↵erent
cryomedia, 10%wt DMSO with FBS or hPL.
On thaw, groups of cells preserved in cryomedia made up of 10%wt DMSO and hPL or
FBS were then cultured in two di↵erent culture media- normal DMEM growth medium
supplemented with 10%wt FBS or with 5%wt hPL as described in Section 3.3.6, to give four
studied lines, see Table 6.2. For normal hMSC culture, FBS is supplemented to DMEM at
a concentration of 10%wt (Section 3.3.3) however 5%wt hPL was used, this was selected
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because it is a) in line with manufactures recommendations and b) a brief comparability
study of media supplemented with 2%wt, 5%wt and 10%wt hPL in DMEM found that 5%
was the most statistically similar to 10%wt FBS. These data can be found in Appendix F. A
study of whether cells expanded prior to cryopreservation in an hPL supplemented medium
is described in Section 6.2.3.
They were immediately assessed for viability and for attachment three hours later. The cells
were then cultured for three serial passages with medium aspirate samples taken at both
feed and passage. After three passages the cells were assessed for their phenotype using the
previously defined multi-parameter flow cytometry assay.
Experiments were carried out in triplicate with each measurement in duplicate.
Table 6.2: Di↵erent media supplement and cryopreservation vehicle solution compositions
for hPL supplementation experiment
Culture Supplement
FBS hPL
Cryopreservation
Vehicle Solution
FBS Control FBS/hPL
hPL FBS/hPL hPL/hPL
6.2.1.1 On Thaw Viability and Three Hour Attachment
Considering first the immediate cellular response, it was observed that cells cryopreserved
in a 10%wt DMSO solution with hPL or FBS recovered to at least 91% viability on thaw.
This was also previously shown in Section 6.1.2, but analysing data from just these two
groups shows strong statistical similarity. An independent samples t-test reports a p-value
of 0.788 showing the means at 91.1±5.3% and 91.6±4.9% for the cells preserved in FBS
and hPL respectively are almost equivalent. The only other study looking into using hPL in
a cryopreservation medium found similar results: viability on thaw in excess of 90%[275].
After three hours in the cells’ respective culture media, attachment e ciency was deter-
mined (Figure 6.2a). Here four data sets were analysed. All four groups were statistically
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(a)
(b)
Figure 6.2: (A) 3hr Attachment E ciency and (B) Daily Fold Expansion Rate over the
first passage post-thaw of bone marrow derived hMSCs after cryopreservation in cryomedia
containing FBS or hPL as vehicle solution with 10%wt DMSO used as a CPA, and then
culture in media containing either 10%wt FBS or 5%wt hPL. Data are the mean of duplicate
measurements from three independent experiments ±SD. * and ** represent statistically
similar homogenous subsets (p<0.05.
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similar (ANOVA reports a significance of p=0.196) with an average attachment e ciency
of approximately 82%. The highest attachment was in the hPL/hPL group at 86.1±6.7%.
There was also no reported significant di↵erence between paired supplement groups (e.g.
FBS/hPL and FBS/FBS were both preserved in FBS) although a study from Naaijkens et
al [198] did show quicker attachment (over 10 minutes) of hPL cultured cells compared to
those cultured with FBS but that the two groups had statistically similar attachment after
three hours.
6.2.1.2 Growth Over Three Passages
The cells were then cultured for three serial passages in the respective growth media. At
each passage, the cell populations were assessed for both viability and number, and from
this the growth rate determined.
First the growth rate over the first passage on thaw was determined, this is shown in Fig-
ure 6.2b. Here for the first time some divergence between the four groups was observed.
Tukey’s test showed that the FBS/FBS and hPL/FBS groups are similar and the FBS/hPL,
hPL/FBS and hPL/hPL were also similar. This demonstrated that the presence of some
hPL in the system did appear to improve the rate of growth on thaw to levels comparable
to stable culture. The fastest growth occurred in the hPL/hPL group at 0.73±0.10fold ex-
pansions/day, faster (although not significantly) even than the previously gathered baseline
characteristics for unfrozen cells described in Section 4.4 at 0.61±0.10fold expansions/day.
The underlying cause of this is however the culture supplement, a t-test shows that there was
significantly lower growth (p<0.01) in cells cultured in FBS than those in hPL, regardless of
the cryopreservation supplement. This shows that at least over the first passage in place of
FBS, hPL used as a vehicle solution provides for statistically similar recovery on thaw but
when it is used as a culture supplement subsequent growth is statistically faster, the study in
Section 6.2.3 investigates whether pre-freeze expansion in hPL a↵ects further growth (and
other metrics) on thaw.
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Next, total growth over the three passages was considered (Figure 6.3a). Over the course
of the three passages, the variance causing the lower growth in the control FBS/FBS group
has been alleviated and all four groups are statistically similar (p=0.104). Nevertheless, a
peak was observed in the hPL/hPL group at 9.24±0.76fold expansions. Looking further at
the cumulative growth gradients also shows no significant di↵erences across the four lines.
In a growth context, taking both the short and long term data establishes two recommen-
dations for process development. If the product is thawed and immediately transplanted to
patients or significantly processed on thaw, using hPL as both a cryopreservation vehicle and
a culture supplement may allow for improved proliferation. However, increased growth rate
could mean a population would reach senescence quicker due to the hMSCs propensity to
reach a population doubling limit of 10-40 fold expansions[13] but Gri ths et al [99] have
shown that switching senescent hMSCs to hPL supplemented medium from FBS supple-
mented medium can rejuvenate the cells. Nevertheless, using a hPL system for cell bank
growth for example, gave statistically similar growth to an FBS system.
Lastly, viability was determined at each passage, in Table 6.3 below, the average values
across all three passages is shown. No significant di↵erences across the four populations
were observed, indicating stable, healthy populations.
Table 6.3: Average viability over three serial passages of bone marrow derived hMSCs during
one passage after cryopreservation in cryomedia containing FBS or hPL as vehicle solution
with 10%wt DMSO used as a CPA, and then culture in media containing either 10%wt
FBS or 5%wt hPL. Data are the mean of duplicate measurements from three independent
experiments ±SD
Cryo
Vehicle
Culture
Supplement
Viability
FBS FBS 95.4±1.8%
FBS hPL 97.5±0.6%
hPL FBS 97.2±0.8%
hPL hPL 97.2±1.0%
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(b)
Figure 6.3: (A) Total Growth and (B) Cumulative growth of bone marrow derived hMSCs
after cryopreservation in cryomedia containing FBS or hPL as vehicle solution with 10%wt
DMSO used as a CPA, and then culture in media containing either 10%wt FBS or 5%wt
hPL for three serial passages. Data are the mean of duplicate measurements from three
independent experiments ±SD.
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6.2.1.3 Metabolism
Medium samples were taken for metabolite analysis at feed and passage and analysed with
the Nova Bioanalyser. Glucose uptake and lactate and ammonium production were analysed
(Figure 6.4a). Considering the first passage on thaw it was first observed that the yield of
lactate from glucose of the cells is stable, Figure 6.4b. There was no significant di↵erence
across the four groups, nor were the results di↵erent from the earlier observed baseline
(Section 4.4). This indicated that the cells’ metabolic activity, at least for this pathway, is
operating normally. Further, there were no significant di↵erences in ammonium production
across all four groups. This indicated that glutamine metabolism is operating normally
despite the changes in cryopreservation and culture media.
The data also showed that using hPL in place of FBS in cryopreservation caused no significant
changes in glycolysis. Using a t-test to compare just the cryopreservation vehicle solutions
used showed a significance of p=0.248 for glucose uptake and p=0.912 for lactate production.
When however the data for the di↵erent culture supplements were assessed significant dif-
ferences were observed. The FBS/FBS group took up 10.61±0.96pMol/cell.day whereas the
FBS/hPL and hPL/hPL groups took up 7.00±1.15pMol/cell.day and 8.21±1.10pMol/cell.day
respectively. The results were similar for the lactate production: lowered in the hPL cultured
cells. Tukey’s post-hoc ANOVA test reports that the metabolism data from FBS cultured
cells and hPL cultured cells formed statistically di↵erent homogenous subsets. Gri ths et
al [99] observed that hPL culture caused reduced glucose consumption as was observed here,
but with increased waste product production e.g. lactate, the authors here noted that this
was possibly due to subtle cell physiology di↵erences. These experiments were performed
with an entirely di↵erent hMSC line likely to have further biological di↵erences which may
cause the di↵erence in results.
As the metabolic yields are “normal” for just-thawed cells and with the previously determined
growth data, it can be determined that the lower glycolysis rate was more beneficial to the
cell population or process than detrimental. The hPL cultured cells grew as fast- if not faster
than FBS cultured cells and consumed less glucose. This suggests that the biologic content
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(b)
Figure 6.4: (A) Metabolite Flux (B) Yield of lactate from glucose of bone marrow de-
rived hMSCs after cryopreservation in cryomedia containing FBS or hPL as vehicle solution
with 10%wt DMSO used as a CPA, and then culture in media containing either 10%wt
FBS or 5%wt hPL. Data are the mean of duplicate measurements from three independent
experiments ±SD. * and ** represent statistically similar homogenous subsets (p<0.05).
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of hPL did cause subtle di↵erences in the cells physiology, which caused the increased growth
rates observed earlier[99, 115].
6.2.1.4 Phenotype
After being cultured in the respective medium for three passages, cells were assessed for
phenotype by using the multi-parameter flow cytometry assay. Single parameter data was
converted to multi-parameter values using the process described in Section 4.4.3 and Figure
4.21. This was to determine if cryopreservation and subsequent culture in hPL containing
medium a↵ected the cells’ identity. As shown in Figure 6.5 it is clear that the cells’ identity
had not in anyway been a↵ected. The co-expression ranged from 94.4-95.2% indicating
good cellular phenotypic expression of the five markers here selected as characteristic of
hMSCs. These results were similar to the previously gathered baseline (Section 4.4) and
other studies, Gri ths et al [99] found that hPL culture enabled rapid expansion without
a↵ecting immunophenotype.
Using human based culture supplements are usually deprecated due to cost and availability
of material[241] (human serum, for example is more than three times the price of FBS[253]
although this may drop with economies of scale) but using culture supplements for clinical
application using the target species is clearly beneficial, as has already been argued. These
data show that pooled human platelet lysate, like the Stemulate hPL used here did not have
any a↵ect on the cells’ ability to express the required extracellular markers.
6.2.2 Further Analysis of Chosen Candidate
The data in Section 6.2.1 showed that neither of the three medium combinations was sta-
tistically better for cell health and quality. The aim here was not to improve cell viability
and fate post-thaw, but to develop a system that was functionally similar to the current
paradigm but demonstrably better for an application to cell therapies.
A key benefit of hPL is that it is human based and therefore replacing FBS in the system with
it will meet certain regulatory desires: a move away from animal products in cell therapies has
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Figure 6.5: CD73+, CD90+, CD105+, CD34- and HLA-DR- of bone marrow derived hM-
SCs after cryopreservation in cryomedia containing FBS or hPL as vehicle solution with
10%wt DMSO used as a CPA, and then culture in media containing either 10%wt FBS or
5%wt hPL. Data are the mean of duplicate measurements from three independent experi-
ments ±SD. Based on >5000 events.
been strongly advised but not required by the FDA[24]. Using hPL as both a cryopreservation
vehicle solution and medium supplement is inherently better than any system using FBS and
so this was chosen as a candidate for further analysis. This candidate was investigated
further and compared to a control system- FBS/FBS. A further aim of this experiment was
to investigate a possible process change from FBS to hPL without any detrimental changes
on outputs, ideally improvements as with growth would be observed.
6.2.2.1 Cell Size
First, cell size was analysed over the course of a passage. Increased cell size has been shown
to be a response to stress or osmotic imbalances[84]. Table 6.4 shows that the hPL preserved
cells were significantly larger on thaw (p=0.001), however after being fed and then passaged
with hPL-supplemented medium seven days later, the cells are similarly sized. It can be
inferred that the swelling at thaw has no e↵ect on cell health, the cells recovered quickly
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and the stable proliferation and metabolism was noted above, although increased cell size
has been associated with increased senescence[29], and so smaller cells could be related
to reduced senesence increasing the time that cells can proliferate for. Gri ths et al [99]
showed that hMSCs cultured in hPL supplemented medium were significantly smaller than
those cultured in FBS, although a higher FBS supplement concentration (16%wt) was used
in their experimentation. The cells in the present experiment were not significantly smaller:
p=0.105 (Day 3) p=0.018 (Day 7), the lower FBS concentration compared to that used
Gri ths et al could have accounted for this.
Table 6.4: Average cell diameter of human mesenchymal stem cells over one passage post-
thaw after cryopreservation and then subsequent culture in cryomedia and culture media
containing FBS or hPL. Data are the mean of duplicate measurements from three indepen-
dent experiments ± 95% confidence interval.
Cryo Vehicle Solution/ Cell Size (µm)
Culture Supplement Day 0 (Thaw) Day 3 (Feed) Day 7 (Passage)
FBS/FBS 18.5±0.6 16.2±0.3 17.9±0.7
hPL/hPL 19.7±0.1 15.9±0.6 17.0±0.3
6.2.2.2 IDO Expression and Function
Three days post-thaw and subsequent culture with FBS or hPL supplemented media, the
cells were fed with cytokine spiked media to induce IDO expression. Using the method
described in Section 3.10, IDO function can be correlated to kynurenine expression. This
was previously discussed in more detail in Section 5.3.2.2, briefly however the cytokines
induce an inflammatory environment causing cells to activate their tryptophan cascade which
ultimately produces kynurenine which the assay measures.
As is shown in Figure 6.6, the di↵erently supplemented media did not have any e↵ect on
cellular IDO function. A plateau is reached on day 2 post feed of approximately 0.4nMol/cell
and both cell groups had statistically similar expression on all four assessed days. Peaks
of 0.453±0.045nMol/cell and 0.429n0.016µMol/cell were observed for the FBS/FBS and
hPL/hPL groups respectively. How culturing cells in hPL-supplemented medium a↵ects IDO
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Figure 6.6: Kynurenine activity of bone marrow derived cells after being fed with a cytokine
spiked medium three days after cryopreservation in cryomedia containing FBS or hPL as
vehicle solution with 10%wt DMSO used as a CPA, and then subsequent culture in media
containing either 10%wt FBS or 5%wt hPL. Data are the mean of duplicate measurements
from three independent experiments ±SD.
function has not been studied in great depth in scientific literature, Copland et al [53] noted
significant down-regulation of IDO in cells cultured in unfractionated hPL although using
a fibrinogen-depleted hPL the immunomodulatory function was restored. Another study
also noted reduced immunomodulatory function in hPL-cultured hMSCs raising questions
for clinical e cacy[3], although this was using a heparinised-hPL formulation whereas the
hPL used in these experiments is filtered removing the need for heparin. However, a study
using expired platelets like the Stemulate hPL product used here showed no significant e↵ect
on immunomodulatory function[134]. Ultimately, questions remain for how hPL a↵ects
hMSCs’ vital immunomoedulatory function, however in this experiment cryopreservation and
subsequent short-term culture in hPL-containing media did not a↵ect IDO function, defined
by means of kynurenine expression.
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(a) Adipocytes (b) Chondrocytes (c) Osteocytes
Figure 6.7: Di↵erentiation capacity of bone marrow derived human mesenchymal stem
cells after cryopreservation and subsequent culture in hPL containing media depicting (A)
Adipogenic, (B) Chondrogenic and (C) Osteogenic di↵erentiation. Observed through a 10x
objective lens. Scale bar represents 0.1mm. Representative images of four repeats.
6.2.2.3 Di↵erentiation
The necessity to observe di↵erentiation ability of hMSCs has previously been noted. Jonsdottir-
Buch et al [134] showed that cultures supplemented with hPL produced in the same way as
Stemulate do not have changed di↵erentiation capacity but noting improved expression of
the osteo-specific marker RUNX-2.
One passage post thaw, cells frozen and cultured in hPL supplemented media were cultured
in di↵erentiation specific media and on completion of these protocols stained to detect
successful di↵erentiation. Figure 6.7 shows that the cells maintained their di↵erentiation
capacity.
6.2.2.4 Additional Cell Line
In the previous experiments just the cell line M7 was used. To confirm the validity of
the conclusions an additional hMSC line, M4 was studied. A similar panel of analysis was
conducted on cells frozen in hPL containing medium and then cultured in hPL contain-
ing medium. The cells were then assessed for on-thaw viability, 3hr attachment, growth,
metabolism and phenotype and the data acquired compared to the equivalent from M7.
Cells were assessed first for on-thaw viability and attachment, Figure 6.8a shows that there
was no statistical di↵erence between cell lines or cryo vehicle/culture supplement. M4’s
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hPL/hPL group had similar attachment at 78.9±6.1% compared to M7 hPL cultured cells at
86.1±6.7%. On-thaw viabilities for all four groups were also all statistically similar averages
ranging from 92.8%-93.8%.
The same increase in growth rate observed in M7 was observed in M4. Figure 6.8b shows
that FBS/FBS cultured M4 cells grow at 0.52±0.08 fold expansions/day whereas hPL/hPL
cells grow at 0.73±0.05 fold expansions/day. Increase in proliferation due to culture with
hPL has been noted several times[68, 99, 192] and this repeats the result from the earlier
experiments in Section 6.2.1.
When the e↵ect on cell metabolism of M4 after culture in M4 was assessed, no changes
in yield of lactate from glucose were observed as with M7. Changes in glucose uptake and
lactate production rates were however observed. Platelet lysate cultured M4 cells, took up
8.41±0.49 pMol/cell.day glucose and produced 15.56±0.99 pMol/cell.day lactate. These
metabolic values for M4 hPL cultured cells are statistically di↵erent from similarly cultured
M7 cells and M4 cells cultured with FBS medium with glucose uptake rates- for example-
at 10.61±0.96 pMol/cell.day and 10.32±0.68 pMol/cell.day respectively. Whilst a di↵erent
response was observed here changing the cells growth and cryopreservation medium caused
significant changes in metabolism. Observing yields of lactate from glucose (see Figure 6.8c)
showed no significant di↵erences between the two cell lines and media regimes.
No changes are observed in M4’s cellular immunophenotype after cryopreservation and cul-
ture in hPL containing media (Figure 6.8d). As no change was observed in M7 the same
was expected for the M4 line. Cells cultured in FBS did retain the MSC phenotype so it was
unsurprising that hPL derived from humans also allows cells to maintain the characteristics
of hMSCs.
6.2.3 hPL as a Through Culture Supplement
The previous experiments have focused on transferring cells to a hPL based process at
the banking process- using the platelet lysate as a cryopreservation vehicle solution and
subsequent culture supplement. Slight improvements in cell growth were observed. However
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(a) (b)
(c) (d)
Figure 6.8: (A) On-Thaw Viability and Attachment, (B) Fold Expansion Rate over one
passage, (C) Metabolic Yield of Lactate from Glucose and (D) Phenotypic Co-Expression of
CD73+, CD90+, CD105+, CD34- and HLA-DR- of two independent lines of bone marrow
derived human mesenchymal stem cells after cryopreservation and subsequent culture in
hPL or FBS containing media. Data are the mean of duplicate measurements from three
independent experiments.
FBS was still used in these systems in the pre-banking growth, therefore the process would
still contain animal based components for an important part of product development and
this would mean the concerns discussed in Section 6.2 would still apply.
Using hPL as the culture supplement in the pre-banking growth allows the entire growth,
preservation, production and delivery of a product to be animal component free (with respect
to culture/cryo supplementation). In this series of experiments, cells were converted to hPL-
supplemented medium at the earliest possible stage- at feed one passage post-thaw from a
master cell bank. These cells were then grown from passage 2 to passage 5 in hPL-based
medium, preserved in a hPL-based cryomedium for one week, thawed and then grown for
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three serial passages in a hPL-based medium. The cells were then analysed for on-thaw
viability, attachment, growth, metabolism and phenotype. These data were then compared
to the earlier FBS/FBS and hPL/hPL cultures and any overall improvements noted. Given
the conclusion of the experiments in Sections 6.2.1 and 6.2.2; significant di↵erences from
the hPL/hPL group are not expected, the aim of this experiment was merely to note that
an entirely FBS-free system was possible without any detrimental e↵ect on cell viability,
proliferation, metabolism or identity.
Figure 6.9b shows that as with the previous experiment the change in medium supplementa-
tion strategy did not a↵ect the cells immediately post thaw. All three groups had statistically
similar on-thaw viability and attachment three hours later.
When growth is observed, as shown in Figure 6.9c, the hPL/hPL/hPL cells grew at a similar
rate compared to the FBS/hPL/hPL cells. Cells cultured in hPL grew significantly faster
compared to those cultured in FBS in the first two passages post-thaw and the result here
indicated that prior adaption to hPL supplemented medium did not increase or decrease the
proliferation rate post thaw. The strategy of using hPL as the culture supplement for the
pre-banking growth appears to only have the additional benefit of removing an additional
source of animal components in the process.
In Table 6.5 and Figure 6.10a it is clear that the hPL/hPL/hPL cells responded in the same
way to the platelet lysate culture as the FBS/hPL/hPL cells. Similarly reduced glycolysis
rates were observed compared to cells entirely cultured in FBS. Despite these reduced rates
of glucose consumption and lactate production, the overall yield of lactate from glucose
remained at a similar level at 1.87±0.26mol/mol for the hPL/hPL/hPL cells. Similar am-
monium production rates were also observed across the three groups indicating the cells are
also not reliant on the glutaminolysis process.
The phenotypic identity of the cells was also assessed. As shown in Figure 6.10b there was
no significant di↵erence across all three groups showing that despite the substantially longer
culture in hPL based media there was no di↵erence in co-expression of the extra-cellular
markers identifying hMSCs. The group cultured pre-freeze in FBS then frozen and cultured
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(b)
(c)
Figure 6.9: (A) On-Thaw Viability, (B) 3hr Attachment and (C) Cumulative Growth over
three serial passages of human mesenchymal stem cells grown, cryopreserved and resusci-
tated with three di↵erent medium regimes- containing either hPL or FBS. Data are the
mean of duplicate measurements of three independent experiments ±SD.
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(b)
Figure 6.10: (A) Metabolic yield of lactate from glucose over the first passage post thaw
and (B) Phenotypic co-expression of CD73+, CD90+, CD105+, CD34- and HLA-DR- one
passage post thaw (based on >5000 events) of bone marrow derived human mesenchymal
stem cells resuscitated with three di↵erent medium regimes- containing either hPL or FBS.
Data are the mean of duplicate measurements of three independent experiments ±SD.
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Table 6.5: Metabolic uptake and production rates over the first passage post thaw of human
mesenchymal stem cells grown, cryopreserved and resuscitated with three di↵erent medium
regimes- containing either hPL or FBS. Data are the mean of duplicate measurements of
three independent experiments ±SD.
Media Regime Glucose
Uptake
(pMol/cell.day)
Lactate
Production
(pMol/cell.day)
Ammonium
Production
(pMol/cell.day)
Pre-Banking
Supplement
Cryo
Vehicle
Solution
Culture
Supplement
FBS FBS FBS 10.6±1.19 20.51±3.77 2.40±0.41
FBS hPL hPL 8.21±1.38 14.09±2.12 2.54±0.43
hPL hPL hPL 6.56±1.12 12.00±0.54 2.21±0.34
in hPL containing media had a co-expression of 95.2±1.3% compared to 95.7±2.5% for the
group cultured entirely with hPL based media.
Ultimately the results of this experiment showed that there were no additional benefits (from
the perspective of the metrics investigated) to using hPL throughout culture: from cell bank
growth, through preservation and then on to production or delivery post-thaw. The benefit
however is from a more nuanced process perspective. These results show that it is entirely
possible to convert a process to using only non-animal derived components- in this case hPL-
without any detrimental a↵ect on cell proliferation or growth. Whilst the full gamut of tests
explored in Section 6.2.2 were not performed on the hPL-through culture group in the tests
explored it was statistically similar to the hPL/hPL group in those that were investigated.
Further, no substantial di↵erences were made to the culture regime so it is likely the cells
would perform similarly in these additional tests.
6.3 Concluding Discussion- Does hPL solve the Xeno Issue?
In this Chapter the e cacy of human platelet lysate as an alternative cryopreservation vehicle
solution was defined, for the first time in substantial detail after Taylor et al [275] published
preliminary results in 2014. The screen experiment showed it to be roughly equivalent to
the current standard, FBS and certain commercial alternatives. Cook hPL “Stemulate” was
The Xeno Issue 203
selected for further analysis as it meets several aims of this chapter- to be animal product
free, commercially available and have low batch-batch variation. Further analysis showed that
hPL is equivalent to FBS when used as both a culture and cryo supplement. For viability,
attachment, identity and function cells preserved and cultured in hPL acted statistically
similarly to those preserved and cultured in FBS. The data from metabolic analysis showed
reduced glycolysis rates, but with similar yield of lactate from glucose indicating no real
significant e↵ect on the overall health of the cells. Cells grown in hPL containing medium
grew significantly faster than cells in FBS containing medium in the first passage on-thaw
(0.73±0.05 fold expansions/day vs. 0.54±0.03 fold expansions/day), although data over
three serial passages showed no overall a↵ect on cells proliferation in stable culture.
Questions remain for the validity of use of hPL in cell therapy processes. Like FBS, platelet
lysate is derived from a wide group of individuals and then pooled in large batches to reduce
variation. Despite eliminating any xenological issues, risks remain with other toxins which
may not currently be understood. Whilst responding similarly, experiments here were only
performed on two bone-marrow derived cell lines. Further what e↵ect hPL has on the
immune function and whether this is important on therapeutic capacity must be defined.
The results here however show that human platelet lysate treated such that heparin is
not required can be used as a culture supplement in growth medium and as the vehicle
solution in cryopreservation. When growing cells for culture banking, hPL provides for faster
growth whilst retaining cells identity and metabolic activity. Overall, hPL allows for the main
animal-sourced component in both culture and cryopreservation protocols to be replaced with
a commercially viable human based alternative, further the present study has shown that
improvements in process outputs are possible with an hPL based system.
Chapter 7
Defining Delivery
The previous two chapters focused on the make-up of the medium that the cells are kept
in when cryopreserved. This chapter however focuses on process considerations, primarily
thawing, and briefly looking into a GMP grade alternative to normal polypropylene cryovials.
Thawing, as was described in Section 2.8.2, is an area of the cryopreservation process sorely
lacking in research. There are only a handful of studies looking primarily at the actual process
of thawing. Some studies do look at alternative techniques immediately after the cell suspen-
sion reaches 37°C- dilution with fresh medium being dropwise or stepped for example[279].
There is some evidence of groups investigating “dry” thawing methods- usually an incubator,
but the benefit of this, other than hygiene, has not been discussed[169, 188]. Further, how
heat is transferred into the vial in a “dry” or “wet” thawing device needs to be defined
such that it can be optimised. Products that have made it to market like Prochymal have
clearly shown that it will be physicians or other medical sta↵ performing the thawing as
opposed to scientific operators[33]. These medical sta↵ may not have the full awareness
of the sensitivities of cell therapies and therefore a robust process backed by good sciences
is necessitated for thawing. This chapter aims to look at thawing through an “engineering
lens” first and then investigate improvements around the delivery of cell therapies to the
patient. Here delivery is defined as the process of transporting a cryopreserved therapy in a
regulated vessel and then thawing prior to infusion into a patient.
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7.1 Thawing Model
The aim of this study was to develop a model to determine the rate at which heat energy
is delivered to a vial during a thawing process, the aim was to expand upon the protocols
which use phrases like “a trace of ice”[58, 276]. From both a clinical, and manufacturing
perspective this is not viable for protocols as it can’t be quantified. On a broader level, the
purpose of this investigation was to develop an improved thawing protocol.
The true di↵erence between a “wet” and “dry” vessel has not yet been characterised nor
how this a↵ects the rate of thawing. In this section, principles of heat transfer were used to
develop a mathematical model that quantifies how energy is transferred into a cryovial as
it thaws from cryopreservation temperatures to above freezing, modelled as -150°C to 1°C.
As is the case with all heat transfer engineering, the model makes several assumptions and
these have been noted below.
7.1.1 Model Input
In a thawing process, a cryovial is taken from cryostorage, usually in a nitrogen dewer, and
immediately placed into a thawing vessel. It is then left there until it has thawed. For the
purposes of this model, it has been assumed that the thawing vessel is set to a temperature
and does not change from this. It is, in e↵ect, isothermal. In these experiments, 1.8mL
cryovials were used allowing for the storage of 1mL of cell or tissue material, suspended in a
CPA at ultra-low temperatures usually in the vapour phase of liquid nitrogen, i.e. <-150°C.
These cryovials are small polypropylene cylindrical tubes with a internally threaded lid.
The vial’s geometry was determined using a vernier calliper and shown in Figure 7.1 is as
follows:
• HV the total height of the vial (39mm)
• HC the height of cell material to make up 1mL (15mm)
• d the diameter of the cryovial (10mm)
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Figure 7.1: Schematic of polypropylene vial geometry showing key measurements
• xw the thickness of the cryovial wall (1mm)
Therefore, the volume of cell material in a cryovial was determined to be 1.18x10-6m3, and
the surface area of the cell material was 6.28x10-4m2. This was the surface through which
heat was transferred into the vial.
After removal from cryostorage, the cryovial, in the case of this model was transferred to
either an incubator or a waterbath. These “thawing vessels” will heat the vial from an
assumed temperature of -150°C to 1°C, meaning the total change in temperature is 151°C.
The material making up the “thawing vessels” -water and air- have di↵erent heat transfer
coe cients, and thus transfer heat at di↵erent rates. Additional materials could be modelled
such as a metal heat block or a methanol bath, these would give di↵erent heat transfer
characteristics and thus a di↵erent thawing profile.
By adding in a number of assumptions and heat transfer principles, a mathematical model
for determining the vial thaw rate was constructed.
7.1.2 Key Assumptions
1. The cryovial has exactly 1mL of cell suspension.
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2. In absence of specific metrics, it is assumed that the cell solution has similar ther-
mal properties to water. FBS as a solution is mostly water with various compounds
dissolved in it.
3. Heat is transferred uniformly into the vial.
4. Under the lumped capacity model, the temperature at the boundary is the same as in
the centre of the solid, if the Biot number is less than one[255]:
Bi =
hLc
k
(7.1)
Where:
• h is the heat transfer coe cient of the material holding the sample (24.5W/m2K)
• Lc is the characteristic length [Volume/Area] (1x18-6m3/6.28x10-4m2=1.88x10-3m)
• k is the thermal conductivity (2.72W/mK)
• Bi is the Biot number, which was determined to be 0.016, allowing the lumped
capacity model to be used (dimensionless)
5. The thawing vessel temperature was isothermal despite the addition and increase in
temperature of the vials, due to the sheer size in comparison and the constant heating
of the vessel.
6. The cell material in the vials all started uniformly at -150°C and the model determines
the rise up to 1°C.
7. There was no change in any of the heat transfer coe cients with time.
8. Heat was transferred linearly in to the vial, whilst heat of fusion is used, latent heat is
not modelled.
7.1.3 Model Equations
First the required energy to fully thaw a vial, from -150°C, i.e. in the gas phase of LN2 to
1°C is estimated. This is derived from the standard heat balance Equation, with the value
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for enthalpy of fusion added, this is the energy required to phase change an object’s state
from solid to liquid[54]:
QT = mCp T+ Hfus (7.2)
Where:
• m is the mass of the sample (g), derived from a sample volume of 1mL and a density
of 1013kg/m3 giving a value of: 1.19g
• Cp is the heat capacity of the solution (J/gK), which in the case of this solution
is 1.781J/gK (determined as the average of heat capacities of water from -150°C-
1°C[284].
•  T is the total change in temperature (K) derived from a start temperature of 123.15K
to 274.15K, i.e. 151K
• Hfus is the enthalpy of fusion, in this case assumed to be that of water, 334J/g[160].
• QT is the energy, or heat required to thaw a vial to 1°C (J)
This gave a value for the heat of thawing, and therefore the energy required to heat and
thaw a vial to 1°C to be 720J.
Next, the rate of heat transfer from the thawing vessel into the cryovial was calculated. The
rate was modelled using the following equation[54]:
QR = UA T (7.3)
Where:
• QR is the heat transfer rate (W)
• U is the overall heat transfer coe cient (W/m2K)
• A is the area of heat transfer (m2)
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•  T is the change in temperature (K or °C)
Heat is transferred through a three part system into the cryovial.
The overall heat transfer coe cient is calculated as follows:
1
U
=
1
ho
+
xw
kw
+
1
hi
(7.4)
Where:
• ho is the heat transfer coe cients of the the thawing vessel fluid (W/m2K) (Water=93.4W/m2K,
Air=10.3W/m2K[54])
• xw the thickness of the wall (m)
• kw the thermal conductivity of the wall (W/m K)
• hi is the heat transfer coe cient of the cell material (W/m2K)
The area of heat transfer was defined to be the cell material, modelled as a cylinder:
A = 2⇡rHC + 2⇡r
2 (7.5)
Where:
• r is the radius of cell material, in this case 0.005m previously defined in Section 7.1.1
The heat transfer rate into the vial changed with the temperature at the cell material. The
temperature of the vial never truly reached the temperature of the vessel, instead passing
alongside an asymptote as the heat transfer rate approaches, but never reached 0W. This
is known as transient heat transfer[54] and required the model to calculate heat transfer as
a di↵erential based upon the temperature inside the cryovial. Based on assumption 5, the
temperature of the vessel does not change, and so it is just the temperature inside the vial
that must be assessed using the di↵erential. As such, combining Equations for heat transfer
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(7.3), coe↵cients (7.4), area (7.5) and forming the di↵erential between heat transfer rate
and cell material temperature the full equation for the model was determined as:
dQR =
Tv   TCdTC
1
ho
+ xwkw +
1
hi
A (7.6)
Where:
• TV is the vessel absolute temperature (K)
• TC is the absolute temperature of the vial (K)
• QR is the heat transfer rate of energy into the cryovial (W)
This equation was then integrated to determine the changing heat transfer rate as the vial
warmed, however for model e ciency, this was approximated by assuming linearity of both
increasing cell material temperature, and change in heat transfer rate. Theoretically, the
temperature of the cell material would get exponentially close to that of the thawing vessel
as the heat transfer rate asymptotically approaches 0W. As all thawing vessels modelled will
be hotter than the end point of the thawing process- 1°C, this asymptote is not modelled.
Given these assumptions, the average heat transfer rate can be determined at a range of
vessel temperatures.
7.1.4 Model Output and Analysis
The previously derived equations and values can then be used to define the rate of heat
transfer into a vial from the two di↵erent thawing vessels. This di↵erence in heat transfer
rates is shown in Figure 7.2.
It is clear that less heat was transferred into the vial from the incubator (air) than the
water-bath. This was due to di↵ering thermic properties of the fluids causing a higher heat
transfer coe cient and thus more heat transferred. Using the previously calculated value of
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Figure 7.2: Average heat transfer rates into a polypropylene cryovial at various temperatures
of an ’air’ incubator and a waterbath determined using Equation 7.6
720J, the time taken to fully thaw a vial at varying temperatures can be derived.
tT =
QT
QR
(7.7)
Where:
• tT is the time taken to thaw a vessel at certain conditions (s)
As would be expected, the cooler the vessel, the lower the heat transfer rate and thus
the greater the time to thaw the vial. This is shown in Figure 7.3. The time to thaw
asymptotically reached infinity as the heat transfer rate reached 0W.
The time to thaw also changed with heat transfer rate, but there was no change with respect
to material of the thawing vessel, as ultimately the thermal energy transferred into the vial
is the same regardless of the material making up the thawing vessel.
The commonly accepted method for thawing is to leave a cryovial in a water bath at 37°C
for 3-4 minutes. According to the model in 210seconds (3.5minutes) 764.4J was transferred
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Figure 7.3: Time to thaw 1mL cell suspension inside a polypropylene cryovial, as determined
by equation 7.7
into the vial, relatively similar to what the model predicts was required to fully thaw a vial.
When a vial was thawed, there was some lag between removal from the cryostore and being
added into the appropriate thawing vessel. The room at 20°C had a heat transfer rate of
0.55W and the vial spends approximately 30seconds being transferred means just 18.3W is
transferred over this period the model predicts that this lag would cause a temperature rise
of 3.5°C, 2.3% of the total temperature rise.
As previously mentioned, a better quantifiable metric for thawing a vial is likely to be the
heat transfer rate. The water baths used in this study allowed a range of accessible heat
transfer rates from 3W-4.5W and the incubator a range of 0.5W-0.9W.
The di↵erences in heat transfer e cacy allow for a more robust understanding of heat
transfer, and therefore allow for better understanding of the thawing process. This model
however only models a 1mL cryovial and further work will be required to understand how a
larger vial, or cryobag thaws. As the lumped capacity will not be valid in larger vessels, an
additional derivation will be required. Further, only a small range of heat transfer rates are
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accessible using the waterbath as a thawing vessel. Possible alternatives include a metallic
heat block as metals allow for far higher heat transfer.
7.1.5 Model Validation
Whilst this model used understood empirical physical relationships, it could not be regarded
as valid, or useful for experimental purposes, unless it is validated. To do this, vials containing
growth medium (used as a representation of cell suspension) were frozen and then thawed
at four di↵erent heat transfer rates, using an incubator, a lab bench (i.e. room temperature)
and a water bath. The temperatures below were validated using a temperature sensor, these
data are shown in Appendix B.
Table 7.1: Temperature and associated modelled heat transfer rates for thawing model
validation experiment
Thawing Vessel Temperature (°C) Heat Transfer Rate (W)
Waterbath 37 3.32
Waterbath 50 4.03
Incubator 37 0.65
Lab Bench 20 0.55
The vials were then timed as they thawed and observed, with timing stopped once the “last
ice crystal” disappeared, indicating the whole fluid was above 0°C. This was carried out in
triplicate.
Figure 7.4 shows that in all four investigated circumstances the model is at least 95% accu-
rate, it can therefore be deemed valid for the thawing of polypropylene cryovials. Additional
work will be needed to convert it for larger volume vials, or cryobags but it can be used to
determine the rate at which cells in 1.8mL polypropylene vials thaw combining thaw vessel
temperature and thawing time under one metric.
Whilst the model described only assessed small cryovials in two thawing vessels, it is an
important preliminary step in increasing understanding of how the heat that thaws vials
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Figure 7.4: The time taken to thaw the cell suspension contained in a cryovial determined
experimentally (Data are the mean of three independent experiments ±range) and as de-
termined by the vial thawing model (Equation 7.6)
operates. Further work is needed to expand into both additional geometries, for example
larger vials and cryobags, and to other, potentially more e cient, thawing devices such as
a heat block. Nevertheless, the findings here are a platform to understand the physical
activity happening as a cell theraputic thaws and ultimately improve the quality of products
transplanted to patients.
7.2 Defining Thawing
There are numerous process parameters that can a↵ect post-thaw viability. Mitchell et
al [190] in a 2014 paper proposed five for hESCs- thawing bath temperature, exposure time
to thaw bath, temperature of dilution medium, seeding density and state of cells during
cryopreservation. In their report thaw bath temperature and exposure time and temperature
of dilution media had significant e↵ects on cell adherence post thaw, whereas seeding density
did not. Additionally it was found that input-cell quality was significant but not-independent
of other factors i.e. suboptimal input cells adhered by up to 11% more when exposed to a
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higher thaw bath temperature. There is limited additional literature on the a↵ect of other
parameters in a thawing process.
An aim of this experiment was to determine a thawing platform and so for all forthcoming
studies, identical input material was used. This was such that any a↵ects, beneficial or
detrimental, can be assured to be independent of the freezing or pre-culture processes.
First, three parameters were screened for their a↵ect on cell health and then a combination
of the three were used to define beneficial and detrimental protocols and analysed in depth.
7.2.1 Screening Critical Process Parameters
An OFaT experiment was used to study the a↵ect of three parameters based on both the
findings of Mitchell et al [190] and two which were considered to be related to thawing as a
process for clinical delivery, briefly.
• Thawing Rate- To assess what happens if a range of thawing rates are used, as defined
by the thawing model determined above in Section 7.1.
• Dilution- To assess if the dilution ratio with fresh media on-thaw is increased or de-
creased.
• Pre-Thaw stabilisation- To determine what happens in cryovials that are warmed prior
to actual thawing to -80°C or even -20°C.
Human mesenchymal stem cells were cultured to passage 6 and then frozen. After thawing
according to the parameter investigated (detailed below) they were assessed for on-thaw
viability, 3hr attachment and 72hr yield. Measurements were completed in duplicate and
experiments in duplicate.
7.2.1.1 Thawing Rate
Heat transfer rates in the range 3-4.5W, as defined by the model in Section 7.1 were ac-
cessible with a normal laboratory heated water-bath. Table 7.2 shows these heat transfer
Defining Delivery 216
rates studied, along with associated water-bath temperatures and exposure times to ensure
an equivalent thaw occurred. In e↵ect the model combined the significant thaw bath tem-
perature and exposure time as examined by Mitchell et al [189]. Cells were removed from
cryostorage and thawed according to the respective parameters to allow 720J to be trans-
ferred into the vial. They were then diluted in a ratio of 1:4 with fresh medium and then
analysed.
Table 7.2: Thawing Rates and associated waterbath temperature and exposure time used
in thawing rate OFaT experiment
Thawing
Rate (W)
Temperature
(°C)
Time
(secs)
3 26.1 240
3.32 37 216
3.5 42.9 206
4 59.7 180
4.5 76.4 160
The data from the present experiment are shown in Figure 7.5. There were significant di↵er-
ences from the 3.32W control in all three metrics for cells thawed at 4.5W, and additionally
attachment and yield for the 4W group. The cells thawed at 4W, despite having poor attach-
ment recovered to a statistically similar rate when the yield from attached cells is calculated
to be 218.2±33.6% for 3.32W versus 216.5±26.9% for 4W.
Using a rate of 4.5W proved to be catastrophic after 72hr, with e↵ectively 100% cell death
observed here. The cells here were exposed to a temperature of 76.4°C for almost three
minutes. The Biot correlation, built into the model, predicted that the frozen content
operates homogeneously. Nevertheless, the model’s physical validity has been demonstrated
above in Figure 7.4 and so it was likely to be the fact that the Biot assumption does not
apply biologically: some cells, close to the wall of the cryovial will likely be exposed to lethally
high temperatures and this ultimately causes the catastrophic failures in culture. That the
cells that survived thawing at 4W grew at an similar rate to the control group shows that the
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Figure 7.5: (A) On thaw viability, (B) 3hr attachment and (C) 72hr yield of bone marrow
derived human mesenchymal stem cells after thawing with three di↵erent heat transfer
rates. Data are the mean of duplicate measurements from three independent experiments
±SD. * represents a statistically significant di↵erence (p=<0.05).
Defining Delivery 218
increased temperature immediately killed some of the cells rather than inducing continuing
biological e↵ect in the remaining population.
The cells are broadly tolerant to a range of 3 to almost 4W, a temperature range of 26°C to at
least 46.9°C, and as was shown in Section 5.3.1 lower temperatures also do not significantly
a↵ect cell health on thaw.
7.2.1.2 Dilution
To assess whether dilution immediately after thaw has any a↵ect on cell health and prolifer-
ation a range of 1:0-1:10 was investigated. Cryopreserved cells were normally quenched with
fresh medium at a ratio of 1:4, i.e. a total of 5mL of cell suspension. In the case of 1:0, the
cells were removed from the cryovial into an empty centrifuge tube.
It was shown that there was no e↵ect on immediate on thaw viability, all six groups are
statistically similar, with an overall average of 94.4% (Figure 7.6a). Indeed observing 3hr
yield and 72hr yield (Figures 7.6b and 7.6c) all but the 1:0 group are statistically similar, with
an average of 80.7% for attachment and 175.4% for yield. This shows that increasing the
diluting ratio does not increase cell viability or proliferation. However, not diluting on thaw
and processing cells in the cryomedium- the 1:0 group did cause drops in attachment and
yield, 64.6±3.7% and 151.8±4.1% respectively. These results correlated with the Freeze +
Exposure group from Section 5.2, here leaving cells in the DMSO containing medium for an
hour post thaw did cause significantly reduced attachment and proliferation on thaw. The
reduced attachment and proliferation on thaw did indicate that the washing step to remove
DMSO from cells is crucial. These data show that failing to wash cells was e↵ectively
the same as over 60minutes exposure to DMSO, further detrimental e↵ects may have also
occurred.
The delayed response and thus di↵erence between perceived and actual variability in the 1:0
group was likely due to DMSO remaining in the system and slowing adherence. There was
no statistical di↵erence in the yield from attached numbers across all six groups- an overall
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Figure 7.6: (A) On thaw viability, (B) 3hr attachment and (C) 72hr yield of bone marrow
derived human mesenchymal stem cells after thawing and then dilution with fresh medium
at a range of ratios. Data are the mean of duplicate measurements from three independent
experiments ±SD. * represents a statistically significant di↵erence (p=<0.05).
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average of 220.8%, indicating that there was no further damage to the 1:0 group cells and
the lowered yield was due to a smaller seed population.
7.2.1.3 Pre-Thaw Temperature
Cryopreservation protocols usually advise storage in the vapour phase of LN2 vessels[58, 276].
This ensures preservation at around -150°C, theoretically ad infinitum so long as the liquid
nitrogen is kept topped up. Shipment as previously discussed in Section 2.8.5 is likely to be
a sensitive part of the cell therapy delivery chain with awkward process currently in place.
This experiment is designed to simulate shipment scenarios such as cool blocks, dry ice or
catastrophic failure of a LN2 shipment solution causing a rise to -20°C.
Stored cryovials of hMSCs were either thawed immediately and assessed, or stored in a -
80°C or -20°C freezer for an hour to allow them to warm to these temperatures. They were
then thawed in a 37°C waterbath to allow for 720J (the default amount) of energy to be
transferred, this took 216seconds.
First considering the cells first warmed to -80°C, no significant di↵erences were observed as
compared to the -150°C control group. This is to be expected- cryopreservation protocols
usually suggest controlled freezing to -80°C and as the range of these temperatures was below
the ice nucleation range- usually between -5°C and 20°C, but sometime as low as -30°C[194].
Cycling therefore between -150°C and -80°C would not be expected to cause damage to the
cells. An argument could additionally be made for storage in -80°C mechanical freezers but
these are prone to both power and mechanical failures as well as unexpected temperature
increases due to door openings etc. Further, whilst these data show that short term storage
at -80°C does not a↵ect cell viability on thaw, a very early study showed that after 3 years
bone marrow cells stored at dry-ice temperatures i.e. -69°C to -70°C “were almost entirely
destroyed” [168] and an even earlier study stated that cells stored in dry ice “for periods of
up to 1 year maintain their normal morphology. However changes become apparent by 2
years and were severe by 3.”[210]
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Figure 7.7: (A) On thaw viability, (B) 3hr attachment and (C) 72hr yield of bone marrow
derived human mesenchymal stem cells after thawing from three di↵erent storage temper-
atures. Data are the mean of duplicate measurements from three independent experiments
±SD. * represents a statistically significant di↵erence (p=<0.05).
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After one hour storage at -20°C there was significant damage to the cells. Viability dropped
to 84.8±1.7%. Significant detrimental di↵erences are also observed in attachment and
72hr yield, 55.0±7.6% and 116.1±25.3% respectively, although the yield of cells thad had
attached after 3hrs was similar to the other two groups. Again, it appears that whilst some
cells did die, those that survived were able to grow at normal growth rates according to the
baseline from Section 4.4. Lastly there was higher variance in the all three -20°C groups
as compared to the control and -80°C group. A hypothesis for the cause of both the drops
in viability and adherence and the increased variability could be that ice-crystals are re-
nucleating as the vials warm to -20°C, Toner and Cravalho[283] have shown mathematically
and physically that the formation intracellular ice catalysed by cell membranes or intracellular
particles starts to occur at -35°C this could have been the cause of the reduced viability and
proliferation here. As for the increase in variance, this could have been due to the fact that
as the cell suspension warmed ice started to spontaneously recrystallise[283].
7.2.2 Confirming Protocol Development
The data from screening the process parameters above suggested that the current process-
37°C (3.43W) waterbath, standard dilution (1:4) and no pre-thaw stabilisation was, for these
parameters at least, e↵ectively optimal. To confirm this, the current standard protocol was
compared to protocol that was predicted to be detrimental to the cells based on the findings
in Section 7.2.1. The two protocols therefore investigated were:
Table 7.3: Thawing Protocols used to confirm validity of developments
Parameter Optimal Detrimental
Thawing Rate 3.43W 4W
Temperature 37°C 59.7°C
Time 216s 160s
Dilution 1:4 1:0
Pre-Thaw Stabilisation None -20°C
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Vials in triplicate were thawed according to these protocols. Immediately after thaw, cells
were assessed for on-thaw viability and then seeded into tissue flasks. After 3hrs cells were
assessed for attachment e ciency. The cells were then cultured for two passages, here
growth, metabolic activity, phenotypic expression, di↵erentiation capacity and kynurenine
expression were assessed. All experiments were completed in triplicate and measurements
were in duplicate.
7.2.2.1 On-Thaw Viability and 3hr Attachment
Once the cells had completed thawing they were removed from the cryovials and the optimal
cells were quenched with fresh medium. The cells were then immediately assessed for viability.
The data in Figure 7.8a shows that the detrimental protocol used caused significantly lower
viability on thaw, cells thawed with the optimal protocol recovered to 96.6±1.1% viability
whereas the detrimentally thawed cells recovered to 85.6±6.8%. This was a significant
(p=0.003) but not catastrophic drop in viability as the detrimental cells’ viability was well
above the 70% FDA release threshold[38]. Considering attachment however, Figure 7.8b
does show significant (p<0.0005) failure in the cells ability to attach as just 22.5±7.2% cells
attached after three hours.
Considering also the cell size immediately after thaw, the detrimental cells had swelled to
a diameter >20µm (the equipment used to determine size cannot measure cell size above
this). Cells in stable culture have a diameter of 17.9µm and the cells thawed in the standard
protocol were shown to have a diameter of 18.5±0.48µm. This swelling at before the
significant adverse e↵ect on attachment is most likely due to cells apoptosing due to heat-
shock before their ultimate death and inability to attach in the first three hours post-thaw.
Fulda et al [84] in a review of cell stress literature state that a “cell’s survival critically depends
on the ability to mount an appropriate response towards environmental or intracellular stress”
and that even mild environmental heat changes (3-5°C) the cell pauses important functions
such as protein transcription, di↵erentiation and development functions. The major increase
in temperature experienced by some of the cells close to the wall of the vial during thawing
even for just a few minutes could have caused the swelling and eventually necrosis.
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Figure 7.8: (A) On Thaw Viability, (B) 3hr Attachment E ciency rates and (C) Cumulative
fold expansions over 1 and 2 passages of bone marrow derived human mesenchymal stem
cells after thawing from cryopreservation with two di↵erent protocols detailed in Table 7.3.
Data are the mean of duplicate measurements from three independent experiments ±SD.
* represents a statistically significant di↵erence (p=<0.05).
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7.2.2.2 Growth
Cells were cultured for two serial passages post-thaw. Figure 7.8c shows that there was a
significant (p=0.002) reduction in fold expansions over the first passage, causing slightly
less total growth after two passages. This reduction in growth over P1 was possibly due
to a hangover of the cell death observed in Section 7.2.2.1 causing a reduced proliferative
population. This was confirmed by determining the growth rate over the last four days
of the passage. Cells were sacrificed and counted at feed and the growth rates over the
last four days of passage were calculated to be 0.76±0.07 fold expansions/day for the cells
thawed with the standard protocol and 0.69±0.05 fold expansions/day for the cells thawed
detrimentally- these results were statistically similar (p=0.138).
At passage 2 the cells grew at equivalent rates- 0.59±0.05 fold expansions/day versus
0.51±0.11 fold expansions/day. The growth data show that the damage at thaw does not
cause any lasting damage on the cells proliferative ability, returning to baseline levels after
less than 72hrs in culture after recovery from cryopreservation. The significantly di↵erent
cumulative growth values shown in Figure 7.8c are only lower due to the smaller seed popu-
lation due to the damage caused by the thawing process. Whilst the cells that survived the
detrimental thawing process grew at similar rates to the normally thawed cells this was under
“ideal” culture conditions. If, for example, cells thawed with the detrimental protocol were
transplanted into an ischeamic or inflammatory environment the recovery might not be as
e cient, therefore to confirm that no additional biological damage was caused metabolism,
identity and function was tested.
7.2.2.3 Metabolism
Medium aspirate samples were taken at passage and feed to determine the rates of change
of the concentrations of glucose, lactate and ammonium in medium caused by cellular
metabolism. Figure 7.9a shows that there was no significant di↵erence in rates of glu-
cose uptake, lactate production and ammonium production. As Figure 7.9a and Table 7.4
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Figure 7.9: (A) Change in Metabolite Concentration and (B) Yield of lactate from glucose
of bone marrow derived hMSCs after after thawing from cryopreservation with two di↵erent
protocols detailed in Table 7.3. Data are the mean of duplicate measurements from three
independent experiments ±SD.
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show, there were no significant di↵erences between either protocols nor are the per cell rates
di↵erent from the baseline characteristics previously shown in Section 4.4.3.
Table 7.4: Rates of change in pMol/cell.day of concentration of glucose, lactate and am-
monium in medium caused by the metabolism of cells thawed with two di↵erent protocols.
Data are derived from the mean ±SD of duplicate measurements from three independent
experiments.
Standard Protocol Detrimental Protocol
P1 P2 P1 P2
Glucose Uptake 10.95±0.38 9.91±1.09 10.68±0.95 10.13±0.29
Lactate Production 19.67±2.08 19.03±1.66 18.82±2.07 19.47±2.64
Ammonium Production 2.03±0.10 2.13±0.12 1.97±0.23 2.19±0.20
Similarly, the yields of lactate from glucose (Figure 7.9b) for the populations thawed with
di↵erent methods were statistically similar.
7.2.2.4 Identity- Phenotype and Di↵erentiation
After the first passage cells were assessed for phenotypic expression of the five key extra-
cellular markers. Figure 7.10a shows that the cells thawed with the detrimental protocol did
not have a significantly changed phenotype nor was it di↵erent to the cells thawed with the
standard protocol. Additionally some cells from each condition were di↵erentiated. After
the appropriate time and staining, it was shown (Figures 7.10b-d) that the cells thawed with
the detrimental protocol did not lose their di↵erentiation capacity.
Overall, these identity data show that despite thawing with the detrimental protocol cell
identity did not significantly change. No change in identity corroborates the analysis from
the previously gathered viability, growth and metabolism data that it was merely cell necrosis
induced by the lethally high thawing temperatures in the first 72hrs causing some cells to
die, but others to remain viable.
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Figure 7.10: (A) Multiparameter expression of CD73+, CD90+, CD105+, CD34- and HLA-
DR- on bone marrow derived hMSCs one passage thawing from cryopreservation with two
di↵erent protocols detailed in Table 7.3. Data are the mean of duplicate measurements
from three independent experiments ±SD. Based on  5000 events. (B-D) Di↵erentiation
capacity of bone marrow derived human mesenchymal stem cells after thawing with a
detrimental protocol (B) Adipogenic, (C) Chondrogenic and (D) Osteogenic di↵erentiation.
Observed through a 10x objective lens. Scale bar represents 0.1mm. Representative images
of four repeats.
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7.2.2.5 Function- IDO Expression
Whilst the data previously discussed showed that there was no significant e↵ect on the
identity and proliferation of the cells (once the damaged cells are taken account of) it was
worth briefly considering if the function of these cells has been changed in any way. The
kynurenine assay was again employed to determine IDO expression. Cells were treated with
a cytokine spiked medium and then assessed for kynurenine expression.
As Figure 7.11 shows there was no significant di↵erence in kynurenine expression between
the two cell populations that had been thawed di↵erently, both reach a plateau of around
0.4nMol/cell after day 2. These data show no significant a↵ect on cell function despite the
use of the detrimental thawing protocol. It is likely that had the cells been exposed to a
lower temperature for longer- 40-50°C for example- function might have changed, as Fulda
et al [84] stated, this would push cells down an apoptotic rather than necrotic route of death.
In the case of 4.0W, which exposes cells to 59.7°C for around three minutes it is quite likely
that the cells on the outside of the vial were heated so much that the result is necrosis in
the first three hours post thaw in vitro.
7.2.2.6 Additional Cell Line
To confirm the conclusion that the detrimental protocol significantly a↵ects more than just
this hMSC line a similar panel of analysis was performed on the M4 cell line after a population
had been thawed using it. Across all five metrics investigated, there was no significant
di↵erences observed between M4 and M7, validating the findings above.
Significant reductions in attachment were observed, with 28.8±3.1% M4 cells attaching
after three hours compared to 25.73±11.6% of M7 cells. Average growth rates in the first
passage post thaw were reduced by 14-20% by the detrimental thawing process. Across all
four groups (M4/M7 and Standard/Detrimental Thawing) there was no significant di↵erence
in metabolic yield of lactate from glucose, with all means in the range 1.78-1.88mol/mol.
The rates of glucose uptake and lactate production were also similar across all four groups-
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Figure 7.11: Kynurenine activity of bone marrow derived cells after being fed with a cytokine
spiked medium three days after thawing from cryopreservation with two di↵erent protocols
detailed in Table 7.3. Data are the mean of duplicate measurements from three independent
experiments ±SD.
average glucose uptake ranging from 9.04-10.96pMol/cell.day and lactate production from
16.91-19.66pMol/cell.day. Lastly, M4 cell phenotype remained unchanged with both M4
groups’ co-expression above 95%.
Data from the M7 experiments showed that it was primarily physical damage to the cells in
the first 72hrs post-thaw, it is not surprising therefore that M4 responded similarly. All hMSC
lines are di↵erent[250, 251] and it has been shown in earlier experiments (see Section 5.3.3)
that even these two lines respond slightly di↵erently to DMSO over-exposure. However, in
the case of thawing, hMSCs all have similar physical characteristics and therefore are likely
to respond to dangerous heat such as that which the cells experience being thawed with the
detrimental protocol in the same way.
Overall, this experiment has shown that the damage caused to cells by the detrimental
thawing process was immediate necrosis caused by the high temperature used and did not
cause any additional biological responses (with the exception of a higher number of dead
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Figure 7.12: (A) On-Thaw Viability and Attachment, (B) Fold Expansion Rate over one
passage, (C) Metabolic Yield of Lactate from Glucose and (D) Phenotypic Co-Expression of
CD73+, CD90+, CD105+, CD34- and HLA-DR of two independent lines of bone marrow
derived human mesenchymal stem cells after thawing from cryopreservation with two dif-
ferent protocols detailed in Table 7.3. Data are the mean of duplicate measurements from
three independent experiments.
cells) which could cause further complications post-clinical application. The higher number of
dead cells present could possibly induce an additional inflammatory response[88, 228] which
could lessen a clinical benefit. However, as the overall consequences of a detrimental thawing
are unlikely to a↵ect patient health it could be suggested that within broad parameters the
method of thawing does not a↵ect product quality but from a commercial perspective losing
as few cells as possible as with the current standard optimum is ideal, this would negate any
response caused by dead cells and reduce the cost of application.
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7.3 CellSeal Vials
7.3.1 CellSeal as an alternative closed cryovial system
Current polypropylene vials do not meet the necessary standards for therapeutic delivery for
one core reason: they are not a closed system. Woods and Thirumala propose three criteria
that an ideal biopreservation container system must meet[306]:
• Closure integrity- the system must be hermetically sealed to ensure the specimen
integrity is maintained throughout the cold chain processes.
• Sample stability- the biopreservation contain must allow for sample stability over long
(theoretically ad infinitum periods).
• Easy material access- the system must allow for simple sample retrieval without con-
tamination, with the added recommendation of easy transfer to an automated system.
Additionally, any new system would need to be easily transferred using existing process
paradigms.
Whilst polypropylene vials do allow for stable samples and easy access they are demonstrably
not a closed system. “Blood” style bags have been used more recently- e.g Prochymal whic
is formulated in 15mL bags [33], as these easily fit into current infrastructures, although
these are only feasible for processes producing tens of doses, rather than what will eventually
need to be hundreds, if not thousands to meet patient demand [232]. Further, concerns with
materials used must be addressed- ethylene vinyl acetate (EVA) undergoes glass-transition
at -15°C questioning its use at cryogenic temperatures (rather than hypothermic ⇡4°C in
blood processes) due to extreme brittleness at low temperatures[141]. Problems also ex-
ist with polypropylene in that manufacturer variability and biological issues are not fully
understood[71]. Alternatives exist, such as cyclic olefin co-polymer (COC) which are often
used to deliver pharmaceutical products[215].
It is with one of these COCs: TOPAS (TOPAS Advanced Polymers GmbH, Frankfurt/M.,
Germany) that CellSeal vials are constructed from[306]. TOPAS is transparent, tolerant of
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a wide range of pH and solvents, further it has thermic properties making it viable for both
cryopreservation and autoclaving sterilisation. A diagram of the system was previously shown
in Figure 3.4 along with a protocol for use in Section 3.7.4. Each feature however has been
designed such that the CellSeal vials meet the three criteria and the other concerns above.
The fill-port is either a needle septum or needless port, requiring Luer syringes to be used-
the needless variant was used for these experiments- the tubing here is EVA allowing sealing
by blood-bag heat sealer or radio frequency (RF) welding to completely close the vial. The
other tube is an air-vent with a polytetrafluroethylene (PTFE) filter to prevent microbes
from entering the system whilst allowing air to leave the system when displaced by cellular
fluid. The tubing can be cut o↵ above the seal to allow for the vials to fit into cryostores-
the 2mL variant, used here, fits into the cryostore boxes used as they are the same diameter
as polypropylene vials.
Removal of cell material was performed by the removal of a foil cover and then inserting
18G needle into the retrieval port at the bottom of the vial[186].
The Woods and Thirumala[306] study performed durability sterility tests by first dropping
both frozen and non-frozen vials from a height of 1m on to a concrete laboratory floor. Fur-
ther, cell seal vials filled with a microbial promoting broth- tryptic soy broth- were immersed
in a “challenge bath” of the bacteria Brevundimonas diminuta a small bacteria representing
a stringent microbial challenge. The results noted no evidence for a reduction in mechanical
strength or microbial contamination of the vials due to the freezing process.
7.3.2 Comparing Polypropylene Vials to CellSeal Vials
Woods and Thirumala[306] also performance tested the CellSeal vials for mesenchymal stem
cell banking using dental-pulp derived stem cells. Their results showed no di↵erence between
the two sizes of CellSeal vials and control polypropylene vials.
To ensure compatibility with laboratory processes used in the experiments here bone mar-
row derived human mesenchymal stem cells (M7) at passage six were frozen in hPL with
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10%wt DMSO. One group was stored in standard polypropylene cryovials, and another in
the previously described 2mL Cook CellSeal vials. After one week in cryostorage the cells
were thawed and assessed for viability, attachment after three hours and yield after 72hours.
Figure 7.13: On thaw viability, 3hr attachment and 72hr yield of bone marrow derived
human mesenchymal stem cells after cryopreservation in polypropylene and CellSeal vials.
Data are the mean of duplicate measurements from three independent experiments ±SD.
As Figure 7.13 shows, there was no significant di↵erences between CellSeal or standard vials
in the metrics investigated, this agrees with the results that have previously been shown by
Woods and Thirumala[306], so it is good that this technology can be successfully transferred
to another laboratory.
7.3.3 Multiple User Test
CellSeal vials could prove to be a practical solution for cell therapy delivery, but to confirm
the usefulness of CellSeal vials and whether the tech transfer is truly successful, multiple
users tested the CellSeal vials.
Three experienced users were invited to freeze cells using the CellSeal vials. They were
instructed to add 1mL of cell solution from the same pool of cells made up as in Section
7.3.2 into the CellSeal vials, seal them and add them to the CoolCell. Following cryostorage
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Figure 7.14: (A) On thaw viability, (B) 3hr attachment and (C) 72hr yield of bone marrow
derived human mesenchymal stem cells after cryopreservation in CellSeal vials processed
by three independent users. Data are the mean of duplicate measurements from three
independent experiments ±SD.
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for one week, users were then instructed to remove cell material using the needles as described
in the CellSeal protocol (Section 3.7.4).
Figure 7.14 shows that the for viability, attachment and yield there was no significant variance
between all three users. However when considering the absolute cell numbers revived, Figure
7.15 shows that around 15.4% of total cells (i.e. including non-viable) were lost over the
course of the process, compared to just 5.4% for normal polypropylene vials.
Figure 7.15: Total Cell Number on Thaw of bone marrow derived human mesenchymal
stem cells after cryopreservation in polypropylene, and CellSeal vials processed by three
independent users. Data are the mean of duplicate measurements from three independent
experiments ±SD.
Users were also asked a series of questions after use. For successful tech-transfer to vials
such as CellSeal operator concerns will need to be taken into consideration. User B found
the vials “a little awkward to use but with practise. . . it would be fairly easy”, User C agreed
saying they were “slightly more cumbersome than conventional cryovials” but that “not
having to remove and hold a cap lowers contamination risk during loading.”
All users noted di culties with the syringe input system “loading dead volume and fine-
control of loading pressure with a syringe is trickier” this causing “build-up of air pressure
which made it di cult to push the cells through the top of the vial. It was also hard to
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handle the syringe; sometimes it moved and the pressure caused leakage of cell sample.”
This is likely the source of the loss of cell number. Lastly the “additional steps in process and
the need to fine-control loading pressure increased processing complexity.” Another source
of variability was that the syringes were operated manually and so ensuring the right volume-
1mL- was added to the vial was troublesome.
More positively, all users agreed the advantage the “absence of a screw top made the
processing simpler as sealing the vial was easy and took no time at all” and that “not having
to manually decap several vials during loading” was an improvement over polypropylene vials.
Ultimately, the process was slowed when filling, but quicker when sealing multiple vials. The
sealer however did cause some issues, successful sealing does not always occur when fluid
remained in the tubes. Once this was successful, the cells were preserved in a viable closed
system. Considering increasing scale, CellSeal vials have a max volume of 5mL, but the
Luer lock port could allow for a several to be filled at once through with a system such as
Sartorius-Stedim’s (formerly TAP Biosystems) Fill-It machine[237] after some modification
to allow for Luer ports.
Removing cells from the vial required the use of an 18G needle, User A ran into di culty
stating that “not all cell material could be removed”- another source of the loss of cell
number encountered. The use of a needle raises concerns of shear damage to cells however
in a study looking into the application of stem cells with catheters by Walker et al [289]
found that the use of needles similar to those used here did not significantly a↵ect murine
or human MSC viability after injection but did observe a slight decrease after 24hrs but no
change in immunophenotypic identity. Shear stress is induced as fluids pass material surfaces
as opposed to normal stress where the stress is vertical to the surface. Further Garvican et
al [88] did notice increased apoptosis of equine MSCs when a 21G or 23G needle was used
advising a larger 19G needle be used, the use of an 18G needle in the present experiment
would indicate that damage to cells caused by shear stress as the cells pass the needle walls
was not a risk.
Ultimately, the CellSeal vials did present significant advantages for clinical application. The
volume of the 5mL variant would allow for volumes near to clinical requirements: Clincke et
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al [47] froze at 5x107CHO cells/mL and achieved excellent viability. The issues with cell loss
are concerning, but would likely be eliminated with practise. Further, these vials would fit
into normal cryostorage protocols with minimal modification. The 2mL vials used here fit
into both the CoolCell and cryostores used.
This system allowed for a clinical grade closed system for the application of delivering cell
therapies to the patient.
7.4 Concluding Discussion- Defining Delivery?
The aim of this chapter was to assess certain process characteristics on the delivery end
of a cell therapy process. The data have shown that cells are broadly tolerant of some
aspects of a thawing process whilst sensitive to the high temperatures required to raise
the thawing rate. Using heat transfer principles to model the physical state of the cell
material in a cryovial opens up a whole new area of parameters for analysis. The model
described in Section 7.1 only focuses on standard 1.8mL polypropylene vials however given
the nature of heat transfer principles, modification to include large vials (for example CellSeal
vials assessed in Section 7.3), cryobags or delivery methods not yet designed would not be
di cult. However the biological validity of the model did raise some questions- significant
cell death was observed once the heat transfer rate and thus water bath temperature was
increased to lethal temperatures. The cells that were exposed to the high temperatures
thawing protocols but not killed did not exhibit any detrimental biological changes after the
thawing event.
The CellSeal vials studied here present an interesting alternative to polypropylene vials. They
meet the GMP requirement of being a functionally closed system although some users testing
the vials found CellSeal vials di cult to use at first, but the closed-system benefits easily
outweigh any use issues which will be eliminated with repeated use and training.
It is likely that thawing will be performed by medical rather than production sta↵ close to
the patient and so ensuring a well defined, well understood protocol is used will help improve
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patient health. Defining delivery is vital for the safe and repeatable clinical application of cell
therapy products. Good thawing protocols and viable closed-system vials will ensure that
cryopreserved products can be transported successfully to patients time after time.
Chapter 8
Summary, Conclusions and Further
Work
8.1 Summary
The title of this thesis is “Exploring the improvement of human cell cryopreservation”. A
number of cell therapeutics are approaching the market with hundreds in human clinical
trials and countless more in early stage investigations[201]. To ensure successful delivery to
patients e cacious preservation technology will be vital. With this in mind, the vision of this
thesis was to assess core issues facing the development of these technologies and provide for
certain improvements to the current work. In Chapter 2 the state of the art was discussed
and six key issues with the current technology assessed. From these, three were selected as
objective problems that the work of this doctoral thesis could aim to improve: the toxicity of
DMSO, the detrimental use of animal sera and the ambiguous nature of thawing protocols.
The FDA present a release criterion for cellular products of >70% viability on thaw [38].
Studies into the e↵ect of cryopreservation are only now starting to look beyond on-thaw
viability and it is clear that for significant progress to be made in the development of cell
therapies, primarily in the transition to much higher scale production a multi-disciplinary
approach is needed. This thesis has used concepts of biology and engineering to observe
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cryopreservation as a technical process and under this paradigm developed parameters to
improve it.
Before the three selected issues were investigated, first the current standard cryopreservation
process was benchmarked with the two cell lines primarily used in this body of work, a
human osteosarcoma cell line: HOS TE85 and a line of human mesenchymal stem cells
extracted from fresh bone marrow aspirate. The standard 10%wt DMSO in FBS cryomedium
formulation was assessed for e cacy by comparing it to formulations made up of 0-9%wt
DMSO and 6 alternative cryoprotectants by determining on-thaw viability, 1hr attachment
e ciency and yield after 24hrs. From this study, cryomedia made up from FBS and two
concentrations of DMSO, and 10%wt glycerol and 10%wt PrOH were investigated to see
what long term a↵ect these media had on cellular fate after preservation. Cells preserved
with PrOH showed significant di↵erences in growth immediately post thaw and metabolic
activity. After 1-2 passages the rates of growth and metabolism were similar across all four
groups although total cumulative values for growth and metabolic activity in PrOH preserved
cells did have significant reductions due to the earlier changes. Next, bone marrow aspirate
was processed to isolate mesenchymal stem cells, whilst only a tiny proportion of cells in
bone marrow are hMSCs[309], enough were present to form a MCB, the primary line was
then characterised for growth rate, metabolic activity, and phenotype and di↵erentiation
capacity. The characterised primary cells were then compared to a thawed group from the
MCB to see if standard cryopreservation a↵ected the cells in any way.
In Chapter 5 the first issue with cryopreservation to be tackled was the toxicity of the
most widely used cryoprotectant: DMSO. To define the maximum amount of time cells
can be exposed to DMSO before detrimental e↵ects occur three experimental regimes were
utilised with exposure to DMSO-containing freeze medium above freezing for up to two
hours either without, before or after cryopreservation. Both HOS TE85 and the bone marrow
derived hMSCs were thoroughly investigated to determine what e↵ect DMSO had on cellular
fate. Minor reductions in on-thaw viability were observed in both cell lines, but significant
detrimental changes in attachment, metabolic activity and phenotype were observed after
60minutes exposure. This raised questions for scaled up processes requiring in excess of this
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time to preserve successfully. To confirm the 60minute parameter, additional analysis was
conducted with studies looking into cell size, di↵erentiation capacity, an additional metabolic
pathway (glutamnolysis) and immunological function by means of kynurenine expression. By
further validating the conclusion with a separate hMSC line from a di↵erent donor it was
found that exposure to DMSO containing freeze media should be kept to below one hour to
ensure e↵ects potentially harmful to patients do not occur.
The other key component in freeze media is more often than not bovine derived sera. FBS is
extracted from cattle and this has numerous issues including ethics, xeno-toxicity and cost.
The aim of Chapter 6 was to select an alternative that has the possibility of solving these
significant issues. First various alternatives to FBS as a vehicle solution were screened, these
included hPL, commercially available complete cryomedia and growth medium. By assessing
for on-thaw viability, 3hr attachment and 72hr yield a viable candidate was selected for further
analysis- hPL. The study then investigated using hPL as a cryopreservation vehicle solution
in combination with using it for culture supplementation also in place of FBS. The data
showed that after entirely replacing FBS in the system with hPL demonstrable advantages
were observed. There were no detrimental e↵ects although a reduced rate of glucose/lactate
metabolism was observed and slightly increased growth rate, further there was no change in
immunological function. The study showed that it was entirely possible to remove the most
controversial animal-component from in vitro cell culture of clinical relevant stem cells with
only process improvements observed.
The final experimental chapter- Chapter 7- entitled “Defining Delivery” more practical ele-
ments of the cryopreservation process were focused on: thawing and product delivery. These
are key phases in the delivery of a therapy, even more so when it is assumed that medical
sta↵ will be performing the thawing on arrival at the clinical site. To improve the process of
thawing, studies of which are notably lacking in the literature, first a model based upon heat
transfer principles was developed. This model allowed for the heat transfer rate (in Watts)
of a specific thaw vessel (e.g. water bath) to be defined as opposed to the temperature and
thaw-time. Screen experiments were then performed using the thawing model and two addi-
tional parameters: dilution ratio on thaw and pre-thaw temperature. From this the tolerance
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of cells to the parameters was shown and the standard protocol compared to a detrimental
protocol based on the results of the screen experiments. Cells thawed with both the standard
and detrimental protocol were then thoroughly analysed and it was found that poor thawing
appears to only mechanically damage the cells, slower growth rates were observed but it
was inferred that this is due to the catastrophic cell loss caused by the heat damage in the
detrimental protocol. The last phase of this chapter was a brief study on CellSeal cryovials.
Polypropylene vials are unable to be used in a clinical setting as the environment where the
cells are preserved is opened when fluid is added or removed, CellSeal vials are a closed
system and therefore a solution to this concern. Cells responded in the same way to CellSeal
vials as they do to normal polypropylene vials, although users investigating the new vials
noted di culties in processing although these would be removed after repeated practice.
This thesis presents answers to three important concerns with cryopreservation as the cell
therapy industry expands. The results present interesting opportunities for further work with
questions raised in the experimental work, and the additional issues noted in the review of
literature. Cryopreservation is a peripheral but vital step in the commercialisation of cell
therapies.
8.2 Conclusions
The overall conclusions of this thesis are explained in detail below, Figure 8.1 however
summarises the key points in a flow chart. The flow chart shows the key steps in the
cryopreservation of a cell product with elements of the findings of this thesis input showing
an improved protocol and therefore how the aim of this thesis was met.
• The widely cited formulation of 10%wt DMSO[51, 80, 121, 159, 302] in FBS was, when
compared both to other concentrations of DMSO and alternative cryoprotectants, the
most e cacious. Results in Sections 4.1.3 and 4.2 showed that it was statistically
similar to 7-9%wt DMSO formulations and commercial blends. Some cryoprotectants
such as ectoine are catastrophic for the HOS TE85 cells studied inducing massive cell
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Figure 8.1: Overall thesis conclusions relevant to key process steps in a cryopreservation
protocol
loss and detrimental phenotype changes. Only from a processing perspective, however,
does cryopreservation have a long term e↵ect. In Section 4.3 statistically di↵erent
growth was observed in cells preserved with 10%wt glycerol and PrOH. Significantly
changed glucose/lactate metabolism was observed in cells preserved in PrOH, with
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over ten passages a cumulative uptake of glucose of 54.18±2.70 pMol/cell compared
to 44.10±1.74 for 10%wt DMSO preserved cells. Whilst most of the significantly
di↵erent activity occurred in passages 1-3 post thaw, the overall a↵ect was substantially
changed metabolism.
• In Section 4.4.4 it was found that freezing the bone marrow derived hMSC line in-
vestigated did not to change growth, metabolic and phenotypic characteristics. This
indicated that any changes in cellular response from further experiments involving
cryopreservation were entirely due to the experimental parameters.
• In Chapter 5 the broad DMSO toxicity experiment ultimately showed a key parameter:
cells must not be exposed to a cryomedium containing 10%wt DMSO for longer than an
hour. The data from HOS TE85 cells and two hMSC lines clearly showed detrimental
e↵ects occurring after this point. For example, considering first attachment hMSCs
exposed for 30minutes post thaw attached at a rate of 86.9±6.9% this was similar
to a control group (83.2±8.4%). The group exposed for 120minutes however had
significantly lowered attachment at 52.7±4.0%.
• Attachment e ciency strongly correlates to long term growth Using data from the
DMSO toxicity experiment hMSC attachment e ciency determined after three hours
was found to strongly correlate with growth over five passages- average error of just
1.64%. The benefit of this would allow for quick determination of cells’ proliferative
capacity quicker than would otherwise be allowed. Conducting the same analysis on
similar data from experiments performed on the HOS TE85 cells found similar strong
correlation- average error of 6.3%.
• Whilst the HOS TE85 line and two hMSC lines showed similar overall detrimental
metabolic responses to DMSO overexposure- increased yield of lactate, the two hMSC
lines had di↵erent overall metabolic responses- M4 had lower glucose uptake and
lactate production rates compared to M7 after 120minute exposure. These results
show that even two similarly isolated hMSC lines react di↵erently to certain stimuli
and so the need for a bespoke solution for cryopreservation is key.
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• Studies described in Chapter 6 found that hPL was a viable alternative to FBS as
both a cryopreservation vehicle solution and as a culture medium supplement. Whilst
preliminary data has been published relating to the use of hPL as a cryopreservation
vehicle solution[275], here for the first time an in depth study showed its e cacy.
Using hPL as a cryopreservation solution did not improve cell viability or attachment
on thaw, but allowed for an animal component (FBS) to be removed from the process.
Using hPL as a culture supplement for ongoing culture however did present some
slight improvements, growth rate was increased from 0.54±0.03 fold expansions/day if
cultured with FBS to 0.73±0.10 fold expansions/day when cultured with hPL. Further,
reduced glucose uptake and lactate production rates were observed, although with
similar overall yields of lactate from glucose.
Ultimately, using hPL presented a solution to both the ethical and xenological con-
cerns with bovine derived sera. Whilst still being derived from primary donors and so
having similar bio-toxin issues, Stemulate, the hPL product used from Cook Medical
is produced in large batches under GMP conditions with low batch-to-batch variabil-
ity. Additionally using it as proposed would not represent the significant increase in
investment that the use of serum-free media would.
• In Section 7.1, Equation 7.6 was defined, (repeated below as Equation 8.1). It allowed
for the determination of the rate of heat transfer into a vial by a thawing vessel- for
example water bath or incubator. The equation system first defined the total amount
of energy required to thaw 1mL of cell suspension in a 1.8mL standard polypropylene
cryovial- 720J. According to the model, which was validated to be over 95% accurate,
a standard 37°C water bath transfers 3.32W to a cryovial, thawing the cell suspension
in 216seconds, in line with expectations.
dQR =
Tv   TCdTC
1
ho
+ xwkw +
1
hi
A (8.1)
• By conducting OFaT experiments and then comparing a “detrimental” protocol (pre-
thaw warming to -20°C, 59.7°C water bath, no dilution on thaw) to standard rapid
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(37°C water bath followed by 1:4 dilution with fresh medium) it was determined in
Section 7.2.2 that the whilst there was some tolerance, the standard thawing process
was the most beneficial to cells. Thawing in excess of 55°C caused significant cell
death, but no further biological damage to the cells- despite reduced cell number,
these cells returned quickly to baseline-level growth rates, metabolism and phenotype.
• This thesis has also found time and again that using on-thaw viability as a release
criterion for cell therapeutics is insu cient. Cells regularly appeared to have high
viabilities on thaw- in excess of the 70% threshold proposed by the USA FDA[38] but
were subsequently shown to have low attachment e ciencies, reduced proliferative
capacity, and changed metabolism and phenotype. Ultimately the key concern here
was the di↵erence between perceived and actual viability. Improving the release criteria
for thawed cell products is essential for successful therapeutic delivery.
8.3 Further Work
This thesis started with the aim of providing solutions to a number of core challenges a↵ect-
ing the ultimate development of successful cryopreserved cell therapy products. Whilst novel
solutions have been presented to three of these: the extent of the toxicity of the cryoprotec-
tant DMSO, the use of animal derived products and defining parameters a↵ecting thawing,
the other questions raised in Section 2.8 regarding scale-up, shipment and variability remain
unanswered. Further, the results from Chapters 4-7 also raised a number of questions, it
is the function of this section to formally define these questions and propose further work
following on from this thesis.
• As mentioned above this thesis has not gone into too much detail on scale-up, shipment
and variability. The CellSeal vials investigated in Section 7.3 did present a viable GMP
closed system for cell delivery, but these are still at a small volume and technologies
such Sartorius-Stedim’s “FillIt” system only represent a scale-out rather than a scale-up
solution. Methods also don’t fully exist for shipment- there are concerns with dry-ice
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and LN2 shippers [27, 57], these require quick transport and no hold-ups at borders
with customs, for example. Lastly, the some results from validation experiments with
the M4 cell line have shown varying responses to stimuli on thaw. Assessing the
variability of cells will allow for the development of a platform technology.
• The DMSO toxicity experiments (Chapter 5) raised a number of questions:
– First, DMSO is known to induce di↵erentiation in some cells[314]. The present
study only looked at qualitative di↵erentiation and cells exposed to DMSO for
120minutes still had trilineage di↵erentiation capacity. Should viable di↵erentia-
tion assays be developed, it will be essential to quantify the extent to what (if
any) DMSO over exposure has on this important cellular ability.
– The data showed that the reduce co-expression of the five markers was primarily
due to a significant down-regulation in CD73 expression, a marker responsible for
some immunological functions. Fully quantifying both the extent of this and the
reasons behind the down regulation will improve understanding of the mechanism
of cells toxicity to DMSO.
– Recent papers from Moll et al and Galipaeu [86, 193] have shown that cry-
opreservation can induce reduced immunological function in mesenchymal stem
cells. The results in Section 5.3.2.2 showed that DMSO overexposure appears to
further reduce immuno-function. Determining if any other immunological func-
tion is compromised and again, the extent to which over exposure to DMSO in
combination with freezing causes this should be investigated.
– A preliminary study (Appendix E) using Suspended Ion Flow Tube Mass Spec-
trometry (SIFT-MS) appeared to show that cells exposed to DMSO without
freezing for less than two hours uptake so much that washes do not remove the
DMSO as would normally expected. This experiment should be repeated and
expanded to include both more time points and additionally freezing.
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• The hPL study showed a viable alternative to FBS as both a cryopreservation vehicle
solution and culture supplement, although further tests should be performed to deter-
mine if hPL causes any change in immunological function- including alleviate those
discussed by Moll et al [193]. Alternatively to using biological derived components like
hPL, can the essential components that FBS and hPL provide to cells in cryopreser-
vation and culture be defined and as such an open access standard for serum free
cryopreservation be devised?
• The thawing experiments presented several questions.
– The thawing model derived in Section 7.1 only looks at small cryovials, which ac-
cording to the Biot correlation allows the system to be a “lumped capacity”[256]
with no spacial di↵erences. If the geometry is increased to, for example, larger
vials or cryobags the Biot correlation will not be valid and additional calculations
be required.
– In Section 7.2.1 only three CQAs were investigated, but there could be dozens
more that a↵ect the success of thawing. How do changes in input material change
the output? Should warming be non-linear? What if high heat transfer rates, but
with lower contact temperature was used?
– What is the tolerance of cells to “bad” thawing? The data from the experiments
in Section 7.2 appeared to show that cells are not biologically a↵ected by the
detrimental thawing; the heat causes necrosis and death but the cells that the
survived the heat damage were not a↵ected and proliferated normally with stable
identity and function. This should be further quantified.
This thesis has presented a number of novel results and solutions to three core challenges
in the cryopreservation, but the end of the road has not been reached. Continuing research
will continue to improve cryopreservation for the successful banking and storage of clinically
relevant human cells.
Appendix A
Comparison of Counting Methods
Over the course of the experimental work detailed above, three distinct methods for counting
and viability determination were utilised.
• A Haemocytometer, described in Section 3.4.1, used cells stained with Trypan Blue.
Trypan Blue positive cells were deemed non-viable, as they were unable to push the
solution outside their membranes.
• The NC-100 method, Section 3.4.2, first stained non-viable cells with Propidium Iodide
(PI)- PI was only absorbed by cells with non-integral membrane and therefore deemed
to be non-viable. This was then counted with the NC-100 using fluorescence and
automatic counting. Next, the total cell population is lysed and stabilised, this is then
counted to determine total cell number.
• The NC-3000 method, Section 3.4.3, dual stained cells with Acridine Orange (AO) and
DAPI. The AO stained the entire population whilst DAPI passes through non-integral
membranes. Using either cassettes or slides this was then exposed to fluorescent light
and then counted automatically.
To determine comparability of these three methods, HOS TE85 cells from one stable culture
were counted.
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(a)
(b)
Figure A.1: (A) Cell Number and (B) Population Viability of HOS TE85 cells using three
separate counting methods. Data are the mean of five independent counts of one culture
±SD.
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Figure A.1 shows that the methods for determining both cell number and viability were very
comparable. Further analysis shows that they are at least 97% relative to each other and
therefore similar observations conducted with separate counting methods can be accurately
analysed together.
Appendix B
Temperature of Experimental
Environments
The temperature of several environments was key to experiments in this thesis. To confirm
that the assumed temperature of the environments (e.g. that the fridge was at 4°C, room
temperature 20°C) a temperature sensor was placed inside each environment for seven days.
The data from the sensor was then assessed and compared to both the assumed temperature
and set-point. As Figure B.1 shows and Table B.1, the monthtly average temperature of
the four environments are within 1°C of the expected temperature. The only substantial
variation was observed in the room, this peaked at 23.2°C and this is likely due to external
weather a↵ecting the internal laboratory temperature.
Table B.1: Average temperatures over 28 days of four di↵erent experimental environments
Environment
Average Temperature
(°C)
Room Temperature 20.76
Incubator 36.63
Waterbath 37.25
Fridge 4.03
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Figure B.1: Daily and monthly average temperatures of four environments used in experi-
ments. Data are the mean of four measured points per day.
This study validates the temperatures used in the various experiments in this thesis.
Appendix C
Sample Calculations
In this thesis various measures were calculated from raw data. In this Appendix the methods
by which raw data were converted to results are described
C.1 Cell Number and Viability
C.1.1 Trypan Blue Haemocytometry
The method by which cell number and viability was assessed with a trypan blue haemo-
cytometry assay was described in Section 3.4.1. The Equations C.1, C.2 and C.3 below
previously shown before in Section 3.4.1 are how cell number and viability were determined.
⇢cell =
sv
4
⇥ 2⇥ 10000 (C.1)
Nc = ⇢cell ⇥ a (C.2)
Vc =
sv
sn + sv
(C.3)
Where:
• sv is the sum of viable cells in all four corner squares
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• sn is the number of non-viable cells observed: 5 cells
• a is the volume of culture (mL)
• Nc is the total number of cells
• Vc is the cell population viability (%)
• ⇢cell is the cell density (cells/mL)
For example: In an experiment with a 5mL suspension HOS TE85 cells in the four corners
of a haemocytometer, 24, 26, 20 and 29 viable cells and a total of 5 non-viable cells were
observed.
The average number of cells across four squares is calculated (24+26+20+29=99, 99÷4=24.5),
then multiplied by the trypan blue dilution factor: in this case two before being multiplied
by a correction factor of 10000 to convert into cells/mL. The volume of a haemocytometer
square is 100nL so the correction factor converts it appropriately. Using the above Equation
C.1, cell density can be determined.
99
4
⇥ 2⇥ 10000 = Viable Cell Density (⇢cell) = 495000 cells/mL (C.4)
To determine the total number of cells, Equation C.2 is employed where the cell density is
multiplied by the culture volume.
⇢cell ⇥ 5 = Viable Cell Number(Nc) = 9.9million cells (C.5)
Lastly, viability is worked out as follows using Equation C.3 (previously displayed as Equation
3.3.
99
99+ 5
= Viability (Vc) = 95.2% (C.6)
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C.1.2 NC-100
The nature of the NC-100 method required two counts to be performed. The first counted
non-viable cells and the second the total cell count by diluting cells with a lysing agent to
cause viable cells to become non-viable and thus countable by the PI in the assay. The
viable cell density and number is calculated using Equations C.7 and C.8, shown before as
Equations 3.4 and 3.5.
⇢cell = ((Ct ⇥ 3)  Cn)) (C.7)
Nv = ⇢cell ⇥ a (C.8)
Where:
• ⇢cell is the cell density (cells/mL)
• Ct is the total concentration of cells as displayed from the second NucleoCounter test
(cells/mL)
• 3 is from the dilution of the cells required by the method
• Cn is the concentration of non-viable cells (cells/mL)
• Nv is the total number of viable cells
• a is the total volume of cell suspension (mL)
Viability is calculated as follows (previously Equation 3.6):
Vc =
Ct.3  Cn
Ct.3
(C.9)
For example: In an experiment with hMSCs- Ct, total cell number was found to be 33000.
Cn, non viable cell number was 6000, a, volume was 5mL
(33, 000⇥ 3)  6000 = Viable Cell Density (⇢cell) = 93000cells/mL (C.10)
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Again the total number of cells, was determined by is multiplying the cell density by the
culture volume.
⇢cell ⇥ 5 = Total Viable Cells (Nv) = 465000cells (C.11)
Viability using this method was calculated using Equation C.9.
33, 000⇥ 3  6000
33000⇥ 3 = Viability (V) = 93.9% (C.12)
C.2 Attachment
Attachment is calculated by dividing two cell counts. The first is after one hour in culture for
HOS TE85 cells and after three hours in culture for hMSCs. Previously shown as Equation
3.7, Equation C.13 was the calculation used throughout this thesis.
⌘a =
Nca
Nc0
(C.13)
For example: In an experiment with HOS TE85- Nca, the viable cell count after three hours
was 85400 and 100,000 cells were seeded, Nc0. Attachment was determined thus:
85400
100000
= Attachment (⌘a) = 85.4% (C.14)
C.3 Yield
C.3.1 Yield from Seeded
Yield was determined using two di↵erent calculations in this thesis. The first, from seeded is
very similar to the attachment method above in Section C.2 essentially being 24/72hr (HOS
TE85/hMSC) attachment. The yield from seeded is calculated using Equation C.15, shown
before as Equation 3.8.
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Yc =
Nct
Nc0
(C.15)
For example: After 24hrs 187,000 HOS TE85 cells were counted (Nct), after earlier seeding
100000 cells (Nc0).
187000
100000
= Yield from Seeded (Yc) = 187% (C.16)
C.3.2 Yield from Attached
Alternatively yield can be calcuated using the attached cell number calculated above in
Section C.2. This is calculated by replacing Nc0 (cell seeding number) with Nca (number of
attached cells after 1 or 3hrs (HOS TE85/hMSC))
For example: Using the scenarios described above. Nca=85400, Nct=187000
187000
85400
= Yield from Seeded (Ya) = 219% (C.17)
Here the yield from attached was determined to be 219%.
C.4 Growth
Growth in this thesis was displayed as Fold Expansions/Day. This was determined using
Equations C.18 and C.19
Ncn
Nc0
= Nfe (C.18)
Nfe
Tc
= rfe (C.19)
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Where:
• Ncn is the number of viable cells at the count
• Nc0 is the number of cells seeded
• Nfe is the number of fold expansions
• Tc is the time between the counts at Ncn and Nc0 (days)
• rfe is the growth rate (Fold Expansions/Day)
For example: In an experiment with hMSCs. 125000 cells were seeded (Nc0) and after 7
days (Tc) in culture, 476000 cells were counted (Ncn). The fold expansion rate therefore is
calculated as follows:
476000
125000
= Number of Fold Expansions (Nfe) = 3.81 Fold Expansions (C.20)
3.81
7
= Fold Expansions Rate (rfe) = 0.54 Fold Expansions/Day (C.21)
C.5 Metabolism
C.5.1 Glucose Uptake and Lactate Production
The Nova bioanalyser (method described in Section 3.8) enabled the determination of the
concentration of various metabolites, gases and electrolytes present in growth media. In this
thesis three were investigated at various points. The method of converting the raw glucose
and lactate concentrations was similar.
The change in glucose concentration was determined using the following equation:
Cg = Cfg   Cmg (C.22)
The change in glucose concentration was determined as follows:
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Cl = Cml   Cfl (C.23)
Equation C.24 was previously shown as Equation 3.9 and is the calculation by which the
metabolite concentration (g/L) is converted to a per cell value (pMol/cell).
Mcell =
Cm
103
⇢cell
.1012
Mr
÷ Tc (C.24)
Where:
• Mcell is the metabolite concentration per cell (pMol/cell)
• Cm is the change in metabolite concentrations, either glucose or lacate (g/L)
• 103 this is to convert the concentration to g/mL
• ⇢cell is the cell density (cells/mL)
• 109 this is to convert to g/pL
• Mr is the relative molecular mass (g/mol) in the case of glucose, this is 180.16 g/mol,
for lactate it is 90.08g/mol
• Tc is the duration of the culture in days
Glucose was present in the growth media used in these experiments at ⇡0.9g/L. Lactate is
detected at very low concentrations in fresh medium. These values are then converted to a
per cell value in a similar way.
For example, after two days of culture a HOS TE85 cell suspension had a density of
2.77x106cells/mL (⇢cell) and showed a glucose concentration of 0.67g/L(C(mg)).
The consumption (Cg) was calculated by subtracting the concentration present in fresh
medium (0.91g/L (Cfg))
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0.91  0.67 = Glucose Uptake (Cg) = 0.24g/L (C.25)
Thus, using Equation C.24 and the data above, the glucose uptake per cell is determined:
0.24
103
2.77⇥106 ⇥ 1012
180.16
÷ 2 = Glucose Uptake Per Cell (Gcell) = 2.40 pMol/cell.day (C.26)
This shows that in this case the glucose uptake per cell was 8.46pMol/Cell. The only change
for an equivalent lactate calculation is to replace the Mr of glucose (180.16g/Mol) with that
of lactate (90.08g/Mol).
C.5.2 Ammonium Production
Ammonium production is determined in a slightly di↵erent way as the Nova analyser presents
data in mMol/L. First as with lactate production, the amount present in the medium
(⇡0.12mMol/L is first subtracted:
Ca = Cma   Cfa (C.27)
Then the per cell per day value is calculated as follows (previously Equation 3.10):
Acell =
Cap
103
⇢cell
109 ÷ Tc (C.28)
Where symbols are as before, except
• Acell is the ammonium production per cell (pMol/cell.day)
For example: after three days in culture a population of hMSCs were detected to have a
density of 75,000 cells per mL and an ammonium concentration of 0.8mMol/L, fresh medium
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was found to have 0.12mMol/L, thus using Equation C.28.
0.8  0.12 = Ammonium Concentration (Ca) = 0.68mMol/L (C.29)
0.68
103
75000
⇥ 109 ÷ 3 = Ammonium Production per cell (Acell) = 3.02pMol/cell.day (C.30)
This then gives an ammonium production rate of 3.02pMol/cell.day.
C.5.3 Yield
The most common ultimate fate of glucose after its use in the Kreb’s cycle is conversion
to lactate via pyruvate. This is simply calculated by dividing (in pMol/cell) the glucose
consumed by the lactate produced:
Lcell
Gcell
= Y Lac
Glu
(C.31)
For example: Using the calculation above (Equation C.26) for the glucose consumption
(2.40pMol/cell.day) and a lactate production of 4.18pMol/cell.day.
Using Equation C.31 the yield of lactate from glucose is thus determined:
4.18
2.40
= Yield of Lactate from Glucose (Y Lac
Glu
) = 1.74mol/mol (C.32)
C.6 Alkaline Phosphatase Assay
ALP activity was determined using a colourimetric assay. This was previously described
in Section 3.2.2. The colourimetric plate reader gives a reading and was converted to
appropriate per cell ALP activity by the following calculation.
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For example: The ALP assay was always performed with 5x104 cells, in one case a reading
of 0.348 was observed. An example standard curve has been previously found to be:
CpNP = 278.09R  12.55 (C.33)
Where:
• CpNP is the concentration of pNP (which is proportional to ALP activity) (µMol)
• R is the reading from the colourimetric plate reader
The per cell value is then calculated as follows:
278.08⇥ 0.348  12.55
50000
⇥ 1000 = ALP Activity/cell AALP = 1.68pMol/cell/hour (C.34)
This gives a value of 1.68pMol/cell/hour. The expression is divided by 50000 to derive a
per cell value and then multiplied by 1000 to convert from µMol to nMol. This is a per hour
value as the samples were incubated for one hour.
C.7 Kynurenine Assay
Kynurenine expression was determined using an assay previously described in Section 3.10.
This is a colourimetric assay, where kynurenine mixed with TCA shows up greeny-yellow.
For example: Performing the kynurenine assay on a population of 5.09x105 cells gave a
reading of 0.434. A standard curve had been previously found to be:
CKyn = 773.26R  5.67 (C.35)
Where:
• CKyn is the concentration of Kynurenine (µMol)
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• R is the reading from the colourimetric plate reader
To normalise, first the reading from fresh medium (which is used in the sample) was sub-
tracted. This was 0.168 and so the normalised reading is 0.251.
The per cell value is then calculated as follows:
773.26⇥ 0.231  5.61
5.09x105
⇥ 1000 = Kynurenine Activity per cell AKyn = 0.370nMol/cell
(C.36)
This then gives a value of 0.370nMol/cell.
C.8 Thawing
C.8.1 Thawing Rate
The thawing model, described in Section 7.1 allows a calculation of the rate of heat transfer
into a model. Equation C.37 (previously Equation 7.6) is a di↵erential equation, but as was
discussed in Section 7.1 this was linearised at the start and end temperatures of the modelled
cryovial (-150°C and 1°C respectively).
dQR =
Tv   TCdTC
1
ho
+ xwkw +
1
hi
A (C.37)
Where:
• TV is the vessel absolute temperature (K)
• TC is the absolute temperature of the vial (K)
• ho and hi are the heat transfer coe cients of the thawing vessel material and cell
material (W/m2K)
• xw is the thickness of the cryovial wall (m)
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• kw is the thermal conductivity of the cryovial wall material (polypropylene) (W/m K)
• QR is the heat transfer rate of energy into the cryovial (W)
• A is the heat transfer area of the cell material in a cryovial (m2)
To linearise two calculations of Equation C.37 with TC as -150°C (123K) and 1°C (274K)
were calculated, for example in a 37°C (310K) waterbath with 1mL of cell suspension (area
6.283x10-4m2):
310  123
1
93.41 +
0.001
2.72 +
1
100
⇥ (6.283⇥ 10 4) = Heat Transfer Rate (QR) = 5.58W (C.38)
The equivalent calculation with the cell material at 1°C (274K) gave a heat transfer rate of
1.07W, these values were then averaged to give a rate of 3.32W.
C.8.2 Time to Thaw
The time required to thaw a cryovial is calculated using Equation C.39 (previously Equation
7.7)
tT =
QT
QR
(C.39)
Where:
• tT is the time required to thaw (s)
• QT is the heat of thawing which for a 1mL cell sample in a cryovial was previously
calculated in Section 7.1.3 to be 720J
Thus using both the value for heat of thawing and the rate defined above in Section C.8.1
the time to thaw is calculated as follows:
720
3.32
= Time to Thaw (tT) = 216s (C.40)
Appendix D
Cell Stability after Two Hours in
Suspension
The DMSO toxicity experiments in Chapter 5 investigate the e↵ect of DMSO exposure
to cells both before and after freezing for up to two hours. In the various studies in the
chapter any detrimental e↵ects were attributed to DMSO contained in the cryomedium.
One possible alternative cause for the detrimental e↵ects on viability, attachment and other
measures could be the fact that the cells were left in suspension for up to two hours in some
cases, at room temperature. To confirm they hypothesis that leaving cells in suspension
caused no e↵ects on the cells’ health and that the detrimental e↵ects were the fault of
DMSO overexposure the following experiment was designed.
Two groups HOS TE85 cells were investigated. The first were enzymatically detached from
culture plastic and left in a centrifuge tube in MEM-based growth medium for two hours.
The second group were frozen as normal, preserved for one week then thawed as normal, the
cell suspension was diluted, centrifuged and the medium removed, it was then resuspended in
fresh MEM-based growth medium and left for two hours. After the two hour wait period both
groups of cells were assessed for viability and then cultured in six-well plates and assessed
one hour later for attachment and 24hours later for yield.
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(a)
(b)
(c)
Figure D.1: (A) Viability, (B) One Hour Attachment and (C) 24hr Yield of HOS TE85
cells after being held in fresh medium for two hours at room temperature immediatley post
enzymatic detachment from culture plastic or post thaw compared to non-held controls.
Data are the mean of three independent experiments ±SD.
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As the results in Figure D.1 show the cells held for two hours after both culture and freezing
did not have changed viability, attachment or growth compared to the respective control.
Further the slowed growth shown in Figure D.1c in the frozen cells is similar to the previousl
observed baseline (Section 4.1.2). These data therefore indicate that detrimental e↵ects on
these and other measures investigated in Chapter 5 were caused not by being held for two
hours in suspension and most likely the fault of exposure to the DMSO in the cryomedium.
Appendix E
SIFT-MS to determine presence of
DMSO in headspace
Selected-Ion Flow-Tube Mass Spectrometry (SIFT-MS) was utilised to determine whether
DMSO remains in the cell culture system after the cells have been over-exposed to a DMSO
containing medium.
Human mesenchymal stem cells from a stable culture were exposed to a DMSO containing
medium for 5 and 120 minutes, along with a control group (similar to the ”Just Expo-
sure” experiment) described in chapter 5. Exposed cells were then centrifuged, the DMSO
containing cryomedium removed and the cells suspended in growth medium.
Following the exposure the head space above the cell suspension was assessed with the
SIFT-MS and the presence of DMSO determined. The SIFT-MS takes molecules from the
sample headspace and reacts it with the precursor ions, for for this experiment exclusively
nitrosonium (NO+) to generate product ions, as described by Equation E.1 below.
DMSO+ [NO]+  ! NO+ [DMSO]+ (E.1)
The product ions are then counted by the mass spectrometer downstream and this is then
used to determine the cocentration of the DMSO in the original sample vapour. Sule´-Suso
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et al describe a similar method to detect the presence of acetaldehyde and carbon dioxide
in the headspace of potentially cancerous lung cells [267].
As the preliminary data displayed in Figure E.1 shows, the cells exposed for two hours
appear to retain significant amounts of DMSO. The measurement from the headspace of
cells previously exposed to the DMSO medium for two hours is statistically similar to that
of the cryomedium, and di↵erent to that of the growth medium, the control cell group and
the 5mins exposure group.
Figure E.1: Assessment of DMSO ions in headspace above samples containing media and
human mesenchymal stem cells with or without up to two hours exposure to a 10%wt
DMSO containing freeze medium. Assessed with a SIFT-MS, data are log parts-per-billion-
by-volume (ppbv) and the mean of three independent measurements ±SD
The data here appear to indicate that after less than two hours exposure to DMSO containing
cryomedia, cells retain DMSO inside their membranes despite being washed. Cells exposed
to DMSO for periods equivalent to that of a normal freezing process do not retain DMSO,
the SIFT-MS detecting similar levels to that of normal growth medium.
Appendix F
Selection of an hPL Concentration
for Cell Culture
Human Platelet Lysate, produced by Cook Medical under the trade name ”Stemulate” was
used in a series of experiments, primarily in chapter 6.
The manufacturer advises using a concentration of 5%wt in growth medium, but to confirm
this will allow growth of cells in a statistically similar way to FBS-supplemented medium as
comparability study was ran.
Human mesenchymal stem cells from a master cell bank were thawed at P1 and cultured
until feed in DMEM containing 10%wt FBS as described in section 3.3.3. At feed separate
groups were fed with media containing 10%wt FBS as a control and 2%wt, 5%wt and 10%wt
human platelet lysate (hPL). These cells were then cultured in these media for three serial
passages.
Viability for all conditions was in excess of 95%. With regards to growth, as the data in
Figure F.1 show, 5%wt and 10%wt hPL supplemented media provide for significantly faster
growth whereas 2%wt is statistically similar to 10%wt FBS supplemented medium.
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Figure F.1: Cumulative Growth over four serial passages of human mesenchymal stem cells
with adaption from FBS 10%wt supplemented medium to hPL supplemented media. Data
are the mean of duplicate measurements from three independent experiments ±SD.
The manufacturer advises using 5%wt hPL in growth medium for hMSCs and given the
slight significant increase in growth it is sensible to use this concentration in experiments
using hPL supplemented growth medium.
Appendix G
Preliminary Thawing Design of
Experiments Study
This work was completed under the author’s supervision by Pritesh Mistry
In addition to the studies performed in Section 7.2.1, the same parameters investigated in
the OFaT experiments were also investigated using a Design of Experiments (DoE) study.
The preliminary findings of these experiments are displayed here.
Using the same parameters explored in Section 7.2.1 (Thawing Rate, Dilution and Pre-Thaw
Stabilisation) an experimental design was set up using Design Expert (Statease, v8). A
two level, three factor interaction with three replicates (22 × 3) was studied with on-thaw
viability, 3hr attachment and 72hr yield as responses. The limits investigated are shown in
Table G.1. HMSCs were cultured to passage 6 and then frozen in 10%wt DMSO in FBS,
on thaw they were thawed according to the parameters defined by the experimental model.
The first finding was that dilution had no e↵ect on on-thaw viability, attachment or yield,
similar to the results in Section 7.2.1, there only a ratio of 1:0 had any e↵ect on the cells.
The e↵ect of both increased thawing rate and pre-thaw temperature was the same as in
Section 7.2.1, albeit with no interactions which a DoE would enable detection of. Figure
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Table G.1: Limits used in Preliminary Thawing DoE Study
Factor Lower Limit Upper Limit
Rate of Heat Transfer (W) 3.32 4.50
Dilution 1:4 1:10
Pre-Thaw Temperature (°C) -150 -20
G.1 are the plots determined for the viability response. The results of the attachment and
yield responses are similar to the viability results and the data in Section 7.2.1.
These data clearly show that increased thawing rate (therefore thawing vessel temperature)
significantly a↵ects cell viability and that increased pre-thaw temperature does not a↵ect on
thaw viability, but the data from attachment and yield (not shown) make it clear that the
cells are somewhat damaged.
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(a) (b)
(c) (d)
Figure G.1: On-Thaw Viability of hMSCs thawed using parameters defined by a two level
three factor interaction DoE model. (A) Pre-Thaw Temperature (Stabilisation) held at
-150°C (B) Pre-Thaw Temperature (Stabilisation) held at -20°C (C) Thawing Rate held
at 3.32W (D) Thawing Rate held at 4.5W. Data are the mean of duplicate measurements
from three independent experiments.
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